This content is provided for informational purposes only and is not meant to substitute for medical advice, diagnosis, or treatment purposes. ACCC does not endorse or recommend any specific prescription drug or any other information in this publication. The programs represented herein have been set up primarily by drug companies that offer free or low-cost drugs to insured, uninsured, or underinsured individuals who cannot afford their medication. Companies offer these programs voluntarily, and the government does not require the provision of free medicine. All content and links reflect accuracy on this date.

The ACCC Patient Assistance & Reimbursement Guide was updated starting September 8, 2021, and published online in October 2021. This publication is updated four times a year.

Visit accc-cancer.org/PatientAssistanceGuide to download and print the most up-to-date information on cancer drug assistance and reimbursement programs.
This year ACCC is proud to publish the 10th print edition of its Patient Assistance & Reimbursement Guide. ACCC Immediate-Past President Ali McBride, PharmD, MS, BCOP, shared with us last year how cancer programs and practices across the nation have expanded their financial advocacy efforts to include pharmacy and other supportive care staff as part of this critical patient service. Recognizing that our financial navigation and pharmacy members are both “super-users” of this guide and the front-line staff responsible for helping patients with cancer overcome financial toxicity, ACCC made a thoughtful decision to more closely align its Patient Assistance & Reimbursement Guide with the ACCC Financial Advocacy Network (FAN) and the ACCC Oncology Pharmacy Education Network (OPEN). Leveraging color and branding—note the purple and orange hues long associated with the ACCC financial advocacy and pharmacy initiatives—and content, this year’s guide highlights the power of multidisciplinary care and the passion that cancer care teams have for treating our patients’ mind, body, and spirit.

As we head into a new year, we must also learn from our experiences in 2020 with the COVID-19 public health emergency. The impact of this pandemic is felt across all walks of life, especially among our frontline workers and our patients with cancer. Not only are our patients considered an at-risk population for getting COVID-19, but the country’s economic downturn as a result of the worldwide pandemic has taken a serious toll on these patients—regardless of their insurance coverage status. Many of our patients have lost their jobs and/or healthcare coverage, and they need financial assistance now more than ever. I want to take this time to thank all the financial navigators, financial counselors, pharmacy staff, social workers, and anyone else who has helped their patients receive the financial assistance they need.

For those new to financial advocacy, ACCC has updated its patient assistance flowchart (page 14) and developed a practical, step-by-step instruction to guide you as you help your patients access and pay for their cancer therapies. The article (pages 7-13) features members of the ACCC Financial Advocacy Network, who shared with us their experiences and workflows to help guide those new to financial navigation.

I am also excited to share that ACCC has been hard at work looking to the future of this resource and how to best meet the changing needs of its members. Specifically, ACCC is exploring ways to create a robust and user-friendly digital Patient Assistance & Reimbursement Guide as a companion piece to the annual print edition—more news to come on this in 2021.

As the pace of drug approvals and the addition of novel agents increase exponentially, continual education and learning are needed. To help in this effort, the Patient Assistance & Reimbursement Guide is updated on a quarterly basis with the most updated information on cancer drug assistance and reimbursement programs, including directions on how to apply and links to enrollment forms. But we want your help! As you use this guide throughout the year, if you know of any changes, updates, and/or corrections to the information within, let us know. Please direct all comments, questions, comments, and feedback to Maddelynne Parker at mparker@accc-cancer.org.
16  Financial Navigation Flowchart

Pharmaceutical Company Patient Assistance & Reimbursement Programs

AbbVie, Inc. 17
ADC Therapeutics 18
Amgen, Inc. 19
Astellas Pharma U.S., Inc. 21
AstraZeneca 24
Bayer HealthCare Pharmaceuticals, Inc. 26
BeiGene 29
bluebird bio and Bristol Myers Squibb 30
Blueprint Medicines 31
Bristol Myers Squibb 33
Coherus BioSciences 35
Daiichi Sankyo 37
Daiichi Sankyo and AstraZeneca 39
Eisai Co., Ltd. 41
Eli Lilly and Company 43
EMD Serono, Inc. 46
Epizyme, Inc. 48
Exelixis, Inc. 50
Genentech, Inc. 51
Gilead 53
GlaxoSmithKline 54
G1 Therapeutics 56
Incyte Corporation 57
Ipsen Biopharmaceuticals, Inc. 59
Janssen Biotech, Inc. 61
Jazz Pharmaceuticals 63
Karyopharm Therapeutics 64
Kite Pharma 66
Merck 67
MorphoSys 70
Mylan 72
Novartis Pharmaceuticals Corporation 74
Oncopeptides 76
Pfizer, Inc. 78
Pharmacyclics, LLC 80
Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme 82
Sanofi Genzyme 86
Seagen 88
Sanofi Genaissance Pharmaceuticals, Inc. 89
Taiho Oncology 91
Takeda Oncology 93
TerSera Therapeutics 95
Teva Oncology 96
TG Therapeutics 97

Medical Device & Testing Patient Assistance & Reimbursement Programs

Adaptive Biotechnologies 99
Foundation Medicine 101

Other Patient Assistance Programs & Resources

AgingCare.com* 104
AuntBertha.com 104
BenefitsCheckUp® 104
CancerCare* 104
CancerCare Financial Assistance Coalition 105
Co-Pay Relief 106
Good Days® 106
HealthWell Foundation* 106
The Leukemia & Lymphoma Society 107
National Organization for Rare Disorders 108
NeedyMeds 108
Patient Advocate Foundation 109
Patient Access Network Foundation 109
RxAssist 110
RxHope™ 110
Rx Outreach* 111
SingleCare* 111

Quick Reference Guide 112

The ACCC Patient Assistance & Reimbursement Guide was printed in January 2021. This publication is updated four times a year. Visit accc-cancer.org/PatientAssistanceGuide to download and print the most up-to-date information on cancer drug assistance and reimbursement programs.
# Patient Assistance & Reimbursement Assistance Programs

## by drug or product

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Product Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abecma™ (idecabtagene vicleucel) suspension for IV infusion</td>
<td>30</td>
</tr>
<tr>
<td>Abraxane® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)</td>
<td>33</td>
</tr>
<tr>
<td>Adakveo® (crizanlizumab-tmca) for IV infusion</td>
<td>74</td>
</tr>
<tr>
<td>Adcetris® (brentuximab vedotin) for injection</td>
<td>88</td>
</tr>
<tr>
<td>Afinitor® (everolimus) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Alecensa® (alectinib) capsules</td>
<td>51</td>
</tr>
<tr>
<td>Allima® (pemetrexed) for injection</td>
<td>43</td>
</tr>
<tr>
<td>Aliqopa™ (copanlisib) for injection</td>
<td>26</td>
</tr>
<tr>
<td>Alunbrig® (brigatinib) tablets</td>
<td>93</td>
</tr>
<tr>
<td>Aranesp® (darbepoetin alfa) injection</td>
<td>19</td>
</tr>
<tr>
<td>Aromasin® (exemestane) tablets</td>
<td>78</td>
</tr>
<tr>
<td>Avastin® (bevacizumab) injection for IV use</td>
<td>51</td>
</tr>
<tr>
<td>Ayvakit® (avapritinib) tablets</td>
<td>31</td>
</tr>
<tr>
<td>Balversa™ (erdafitinib) tablets</td>
<td>61</td>
</tr>
<tr>
<td>Bavenco® (avelumab) injection</td>
<td>46</td>
</tr>
<tr>
<td>Bendeka® (bendamustine HCI) injection</td>
<td>96</td>
</tr>
<tr>
<td>Besponsa® (inotuzumab ozogamicin) injection for IV infusion</td>
<td>78</td>
</tr>
<tr>
<td>Blenrep (belantamab mafodotin-blmf) for injection</td>
<td>54</td>
</tr>
<tr>
<td>Blincyto® (blinatumomab) for injection</td>
<td>19</td>
</tr>
<tr>
<td>Bosulif® (bosutinib) tablets</td>
<td>78</td>
</tr>
<tr>
<td>Braftovi® (encorafenib) capsules</td>
<td>78</td>
</tr>
<tr>
<td>Brukinsa™ (zanubrutinib) capsules</td>
<td>29</td>
</tr>
<tr>
<td>Cabometyx® (cabozantinib) tablets</td>
<td>50</td>
</tr>
<tr>
<td>Calquence® (alacabrutinib) capsules</td>
<td>24</td>
</tr>
<tr>
<td>Camptosar® (irinotecan hydrochloride) injection</td>
<td>78</td>
</tr>
<tr>
<td>Cometriq® (cabozantinib) tablets</td>
<td>50</td>
</tr>
<tr>
<td>Cosela™ (trilaciclib) for injection</td>
<td>56</td>
</tr>
<tr>
<td>Coteclic® (cobimetinib) tablets</td>
<td>51</td>
</tr>
<tr>
<td>Cyramza® (ramucirumab) injection</td>
<td>43</td>
</tr>
<tr>
<td>Darzalex® (daratumumab) injection for intravenous infusion</td>
<td>61</td>
</tr>
<tr>
<td>Darzalex® (daratumumab and hyaluronidase-fihj) injection for subcutaneous use</td>
<td>61</td>
</tr>
<tr>
<td>Daurismo® (gladsegib) tablets</td>
<td>78</td>
</tr>
<tr>
<td>Defitelio® (defibrotide sodium) injection</td>
<td>63</td>
</tr>
<tr>
<td>Elitek® (rasburicase) IV infusion</td>
<td>86</td>
</tr>
<tr>
<td>Ellence® (epirubicin hydrochloride) injection</td>
<td>78</td>
</tr>
<tr>
<td>Emcyt® (estamustine phosphate sodium) capsules</td>
<td>78</td>
</tr>
<tr>
<td>Emend® (aprepitant) capsules</td>
<td>67</td>
</tr>
<tr>
<td>Emend® (fosaprepitant dimeglumine) for injection</td>
<td>67</td>
</tr>
<tr>
<td>Empliciti® (elotuzumab) for injection</td>
<td>33</td>
</tr>
<tr>
<td>Enhertu® (fam-trastuzumab deruxtecan-nxki) injection for intravenous use</td>
<td>39</td>
</tr>
<tr>
<td>Erbitux® (cetuximab) injection</td>
<td>43</td>
</tr>
<tr>
<td>Erlreada® (apalutamide) tablets</td>
<td>61</td>
</tr>
<tr>
<td>Erivedge® (vismodegib) capsules</td>
<td>51</td>
</tr>
<tr>
<td>Erwineze® (asparaginase Erwinia chrysanthemi) for injection</td>
<td>63</td>
</tr>
<tr>
<td>Exjade® (deferasirox) tablets for oral suspension</td>
<td>74</td>
</tr>
<tr>
<td>Faslodex® (fulvestrant) injection</td>
<td>24</td>
</tr>
<tr>
<td>Femara® (letrozole) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Fulphila® (pegfilgrastim-jmdb) injection</td>
<td>72</td>
</tr>
<tr>
<td>Gardasil® (Human Papillomavirus 9-valent Vaccine, Recombinant)</td>
<td>67</td>
</tr>
<tr>
<td>Gavreto® (pralsetinib) capsules</td>
<td>51</td>
</tr>
<tr>
<td>Gazyva® (obinutuzumab) injection</td>
<td>51</td>
</tr>
<tr>
<td>Gleevec® (imatinib mesylate) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Granix® (tbo-filgrastim) injection</td>
<td>96</td>
</tr>
<tr>
<td>Halaven® (eribulin mesylate) injection</td>
<td>41</td>
</tr>
<tr>
<td>Herceptin® (trastuzumab) injection for intravenous use</td>
<td>51</td>
</tr>
<tr>
<td>Herceptin Hylarta™ (hyaluronidase-oysk) injection</td>
<td>51</td>
</tr>
<tr>
<td>Herzuma® (trastuzumab-pkrb) for injection</td>
<td>96</td>
</tr>
<tr>
<td>Ibrance® (palbociclib) capsules</td>
<td>78</td>
</tr>
<tr>
<td>Iclusig® (ponatinib) tablets</td>
<td>93</td>
</tr>
<tr>
<td>Idamycin® (idarubicin hydrochloride) injections</td>
<td>78</td>
</tr>
<tr>
<td>Idhifa® (enasidenib) tablets</td>
<td>33</td>
</tr>
<tr>
<td>Imbruvica® (ibrutinib) capsules</td>
<td>80</td>
</tr>
<tr>
<td>Imfinzi® (durvalumab) injection for intravenous use</td>
<td>24</td>
</tr>
<tr>
<td>Imlygic® (talimogene laherparepvec) suspension for injection</td>
<td>19</td>
</tr>
<tr>
<td>Inlyta® (axitinib) tablets</td>
<td>78</td>
</tr>
<tr>
<td>Inqovi® (decitabine and cedazuridine) tablets</td>
<td>91</td>
</tr>
<tr>
<td>Inrebic® (fedratinib) capsules</td>
<td>33</td>
</tr>
<tr>
<td>Intron® A (interferon alfa-2b, recombinant) for injection</td>
<td>67</td>
</tr>
<tr>
<td>Iressa® (gefitinib)</td>
<td>24</td>
</tr>
<tr>
<td>Istodax® (romidepsin) for injection</td>
<td>33</td>
</tr>
<tr>
<td>Jadenu® (deferasirox) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Jakafi® (ruxolitinib) tablets</td>
<td>57</td>
</tr>
<tr>
<td>Jemperli (dostarlimab) injection 54</td>
<td></td>
</tr>
<tr>
<td>Jevtana® (cabazitaxel) injection</td>
<td>86</td>
</tr>
<tr>
<td>Kadycla® (ado-trastuzumab emtansine) injection for intravenous use</td>
<td>51</td>
</tr>
<tr>
<td>Kanjinti™ (trastuzumab-anns) for injection</td>
<td>19</td>
</tr>
<tr>
<td>Keytruda® (pembrolizumab) injection</td>
<td>67</td>
</tr>
<tr>
<td>Kisqali® (ribociclib) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Kymriah® (tisagenlecleucel) suspension for IV infusion</td>
<td>74</td>
</tr>
<tr>
<td>Kyprolis® (carfilzomib) for injection</td>
<td>19</td>
</tr>
<tr>
<td>Lenvima® (lenvatinib) capsules</td>
<td>41</td>
</tr>
<tr>
<td>Libtayo® (cemiplimab-rwlc) injection</td>
<td>82</td>
</tr>
<tr>
<td>Lonsurf® (trifluridine and tipiracil) tablets</td>
<td>91</td>
</tr>
<tr>
<td>Lorbrena® (lorlatinib) tablets</td>
<td>77</td>
</tr>
</tbody>
</table>
### Patient Assistance & Reimbursement Assistance Programs

**by drug or product (continued)**

<table>
<thead>
<tr>
<th>Drug or Product</th>
<th>Assistance Type</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lumakras™ (sotorasib) tablets</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Lupron Depot® (leuprolide acetate for depot suspension)</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>Lynparza® (olaparib) tablets</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Mekinist® (trametinib) tablets</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td>Mektovi® (binimetinib) tablets</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Monjuvi® (tafasitamab-cxix) for injection</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>Mvasi™ (bevacizumab-awwb) injection</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Mylotarg™ (gemtuzumab ozogamicin) for injection</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Neulasta® (pegfilgrastim) injection</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Neulasta® Onpro® (pegfilgrastim) injection kit</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Nexavar® (sorafenib) tablets</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>Ninlaro® (ixazomib) capsules</td>
<td>93</td>
<td></td>
</tr>
<tr>
<td>Nivestym® (filgrastim-aafi) injection</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Nplate® (romiplostim) injection</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Nubeqa® (darolutamide) tablets</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>Nyvepria™ (Pegfilgrastim) injection</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Odomzo® (sonidegib) capsules</td>
<td>89</td>
<td></td>
</tr>
<tr>
<td>Ogivri® (trastuzumab-dkst) injection</td>
<td>72</td>
<td></td>
</tr>
<tr>
<td>Onivyde® (irinotecan liposome injection)</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td>Ontruzant® (trastuzumab-dttb) for injection</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>Onureg® (azacitidine) tablets</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>Opdivo® (nivolumab) injection for intravenous use</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>Padcev™ (enfortumab vedotin-ejfv) injection for IV infusion</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>Perjeta® (pertuzumab) injection for intravenous use</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>Pemazyre® (pemigatinib) tablets</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>Pepaxto® (melphalan flufenamide) for injection</td>
<td>76</td>
<td></td>
</tr>
<tr>
<td>Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) subcutaneous injection</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>Piqray® (alpelisib) tablets</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td>Polivy® (polatuzumab vedotin-piiq) injection for intravenous use</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>Pomalyst® (pomalidomide) capsules</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>Portrazza® (necitumumab) injection</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>Procrit® (epoetin alfa) injection</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>Prolia® (denosumab) injection</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Promacta® (eltrombopag) tablets</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td>Reblozyl® (luspatercept-aamt) for injection</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>Retacrit® (epoetin alfa-epbx) injection</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Retevmo™ (selpercatinib) capsules</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>Revlimid® (lenalidomide) capsules</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>Riabni™ (rituximab-arrx) injection</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Rituxan® (rituximab)</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>Rituxan Hycela® (rituximab/hyaluronidase human) subcutaneous injection</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>Rozlytrek® (entrectinib) capsules</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>Ruxience™ (rituximab-pvvr) injection</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Rybrevant™ (amivantamab-vmjw) injection for IV use</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>Rydapt® (midostaurin) capsules</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td>Sandostatin® (octreotide acetate) injection</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td>Sandostatin LAR Depot (octreotide acetate) for injectable suspension</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td>Sarclisa® (isatuximab-irfc) injection for IV use</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td>Sensipar® (cinacalcet) tablets</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Somatuline® Depot (lanreotide) injection</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td>Sprycel® (dasatinib) tablets</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>Stivarga® (regorafenib) capsules</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>Sutent® (sunitinib malate) capsules</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Synribo® (omacetaxine mepesuccinate) for injection</td>
<td>96</td>
<td></td>
</tr>
<tr>
<td>Tabrecta™ (capmatinib) tablets</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td>Tafinlar® (dabrafenib) capsules</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td>Tagrisso® (osimertinib) tablets</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Talzenna® (talazoparib) capsules</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Tarceva® (erlotinib) tablets</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>Tasigna® (nilotinib) capsules</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td>Tazverik® (tazemetostat) tablets</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>Tecartus™ (brexucabtagene autoleucel) suspension for IV infusion</td>
<td>66</td>
<td></td>
</tr>
<tr>
<td>Tecentriq® (atezolizumab) injection for IV use</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>Tepmetko® (tepotinib) tablets</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>Thalomid® (thalidomide) capsules</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>Torisel® (temsirolimus) injection</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Trazimera™ (trastuzumab-qyyp) injection</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Treanda® (bendamustine hydrochloride) for injection</td>
<td>96</td>
<td></td>
</tr>
<tr>
<td>Trisenox® (arsenic trioxide) injection</td>
<td>96</td>
<td></td>
</tr>
<tr>
<td>Trodelvy™ (sacituzumab govatcenc-hziy) for injection</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>Truxima® (rituximab-abbx) injection for intravenous use</td>
<td>96</td>
<td></td>
</tr>
<tr>
<td>Tukysa® (tucatinib) tablets</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>Turalio® (pexidartinib) capsules</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>Tykerb® (lapatinib) tablets</td>
<td>74</td>
<td></td>
</tr>
<tr>
<td>Udenyca® (pegfilgrastim-cbqv) 35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ukoniq™ (umbralisib) tablets</td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>Varubi® (rolapitant) tablets</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>Venclexta® (venetoclax) tablets</td>
<td>51</td>
<td></td>
</tr>
</tbody>
</table>
### Patient Assistance & Reimbursement Assistance Programs

#### by drug or product (continued)

<table>
<thead>
<tr>
<th>Drug/Product</th>
<th>Assistance Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verzenio® (abemaciclib) tablets</td>
<td>43</td>
</tr>
<tr>
<td>Vidaza® (azacitidine for injection)</td>
<td>33</td>
</tr>
<tr>
<td>Vitakvi® (larotrectinib)</td>
<td>26</td>
</tr>
<tr>
<td>Vizimpro® (dacomitinib) tablets</td>
<td>78</td>
</tr>
<tr>
<td>Votrient® ( pazopanib )</td>
<td>74</td>
</tr>
<tr>
<td>Vyxeos® (daunorubicin and cytarabine) liposome for injection</td>
<td>63</td>
</tr>
<tr>
<td>Xalkori® (crizotinib) capsules</td>
<td>78</td>
</tr>
<tr>
<td>Xeloda® (capecitabine) tablets</td>
<td>51</td>
</tr>
<tr>
<td>Xgeva® (denosumab) injection</td>
<td>19</td>
</tr>
<tr>
<td>Xofigo® (radium Ra 224 dichloride) injection</td>
<td>26</td>
</tr>
<tr>
<td>Xospata® (glititinib) tablets</td>
<td>21</td>
</tr>
<tr>
<td>Xpovio® (selinexor) tablets</td>
<td>64</td>
</tr>
<tr>
<td>Xyngulate® (enalaprilat) tablets</td>
<td>21</td>
</tr>
<tr>
<td>Yervoy® (ipilimumab) injection for intravenous use</td>
<td>33</td>
</tr>
<tr>
<td>Yescarta® (axicabtagene ciloleucel) suspension for IV infusion</td>
<td>66</td>
</tr>
<tr>
<td>Yondelis® (trabectedin) for injection</td>
<td>61</td>
</tr>
<tr>
<td>Yonsa® (abiraterone acetate) tablets</td>
<td>89</td>
</tr>
<tr>
<td>Zarfison® (filgrastim-sndz) subcutaneous or intravenous injection</td>
<td>84</td>
</tr>
<tr>
<td>Zejula® (niraparib) capsules</td>
<td>54</td>
</tr>
<tr>
<td>Zelboraf® (vemurafenib) tablets</td>
<td>51</td>
</tr>
<tr>
<td>Zepzelca® (lurbinectedin) for injection</td>
<td>63</td>
</tr>
<tr>
<td>Zoladex® (goserelin acetate implant)</td>
<td>95</td>
</tr>
<tr>
<td>Zolinza® (vorinostat) capsules</td>
<td>67</td>
</tr>
<tr>
<td>Zometa® (zoledronic acid) for injection</td>
<td>74</td>
</tr>
<tr>
<td>Zykadia® (ceritinib) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Zynlonta® (loncastuximab tesirine-lpyl) for injection</td>
<td>18</td>
</tr>
<tr>
<td>Zytiga® (abiraterone acetate) tablets</td>
<td>61</td>
</tr>
</tbody>
</table>

#### Parenteral Administration

<table>
<thead>
<tr>
<th>Drug/Product</th>
<th>Assistance Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abecma™ (idecabtagene viloleucel) suspension for IV infusion</td>
<td>30</td>
</tr>
<tr>
<td>Abraxane® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)</td>
<td>33</td>
</tr>
<tr>
<td>Adakveo® (crizanlizumab-tmca) for IV infusion</td>
<td>74</td>
</tr>
<tr>
<td>Adcetris® (brentuximab vedotin) for injection</td>
<td>88</td>
</tr>
<tr>
<td>Alimta® (pemetrexed) for injection</td>
<td>43</td>
</tr>
<tr>
<td>Aliqopa® (copanlisib) for injection</td>
<td>26</td>
</tr>
<tr>
<td>Aranesp® (darbepoetin alfa) injection</td>
<td>19</td>
</tr>
<tr>
<td>Avastin® (bevacizumab) injection for IV use</td>
<td>51</td>
</tr>
<tr>
<td>Bavencio® (avelumab) injection</td>
<td>46</td>
</tr>
<tr>
<td>Bendeka® (bendamustine HCl) injection</td>
<td>96</td>
</tr>
<tr>
<td>Besponsa® (inotuzumab ozogamicin) injection for IV infusion</td>
<td>78</td>
</tr>
<tr>
<td>Blenrep (belantamab mafodotin-blmf) for injection</td>
<td>54</td>
</tr>
<tr>
<td>Blincyto® (blinatumomab) for injection</td>
<td>19</td>
</tr>
<tr>
<td>Camptosar® (irinotecan hydrochloride) injection</td>
<td>78</td>
</tr>
<tr>
<td>Cosela™ (trilaciclib) for injection</td>
<td>55</td>
</tr>
<tr>
<td>Cyramza® (ramucirumab) injection</td>
<td>43</td>
</tr>
<tr>
<td>Darzalex® (daratumumab) injection for intravenous use</td>
<td>61</td>
</tr>
<tr>
<td>Darzalex Faspro™ (daratumumab and hyaluronidase-fihj) injection for subcutaneous use</td>
<td>61</td>
</tr>
<tr>
<td>Defitelio® (defibrotide sodium) injection</td>
<td>63</td>
</tr>
<tr>
<td>Eltional® (rasburicase) IV infusion</td>
<td>86</td>
</tr>
<tr>
<td>Ellence® (epirubicin hydrochloride) injection</td>
<td>78</td>
</tr>
<tr>
<td>Emend® (fosaprepitant dimeglumine) for injection</td>
<td>67</td>
</tr>
<tr>
<td>Empliciti® (elotuzumab) for injection</td>
<td>33</td>
</tr>
<tr>
<td>Enhertu® (fam-trastuzumab deruxtecan-nxki) injection for intravenous use</td>
<td>39</td>
</tr>
<tr>
<td>Erbitux® (cetuximab) injection</td>
<td>43</td>
</tr>
<tr>
<td>Erwineze® (asparaginase Erwinia chrysanthemi) for injection</td>
<td>63</td>
</tr>
<tr>
<td>Faslodex® (fulvestrant) injection for IV use</td>
<td>24</td>
</tr>
<tr>
<td>Fulphila® (pegfilgrastim-mdb) injection</td>
<td>72</td>
</tr>
<tr>
<td>Gardasil® (Human Papillomavirus 9-valent Vaccine, Recombinant)</td>
<td>67</td>
</tr>
<tr>
<td>Gazyva® (obinutuzumab) injection</td>
<td>51</td>
</tr>
<tr>
<td>Granix® (tbo-filgrastim) injection</td>
<td>96</td>
</tr>
<tr>
<td>Halaven® (eribulin mesylate) injection</td>
<td>41</td>
</tr>
<tr>
<td>Herceptin® (trastuzumab) injection for intravenous use</td>
<td>51</td>
</tr>
<tr>
<td>Herceptin Hylecata™ (trastuzumab and hyaluronidase-oyse) injection</td>
<td>51</td>
</tr>
<tr>
<td>Herzuma® (trastuzumab-pkrb) for injection</td>
<td>96</td>
</tr>
<tr>
<td>Idamycin® (idarubicin hydrochloride) injection</td>
<td>78</td>
</tr>
<tr>
<td>Imfinzi® (durvalumab) injection for intravenous use</td>
<td>24</td>
</tr>
<tr>
<td>Imlygic® (talimogene lahreperepvec) suspension for injection</td>
<td>19</td>
</tr>
<tr>
<td>Intron A (interferon alfa-2b, recombinant) for injection</td>
<td>67</td>
</tr>
<tr>
<td>Ixonyx® (romidepsin) for injection</td>
<td>33</td>
</tr>
<tr>
<td>Jemperli (dostarlimab-gxly) injection</td>
<td>54</td>
</tr>
<tr>
<td>Jevtana® (cabazitaxel) injection</td>
<td>67</td>
</tr>
<tr>
<td>Kadryla® (ado-trastuzumab emtansine) injection for intravenous use</td>
<td>51</td>
</tr>
<tr>
<td>Kanjinta™ (trastuzumab-anns) for injection</td>
<td>19</td>
</tr>
<tr>
<td>Keytruda® (pembrolizumab) injection for IV infusion</td>
<td>74</td>
</tr>
<tr>
<td>Kyprolis® (carfilzomib) for injection</td>
<td>19</td>
</tr>
</tbody>
</table>
### Parenteral Administration (continued)

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Libtayo® (cemiplimab-rwlc) injection</td>
<td>81</td>
</tr>
<tr>
<td>Lupron Depot® (leuprolide acetate for depot suspension)</td>
<td>17</td>
</tr>
<tr>
<td>Monjuvi® (tfasitamab-cxix) for injection</td>
<td>70</td>
</tr>
<tr>
<td>Mvasi™ (bevacizumab-awwb) injection</td>
<td>19</td>
</tr>
<tr>
<td>Mylotarg™ (gentuzumab ozogamicin) for injection</td>
<td>78</td>
</tr>
<tr>
<td>Neulasta® (pegfilgrastim) injection</td>
<td>19</td>
</tr>
<tr>
<td>Neulasta® Onpro® (pegfilgrastim) injection kit</td>
<td>19</td>
</tr>
<tr>
<td>Nivestym® (filgrastim-aafi) injection</td>
<td>78</td>
</tr>
<tr>
<td>Nplate® (romiplostim) injection</td>
<td>19</td>
</tr>
<tr>
<td>Nyvepria™ (Pegfilgrastim) injection</td>
<td>78</td>
</tr>
<tr>
<td>Ogivri® (trastuzumab-dkst) injection</td>
<td>72</td>
</tr>
<tr>
<td>Onivyde® (ritimocan liposome injection)</td>
<td>59</td>
</tr>
<tr>
<td>Ontruzant® (trastuzumab-dttb) for injection</td>
<td>67</td>
</tr>
<tr>
<td>Opdivo® (nivolumab) injection for intravenous use</td>
<td>33</td>
</tr>
<tr>
<td>Padcev™ (enfortumab vedotin-ejfv) injection for IV use</td>
<td>21</td>
</tr>
<tr>
<td>Pepaxto® (melphalan flufenamide) for injection</td>
<td>76</td>
</tr>
<tr>
<td>Perjeta® (pertuzumab) for injection for intravenous use</td>
<td>51</td>
</tr>
<tr>
<td>Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) subcutaneous injection</td>
<td>51</td>
</tr>
<tr>
<td>Polivy® (polatuzumab vedotin-piiq) injection for intravenous use</td>
<td>51</td>
</tr>
<tr>
<td>Portrazza® (necitumumab) injection</td>
<td>43</td>
</tr>
<tr>
<td>Procrit® (epoetin alfa) injection</td>
<td>61</td>
</tr>
<tr>
<td>Prolia® (denosumab) injection</td>
<td>19</td>
</tr>
<tr>
<td>Reblozyl® (luspatcept-aamt) for injection</td>
<td>33</td>
</tr>
<tr>
<td>Retacrit® (epoetin alfa-epbx) injection</td>
<td>78</td>
</tr>
<tr>
<td>Riabni™ (rituximab-arrx) injection</td>
<td>19</td>
</tr>
<tr>
<td>Rituxan® (rituximab) injection</td>
<td>51</td>
</tr>
<tr>
<td>Rituxan Hycela® (rituximab/hyaluronidase human) injection for subcutaneous use</td>
<td>51</td>
</tr>
<tr>
<td>Ruxience™ (rituximab-pvvr) injection</td>
<td>78</td>
</tr>
<tr>
<td>Rybrevant™ (amivantamab-vmjj) injection for IV use</td>
<td>61</td>
</tr>
<tr>
<td>Sandostatin® (octreotide acetate) injection</td>
<td>74</td>
</tr>
<tr>
<td>Sandostatin® LAR Depot (octreotide acetate) for injectable suspension</td>
<td>74</td>
</tr>
<tr>
<td>Sarclisa® (lisutamab-ifrc) injection for IV use</td>
<td>86</td>
</tr>
<tr>
<td>Somatuline® Depot (lanreotide) injection</td>
<td>59</td>
</tr>
<tr>
<td>Synribo® (omacetaxine mepesuccinate) for injection</td>
<td>96</td>
</tr>
<tr>
<td>Tecartus™ (brexucabtagene autoleucel) suspension for IV infusion</td>
<td>66</td>
</tr>
<tr>
<td>Tecentriq® (atezolizumab) injection for IV use</td>
<td>51</td>
</tr>
<tr>
<td>Torisel® (temsirolimus) injection</td>
<td>78</td>
</tr>
<tr>
<td>Trazimera™ (trastuzumab-qyyp) injection</td>
<td>78</td>
</tr>
<tr>
<td>Treanda® (bendamustine hydrochloride) for injection</td>
<td>96</td>
</tr>
<tr>
<td>Trisenox® (arsenic trioxide) injection</td>
<td>96</td>
</tr>
<tr>
<td>Trodelvy™ (sacituzumab govitecan-hziy) for injection</td>
<td>53</td>
</tr>
<tr>
<td>Truxima® (rituximab-abbs) injection for intravenous use</td>
<td>96</td>
</tr>
<tr>
<td>Udenyca® (pegfilgrastim-cbqv) injection</td>
<td>35</td>
</tr>
<tr>
<td>Vectibix® (panitumumab) for injection</td>
<td>19</td>
</tr>
<tr>
<td>Velcade® (bortezomib) for injection</td>
<td>93</td>
</tr>
<tr>
<td>Vida® (azacitidine for injection)</td>
<td>33</td>
</tr>
<tr>
<td>Vyxeos® (daunorubicin and cytarabine) liposome for injection</td>
<td>63</td>
</tr>
<tr>
<td>Xgeva® (denosumab) injection</td>
<td>19</td>
</tr>
<tr>
<td>Xofito® (radium Ra 224 dichloride) injection</td>
<td>26</td>
</tr>
<tr>
<td>Yervoy® (ipilimumab) injection for intravenous use</td>
<td>33</td>
</tr>
<tr>
<td>Yescarta® (axicabtagene ciloleucel) suspension for IV infusion</td>
<td>66</td>
</tr>
<tr>
<td>Zondelis® (trabectedin)</td>
<td>61</td>
</tr>
<tr>
<td>Zarkio® (filgrastim-sndz) subcutaneous or intravenous injection</td>
<td>84</td>
</tr>
<tr>
<td>Zepelca® (lubinectinod) for injection</td>
<td>63</td>
</tr>
<tr>
<td>Ziestenzo® (pegfilgrastim-bmze) injection</td>
<td>84</td>
</tr>
<tr>
<td>Zirabev™ (bevacizumab-bvzr) injection</td>
<td>78</td>
</tr>
<tr>
<td>Zoladex® (goserelin acetate implant)</td>
<td>95</td>
</tr>
<tr>
<td>Zometa® (zoledronic acid) for injection</td>
<td>74</td>
</tr>
<tr>
<td>Zynlonta® (loncastuximab tesirine-lpyl) for injection</td>
<td>18</td>
</tr>
</tbody>
</table>

### Oral Administration

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afinitor® (everolimus) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Alecensa® (alectinib) capsules</td>
<td>51</td>
</tr>
<tr>
<td>Alunbrig® (brigatinib) tablets</td>
<td>93</td>
</tr>
<tr>
<td>Aromasin® (exemestane) tablets</td>
<td>78</td>
</tr>
<tr>
<td>Ayvakit™ (avapritinib) tablets</td>
<td>31</td>
</tr>
<tr>
<td>Balversa™ (erdfatinib) tablets</td>
<td>61</td>
</tr>
<tr>
<td>Bosulif® (bosutinib) tablets</td>
<td>78</td>
</tr>
<tr>
<td>Braftovi® (encorafenib) capsules</td>
<td>78</td>
</tr>
<tr>
<td>Brukinsa™ (Zanubrutinib) capsules</td>
<td>29</td>
</tr>
<tr>
<td>Cabometyx® (cabozantinib) tablets</td>
<td>50</td>
</tr>
<tr>
<td>Calquence® (acalabrutinib) capsules</td>
<td>24</td>
</tr>
<tr>
<td>Cometriq® (cabozantinib) capsules</td>
<td>50</td>
</tr>
<tr>
<td>Cotelic® (cobimetinib) tablets</td>
<td>51</td>
</tr>
<tr>
<td>Daurismo™ (glasdegib) tablets</td>
<td>78</td>
</tr>
<tr>
<td>Emcyt® (estamustine phosphate sodium) capsules</td>
<td>78</td>
</tr>
<tr>
<td>Emend® (aprepitant) capsules</td>
<td>67</td>
</tr>
<tr>
<td>Erleada® (apalutamide) tablets</td>
<td>61</td>
</tr>
<tr>
<td>Erivedge® (vismodegib) tablets</td>
<td>51</td>
</tr>
<tr>
<td>Exjade® (deferasirox) tablets for oral suspension</td>
<td>74</td>
</tr>
</tbody>
</table>
### Patient Assistance & Reimbursement Assistance Programs

#### Oral Administration (continued)

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Femara® (letrozole) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Gavreto® (pralsetinib) capsules</td>
<td>51</td>
</tr>
<tr>
<td>Gleevec® (imatinib mesylate) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Ibrance® (palbociclib)</td>
<td>78</td>
</tr>
<tr>
<td>Iclusig® (ponatinib) tablets</td>
<td>93</td>
</tr>
<tr>
<td>Idhifa® (enasidenib) tablets</td>
<td>33</td>
</tr>
<tr>
<td>Imbruvica® (ibrutinib) capsules</td>
<td>80</td>
</tr>
<tr>
<td>Inqovi® (decitabine and cedazuridine) tablets</td>
<td>91</td>
</tr>
<tr>
<td>Inrebic® (fedratinib) capsules</td>
<td>33</td>
</tr>
<tr>
<td>Inlyta® (axitinib) tablets</td>
<td>78</td>
</tr>
<tr>
<td>Iressa® (gefitinib)</td>
<td>24</td>
</tr>
<tr>
<td>Jadenu® (deferasirox) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Jakafi® (ruxolitinib) tablets</td>
<td>57</td>
</tr>
<tr>
<td>Kisqali® (ribociclib) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Lenvima® (lenvatinib) capsules</td>
<td>41</td>
</tr>
<tr>
<td>Lonsurf® (trifluridine and tipiracil) tablets</td>
<td>91</td>
</tr>
<tr>
<td>Lorbrena® (lorlatinib) tablets</td>
<td>78</td>
</tr>
<tr>
<td>Lumakras® (sotorasib) tablets</td>
<td>19</td>
</tr>
<tr>
<td>Lynparza® (olaparib) tablets</td>
<td>24</td>
</tr>
<tr>
<td>Mekinist® (trametinib) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Mektopi® (binimetinib) tablets</td>
<td>78</td>
</tr>
<tr>
<td>Nexavar® (sorafenib) tablets</td>
<td>26</td>
</tr>
<tr>
<td>Ninlaro® (ixazomib) capsules</td>
<td>93</td>
</tr>
<tr>
<td>Nubeqa® (darolutamide) tablets</td>
<td>26</td>
</tr>
<tr>
<td>Odomzo® (sonidegib) tablets</td>
<td>88</td>
</tr>
<tr>
<td>Onureg® (azacitidine) tablets</td>
<td>33</td>
</tr>
<tr>
<td>Pemazyre® (pemigatinib) tablets</td>
<td>57</td>
</tr>
<tr>
<td>Piqray® (alpelisib) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Prolastix® (pomalidomide) capsules</td>
<td>33</td>
</tr>
<tr>
<td>Promacta® (elotrombopag) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Retevmo® (selpercatinib) capsules</td>
<td>43</td>
</tr>
<tr>
<td>Revlimid® (lenalidomide) capsules</td>
<td>33</td>
</tr>
<tr>
<td>Rozlytrek® (entrectinib) capsules</td>
<td>51</td>
</tr>
<tr>
<td>Rydapt® (midostaurin) capsules</td>
<td>74</td>
</tr>
<tr>
<td>Sensipar® (cinacalcet) tablets</td>
<td>19</td>
</tr>
<tr>
<td>Sprycel® (dasatinib) tablets</td>
<td>33</td>
</tr>
<tr>
<td>Stivarga® (regorafenib) tablets</td>
<td>26</td>
</tr>
<tr>
<td>Sutent® (sunitinib malate) capsules</td>
<td>78</td>
</tr>
<tr>
<td>Tabrecta® (capmatinib) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Tafinlar® (dabrafenib) capsules</td>
<td>74</td>
</tr>
<tr>
<td>Tagrisso® (osimertinib) tablets</td>
<td>24</td>
</tr>
<tr>
<td>Talzenna® (talazoparib) capsules</td>
<td>78</td>
</tr>
<tr>
<td>Tarceva® (erlotinib) tablets</td>
<td>51</td>
</tr>
<tr>
<td>Tasigna® (nilotinib) capsules</td>
<td>74</td>
</tr>
<tr>
<td>Tazverik® (tazemetostat) tablets</td>
<td>48</td>
</tr>
<tr>
<td>Tepmetko® (tepotinib) tablets</td>
<td>46</td>
</tr>
<tr>
<td>Thalomid® (thalidomide) capsules</td>
<td>33</td>
</tr>
<tr>
<td>Tukysa® (tucatinib) tablets</td>
<td>88</td>
</tr>
<tr>
<td>Turalio® (pexidartinib) capsules</td>
<td>37</td>
</tr>
<tr>
<td>Tykerb® (lapatinib) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Ukoniq™ (umbralisib) tablets</td>
<td>97</td>
</tr>
<tr>
<td>Varubi® (rolapitant) tablets</td>
<td>95</td>
</tr>
<tr>
<td>Venclexa® (venetoclax) tablets</td>
<td>51</td>
</tr>
<tr>
<td>Verzenio® (abemaciclib) tablets</td>
<td>43</td>
</tr>
<tr>
<td>Vitakvi® (larotrectinib)</td>
<td>26</td>
</tr>
<tr>
<td>Vizimpro® (dacomitinib) tablets</td>
<td>78</td>
</tr>
<tr>
<td>Votrient® (pazopanib) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Xalkori® (crizotinib) capsules</td>
<td>78</td>
</tr>
<tr>
<td>Xeloda® (capecitabine) tablets</td>
<td>51</td>
</tr>
<tr>
<td>Xospata® (gilteritinib) tablets</td>
<td>21</td>
</tr>
<tr>
<td>Xpovio® (selinexor) tablets</td>
<td>64</td>
</tr>
<tr>
<td>Xtandi® (enzalutamide) capsules</td>
<td>21</td>
</tr>
<tr>
<td>Yonsa® (abiraterone acetate) tablets</td>
<td>89</td>
</tr>
<tr>
<td>Zejula® (niraparib) capsules</td>
<td>54</td>
</tr>
<tr>
<td>Zelboraf® (vemurafenib) tablets</td>
<td>51</td>
</tr>
<tr>
<td>Zolinza® (vorinostat) capsules</td>
<td>67</td>
</tr>
<tr>
<td>Zykdia® (ceritinib) tablets</td>
<td>74</td>
</tr>
<tr>
<td>Zytiga® (abiraterone acetate) tablets</td>
<td>61</td>
</tr>
</tbody>
</table>
Take Your Financial Navigation Services to the Next Level with These Resources

ACCC is committed to bringing knowledgeable resources to financial advocacy professionals, making tangible connections, and improving the patient experience.

These tools can empower you to proactively integrate financial health into the oncology care continuum and help your patients gain access to high-quality care for a better quality of life.

CONNECT WITH PEERS
- Financial Advocacy Discussion Group
- Town Halls on Issues Impacting Financial Advocates
- Virtual Coffee Chats with Leading Experts in Financial Advocacy
- Virtual Financial Advocacy Network Annual Summit

AMPLIFY YOUR KNOWLEDGE
- Financial Advocacy Network Boot Camp
- 2021 Patient Assistance and Reimbursement Guide
- Ready, Set, Go! Financial Advocacy Playbook

Learn more and get involved today at accc-cancer.org/FAN

The ACCC Financial Advocacy Network is supported by Pfizer (Cornerstone Partner), Pharmacyclics, Janssen, and Johnson & Johnson (Silver Partners).

The Association of Community Cancer Centers (ACCC) is the leading education and advocacy organization for the cancer care community. Founded in 1974, ACCC is a powerful network of 28,000 multidisciplinary practitioners from 2,100 hospitals and practices nationwide. As advances in cancer screening and diagnosis, treatment options, and care delivery models continue to evolve - so has ACCC - adapting its resources to meet the changing needs of the entire oncology care team. For more information, visit accc-cancer.org. Follow us on social media; read our blog, ACCCBuzz; tune in to our CANCER BUZZ podcast; and view our CANCER BUZZ TV channel.

The ACCC Financial Advocacy Network is the leader in providing professional development training, tools, and resources that will empower providers to proactively integrate financial health into the cancer care continuum and help patients gain access to high-quality care for a better quality of life.
Cancer is one of the costliest diseases to treat in the United States. According to a 2019 survey conducted by The Mesothelioma Center, 63 percent of patients with cancer and their caregivers struggle financially following a cancer diagnosis. The struggle often continues long after patients’ initial diagnosis into treatment, and it can follow them into survivorship and follow-up care. As the cost of treatment continues to rise, the financial burden that often accompanies a cancer diagnosis is growing to unsustainable levels—the cost of new cancer medications tops the charts at $100,000 or higher annually.

As health insurers continue to shift these growing costs to patients, they result in higher deductibles, co-pays, and co-insurance amounts for cancer therapies, depending on the insurance plan. The COVID-19 pandemic only increased the financial burden on patients, as unemployment and loss of health insurance affect more and more people. According to a survey conducted in March 2020 by the American Cancer Society Action Network, 50 percent of the 1,200 patients and survivors surveyed report that COVID-19 has impacted their healthcare. The same survey also found that 27 percent of the patients in active treatment had to delay treatment due to the pandemic.

We are seeing the ever-increasing cost of care, compounded by the COVID-19 pandemic, not only affecting our patients’ ability to access and pay for their treatment, but also their ability to afford the costs of daily living, including rent, groceries, and transportation. As financial navigators, we are in a unique position to help ease patients’ financial burden of care. Our skill set allows us to serve patients before we even meet them. Armed with patients’ individual insurance and financial information, we can get a head start on formulating a plan that can help patients access the treatment they need, eliminating or reducing the financial toxicity that too often accompanies life-saving cancer care.
Financial Advocacy Programs Meet Patient Needs

In response to an ACCC Financial Advocacy Network survey of ACCC’s member cancer programs in late 2019, 10 percent of respondents (292 people from 153 unique cancer programs) report that their cancer program employs no financial advocates. Asked if respondents have enough full-time staff to meet the demand for financial advocacy services, 36 percent of survey respondents said they do not, and 34 percent replied, “not always.” Of those practices that do have financial advocates on staff, the majority (60 percent) employ just one to three advocates. In some cancer programs, social workers, pharmacists, or other supportive care staff—in addition to their other duties—provide financial navigation services to patients. In this guide, financial advocates are defined as any staff member who has a role in providing patients financial navigation services. Financial navigation programs can vary significantly based on their rural or urban setting and whether they are community cancer programs or affiliated with an academic institution.

This guide helps financial navigators who may be new to their role assist patients with varying insurance status access and afford their prescribed cancer treatment therapies. In the end, we want our patients and their families to focus on their health and not let their finances be a determinant of the care they receive. Here, we present potential approaches to help patients afford their cancer care according to their insurance status.

Patients with Commercial Insurance

Jordan Karwedsky is a financial counselor at Green Bay Oncology in Green Bay, Wisconsin. Karwedsky is also a member of the ACCC Financial Advocacy Network’s Network Task Force and the ACCC Patient Assistance & Reimbursement Guide Task Force.

Always take a proactive approach with patients who need co-pay assistance, regardless of their insurance type. At Green Bay Oncology, when a patient is commercially insured or has an employer-based plan, financial counselors review and discuss with patients their insurance coverage and annual out-of-pocket maximum at their initial consult, so we can begin to address any financial concerns up front. While obtaining insurance authorizations for treatment, we also determine if patients need assistance with their copayment, coinsurance, or deductible. Difficulty affording cancer treatments may be eased by accessing funds from independent foundations or drug manufacturers’ co-pay card programs. We follow up with patients at their chemotherapy teach appointment or initial treatment appointment to discuss any co-pay assistance options that may be available. Discussing patients’ finances can be a tricky situation to navigate because they are not always willing to share their personal financial information with someone they do not know. It is therefore important as a financial counselor to build the foundation of a trusting relationship with your patients from the start. Patients will not likely know their financial options. I have found that many patients are unaware that co-pay assistance programs exist. Many of them want to know, “What’s the catch?” It is important to explain to these patients what independent foundations and manufacturer co-pay programs are, how each works, and what information is needed to determine patients’ eligibility—in terms that they understand. I have found it helpful to compare co-pay cards to the coupons patients use at a grocery store.

There will always be some patients who will say before beginning treatment that they are not interested in co-pay assistance, saying they prefer assistance programs to go to someone who needs it more than they do. Always be sure to follow back up with these patients a month or two into their treatment plan to make sure they are doing okay financially and to help if they now want to access a co-pay program or other assistance.
Patients with Medicare or Who Are Medicare Eligible

Jennifer Paquet, RN, BSN, is a financial navigator at Bassett Healthcare in Cooperstown, New York and is an ACCC Financial Advocacy Network Workforce Task Force Member

Often, new Medicare recipients are sold on low-cost Medicare Advantage plans that feature lower monthly premiums, relatively inexpensive co-pays, and reduced prescription drug prices. While this may be appealing to newly retired Americans, they are often not told when choosing their first Medicare Advantage plan that they will incur higher costs if they are diagnosed with a long-term, costly disease, like cancer.

Choosing an insurance plan is daunting. Many Medicare recipients do not even open the Medicare & You handbook they receive from the Centers of Medicare & Medicaid Services each year. Some say this handbook is not written in a language they understand. This is where a financial navigator’s expertise comes in. We break down the language of insurance options for our patients and make it clear and relevant to them. Financial navigators explain to patients how a given plan works and why the plan works that way. This education allows patients to better understand the details of the plan they choose.

Meeting New Patients

As important as it is to educate patients about their insurance options as soon as possible after diagnosis, be careful not to approach patients until after they first meet with their cancer care team. It is vital that patients first understand the nature of their disease state before they are approached by financial navigators to help them through the financial side of cancer treatment.

When I first meet with patients, I review their benefits investigation with them and answer any questions they have about paying for their care. At this initial meeting with patients, try to obtain as much information as you can. Do not be afraid to ask patients the following:
1. What is your household income?
2. What are your household expenses?
3. What do you pay for your current healthcare insurance plan?

When I first started working as a financial navigator, I was afraid of appearing too invasive when asking for patients’ personal information. I have since learned that when you take time with patients to explain that you work for them rather than an insurance company, you are pleasantly surprised by how comfortable they are giving you the information you need to help them. Assure patients that receiving treatment does not have to be a choice. There is always a solution. Sometimes the solution is not easy to find, but it is there.

Be Prepared

Once you know what type of Medicare plan patients have or if they do not have additional coverage, help them explore other potential insurance options. If an insurance change is an option, whether to a federally funded plan or to include additional coverage, make these options available in customized packets you can present to patients. This packet may include a Medicare Savings Program application and any other state programs for which patients may qualify. For patients with Medicare only, it is imperative to get those patients on a supplemental plan with a short waiting period (e.g., three months or less).

For patients who qualify for income-based assistance, I include a list of independent foundations with open funding. These organizations may help offset out-of-pocket cost for medications. (Aimee Hoch, LSW, explains more on how to help your patients with Medicare and commercial insurance access co-pay and out-of-pocket cost assistance from independent foundations on page 10.) Easing the burdens of household bills helps just as much as mitigating medical costs. By alleviating the expenses of daily living, you free up resources for meeting medical expenses. Financial assistance programs are found in many places. Reach out to social workers in your community, your local department of social services, churches, American Legion halls, etc. You will be surprised by the number of groups that are out there waiting to help patients.

I store all this information on my computer and in our electronic medical record. I always have available to
me patient release of information forms, so I have access to all of the information necessary to help individual patients apply for funding, free medications, and foundational help when these resources are available.

My very last words to every single patient I see are, “You worry about getting through this, and I will worry about the money.” I can never stress enough how very important it is to treat each patient with compassion, laughter, empathy, and love. Be passionate and kind; make sure patients know you are only a phone call away, that you are their financial advocate, and that they matter.

Patients with Medicare or Commercial Insurance

Foundation Co-Pay Assistance Programs

Aimee Hoch, LSW, is an oncology financial navigator at Grand View Health in Sellersville, Pennsylvania and an ACCC Financial Advocacy Network Advisory Committee member.

Knowing what co-pay assistance each patient needs and where to find it—often in short order—is key to successfully securing funding and ultimately creating access to necessary treatment. These four key steps can help financial navigators provide patients access to the co-pay assistance they qualify for from various independent foundations. These organizations offer co-pay assistance and may offer insurance premium assistance and/or some travel assistance.

1. **Always have up-to-date knowledge of open funds.**

One of the most important steps in accessing co-pay assistance via independent foundations is knowing when funds are available. I enrolled in the Patient Access Network’s FundFinder, which is a great tool for helping me track this information. I also monitor the availability of disease-specific funds from various foundations, and I receive alerts on my phone and through email in real time. I also signed up for each foundations’ email newsletter and receive notifications of all open funds a single foundation has. This may seem like it will fill up your inbox, but it is the best way to stay on top of the availability of funds from numerous foundations. I make sure I receive a notification any time a fund with a foundation is made available, so I can apply for assistance on behalf of patients who qualify.

2. **Obtain permission during the initial assessment.**

Foundation funds open and close very quickly, so having the correct patient information and permission ahead of time allows you to act fast to apply for co-pay assistance when it becomes available. During my initial consultation with patients, I take time to educate them about their co-pay assistance options, determine whether they may qualify for and benefit from foundational assistance, and obtain their permission to act on their behalf if a foundation fund that supports their disease and status should open. In most cases, I refer Medicare recipients to foundational assistance. However, patients with commercial insurance may also benefit from foundational assistance if they qualify.

3. **Streamline the application process.**

When I first became a financial navigator, one of my immediate tasks was to set up my account and/or personal portal with each foundation I track. These accounts and online portals allow me to act fast before foundation funds close. Most foundations make staff available by phone to help with this registration, if necessary.

4. **Organize a spreadsheet or list of patients.**

Keeping patient information in an organized spreadsheet or list helps you stay on top of things when applying for assistance or renewing assistance for patients. My spreadsheet includes new and current patients waiting for foundation funds to open, as well as the patients currently enrolled with foundations and the dates indicating when it is time to reapply for assistance on their behalf.
Patients Without Insurance Who Are Medicaid Eligible

Teri Brown is a financial navigator at Kettering Cancer Care in Kettering, Ohio.

I help patients who come to us to pay for their cancer therapies out-of-pocket or when uninsured and who qualify for Medicaid. Over 32 years, I worked in the Greene County Department of Job and Family Services in Xenia, Ohio, which gave me experience and in-depth knowledge of Ohio’s Medicaid program. I have since taught other financial navigators at Kettering Cancer Care the ins and outs of Ohio’s Medicaid program and how to help patients with limited resources apply to Medicaid to pay for life-saving cancer treatment. Patients come to our financial navigation program through many pathways: self-referral or through referrals from various members of the cancer care team, including our social workers, nurses, physicians, pre-certification staff, and schedule review staff.

Once we determine that patients are not commercially insured and are eligible for Medicaid, our financial navigators contact them to discuss the circumstances leading up to their loss of insurance. After speaking to patients, financial navigators complete an online presumptive Medicaid application through the state of Ohio on the patients’ behalf. This allows our patients to be eligible for Medicaid coverage for up to three months on an emergency basis until the Ohio Department of Job and Family Services reviews their case. Most patients are usually approved to receive Medicaid immediately, and they are given a billing number. This enables patients to receive full healthcare services, including hospital, physician, dental, and eye care. Once our patients are granted this interim coverage, we help them complete a full Medicaid application that is reviewed by the local county office. The patient story below illustrates the value financial navigators bring to patients:

I spoke with a young man who was diagnosed with lymphoma. He did not have any source of income or insurance. He also told me that he had previously applied for Medicaid but was denied. As I spoke to this patient, I learned that he is the father of two small children. The mother of the children had both children signed up for Medicaid under her name, making her Medicaid-eligible as well. I then asked the patient about his relationship with the children’s mother. He said it was “very good” and that they share parenting responsibilities. I let him know that, with shared parenting, both he and his children’s mother could place one of their children on Medicaid under their name, which would allow both parents to also be eligible for Medicaid. After this conversation, the patient spoke to the children’s mother, and she agreed to remove one of the children from her Medicaid coverage, so my patient could enroll one of his children and qualify for coverage himself. The applications were approved, and the patient is now able to receive all hospital services without worry.
Patients Without Insurance Who Are Not Eligible for Medicare or Medicaid

Drug Manufacturer Patient Assistance Programs

Jeanie Troy is a patient financial navigator at Lake Region Healthcare, Cancer Care and Research Center in Fergus Falls, Minnesota and is an ACCC Financial Advocacy Network Workforce Task Force member.

When I receive a new patient notification for an uninsured patient, my first task is to determine if they are eligible for Medicaid or to purchase commercial insurance in the case of a recent life-changing event. If a patient is not eligible for insurance coverage, I make their provider aware that the patient is uninsured before their first consult with their cancer care team.

Once a provider establishes a patient’s treatment plan, they will notify me through our electronic health record, so I can begin looking for patient assistance programs for which the patient may be eligible. Our facility now uses a third-party program to help us streamline the financial navigation process. Before we had this great tool, I would usually search the ACCC Patient Assistance & Reimbursement Guide or Google the prescribed medication’s name followed by “patient assistance program” (i.e., “Keytruda patient assistance program”). From the medication’s manufacturer website, you can download the patient assistance program application or complete it online.

I then complete the application with the patient and collect any necessary supporting documents, such as income verification, to send to the manufacturer’s patient assistance program. From my experience, it takes on average one to two weeks to receive an approval. Some programs will send the prescribed medication directly to our facility before the patient starts treatment, while others replace the medication used from our pharmacy after the patient completes each treatment.

If I am unable to identify a manufacturer patient assistance program for a given medication, I investigate independent foundations that may be able to offer support to cover treatment costs. If there is available funding from a foundation, I complete the application for the patient and submit it for consideration.

The last task I do is help that patient apply for assistance through the Community Care program at Lake Region Healthcare. Through Community Care, patients may be eligible to have part or all their remaining balance written off based on their household size and income. If a patient owes any balance beyond that, I work with them to set up an affordable payment plan that works for them.

Patients with Other Government-Funded Programs (e.g., VA, DOD, TriCare)

Patients’ whose insurance is funded by the federal government but is not Medicare—Veterans Affairs (VA), Department of Defense (DOD), and TriCare, among others—usually receive their prescribed oncology medications for free. With every program, you must submit a prior authorization for each medication. Once the prior authorization is complete, insurance should cover the entire cost of the prescribed medication.

TriCare has the only exception. If patients covered by TriCare are out of range of a VA pharmacy to pick up their prescribed medications, they may have to pay a co-pay to have the prescriptions filled at another pharmacy.

Unfortunately, patients in this population are not usually eligible for financial assistance to cover the costs of their medications because their insurance should cover the entire cost. But patients with government-funded insurance may qualify for independent charitable foundations that can help with daily living expenses, like mortgage/rent payments, monthly bills, groceries, travel costs, and more.
Caring for the Caregiver

Financial navigators must practice self-care. Find time in your day or after work to be mindful and do what you need to do to decompress from your day. ACCC has developed some great resources to help you build resiliency and a self-care routine. Examples include the CANCER BUZZ podcast, “Fostering Cancer Care Team Resiliency & Well-Being” and the ACCCBuzz article, “Taking Care in a Pandemic”.

References


# Financial Navigation Flowchart

**STEP 1.** Provider prescribes anti-cancer treatment regimen for patient.

- **No Insurance**
  - Identify if patient qualifies for any state or federal program (i.e., Medicare, Medicaid, etc.). Complete and submit all forms for identified program.

- **Medicaid Program**
  - Verify benefits.

- **Medicare: Eligible (Age 65/Retired/Disabled)**
  - Verify benefits: does the patient have Part A only or Parts A and B?
  - Verify if patient is retiring soon; will their current benefits be retained?

- **Medicare: Part A and/or B Only (Age 65/Retired/Disabled)**
  - Verify benefits.

- **Medicare: Age 65 and retired with a Medicare Supplemental Plan**
  - Verify benefits.

- **Medicare: Advantage Plan (Age 65/Retired/Disabled)**
  - Verify benefits.

- **Other Government Programs (e.g., VA, DOD, TriCare)**
  - Verify benefits.

- **Commercial & Insurance Exchanges (Managed Care)**
  - Verify benefits.

**STEP 2.** Anti-cancer medication(s) order is sent to financial advocacy staff.

- **No Insurance**
  - If no program, identify if replacement medication(s) is available. Check with the pharmaceutical company to see if they have a free medication program or even a compassionate use program.

- **Medicaid Program**
  - Verify prescribed medication(s) are approved/indicated for diagnosis/place in therapy and submit pre-determination or prior authorization if necessary.

- **Medicare: Eligible (Age 65/Retired/Disabled)**
  - If patient is retiring soon and has Part A only, have they applied for Part B? Provide paperwork, if applicable.

- **Medicare: Part A and/or B Only (Age 65/Retired/Disabled)**
  - If patient will retain benefits, their plan may not require Medicare Part B. Check with patient if employer-funded plan requires Part B.

- **Medicare: Age 65 and retired with a Medicare Supplemental Plan**
  - If patient qualifies for Medicare or Medicare Secondary Payer plan. If so, help patient complete and submit applicable form(s).

- **Medicare: Advantage Plan (Age 65/Retired/Disabled)**
  - If not eligible, look at Medicare supplemental plan with a short waiting period (3 months max).

- **Other Government Programs (e.g., VA, DOD, TriCare)**
  - If changing back to Medicare, add a Part D plan and supplemental plan. If changing Advantage Plan, make sure you meet the criteria to change or are in open enrollment period.

- **Commercial & Insurance Exchanges (Managed Care)**
  - If patient has TriCare and is out of range of a Veterans Affairs pharmacy to pick up their prescription, then patients may have a co-pay.

**STEP 3.** Financial advocacy staff identify the patients’ financial status/insurance type(s) and follows the appropriate workflow below.

- **No Insurance**
  - If no program is identified in step 1, look for foundation funding available for any medication(s) not replaced.

- **Medicaid Program**
  - Identify patient’s responsibility for prescribed medication(s).

- **Medicare: Eligible (Age 65/Retired/Disabled)**
  - Go over insurance plan with patient; identify where they can save dollars (i.e., changing insurance, if applicable).

- **Medicare: Part A and/or B Only (Age 65/Retired/Disabled)**
  - Identify if patient is eligible for Medicaid or Medicare Secondary Payer plan. If so, help patient complete and submit applicable form(s).

- **Medicare: Age 65 and retired with a Medicare Supplemental Plan**
  - Go over insurance plan with patient; identify where they can save dollars (i.e., changing insurance, if applicable).

- **Medicare: Advantage Plan (Age 65/Retired/Disabled)**
  - If patient has TriCare and is out of range of a Veterans Affairs pharmacy to pick up their prescription, then patients may have a co-pay.

- **Other Government Programs (e.g., VA, DOD, TriCare)**
  - If patient qualifies for a program or reimburse medication program or even a compassionate use program.

- **Commercial & Insurance Exchanges (Managed Care)**
  - Identify if manufacturer assistance is available and complete and submit applicable form(s); may also be able to file for compassionate use with pharmaceutical company to receive medication(s).
ACCC gracefully thanks Wendy Andrews, practice administrator at University of Arizona Cancer Center, for creating this flowchart, and the ACCC Patient Assistance & Reimbursement Guide Task Force and ACCC Financial Advocacy Network members for their edits and updates.

<table>
<thead>
<tr>
<th>Complete and submit identified foundation program application form(s), if available.</th>
<th>If applicable, identify if patient qualifies for charity care within the cancer program/practice or healthcare system. Complete and submit this paperwork.</th>
<th>Establish a payment plan for any leftover balance (if available) or collect remaining balance.</th>
<th>Follow up with patient at regular intervals during treatment.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identify if replacement medication(s) is available, if necessary; may also be able to file for compassionate use with pharmaceutical company to receive medication(s).</td>
<td>Complete and submit identified program application form(s).</td>
<td>Collect out-of-pocket costs.</td>
<td>Follow up with patient at regular intervals during treatment.</td>
</tr>
<tr>
<td>Look at patient’s treatment plan and associated medication(s); find free-medication program or reimbursement plan, if available; may also be able to file for compassionate use with pharmaceutical company to receive medication(s).</td>
<td>Complete and submit identified program application form(s).</td>
<td>Establish a payment plan for any left over balance (if available) or collect the remaining balance.</td>
<td>Follow up with patient at regular intervals during treatment.</td>
</tr>
<tr>
<td>Look at Medicare Part D plans if patient does not already have this coverage.</td>
<td>Look at patient’s treatment plan and associated medication(s); find free-medication program or reimbursement plan, if available; may also be able to file for compassionate use with pharmaceutical company to receive medication(s).</td>
<td>Complete and submit identified program application form(s).</td>
<td>Establish a payment plan for any left over balance (if available) or collect the remaining balance.</td>
</tr>
<tr>
<td>If an insurance change is not available, identify if foundation assistance is available. May also be able to file for compassionate use with pharmaceutical company to receive medication(s).</td>
<td>Complete and submit identified program application form(s).</td>
<td>If any balance, establish a payment plan for any left over balance (if available) or collect remaining balance.</td>
<td>Follow up with patient at regular intervals during treatment.</td>
</tr>
<tr>
<td>Look at patient’s treatment plan and associated medication(s); find free-medication program or foundation, if available; may also be able to file for compassionate use with pharmaceutical company to receive medication(s).</td>
<td>Complete and submit identified program application form(s).</td>
<td>If any balance, establish a payment plan for any left over balance (if available) or collect remaining balance.</td>
<td>Follow up with patient at regular intervals during treatment.</td>
</tr>
<tr>
<td>Identify if free medication(s) is available, if necessary; complete and submit applicable form(s); may also be able to file for compassionate use with pharmaceutical company to receive medication(s).</td>
<td>Patients in this population are not usually eligible for financial assistance, including manufacturer assistance. To help offset costs, look for independent foundational assistance that can provide assistance with groceries, mortgage/rent payments, vehicle payments, monthly bills, etc.</td>
<td>Complete and submit identified independent foundation program application form(s).</td>
<td>If any balance, establish a payment plan for any left over balance (if available) or collect remaining balance.</td>
</tr>
<tr>
<td>If no manufacturer assistance is available, identify if foundation assistance is available.</td>
<td>Complete and submit identified program application form(s).</td>
<td>If patient qualifies for manufacturer or foundation assistance, send an explanation of benefits (EOB) and/or other paperwork to verify amount owed.</td>
<td>Process payment using the co-pay card or other form of payment the identified program offers.</td>
</tr>
</tbody>
</table>

Follow up with patient at regular intervals during treatment.

Follow up with patient at regular intervals during treatment.

Follow up with patient at regular intervals during treatment.

Follow up with patient at regular intervals during treatment.

Follow up with patient at regular intervals during treatment.

Follow up with patient at regular intervals during treatment.
Supporting Patients Through Their Journey on Jakafi® (ruxolitinib)

IncyteCARES (Connecting to Access, Reimbursement, Education and Support) provides a single point of contact through a registered nurse, OCN®, to assist eligible patients and healthcare providers in obtaining access to Jakafi® (ruxolitinib) and to connect them with continuing support and resources. The program offers:

**REIMBURSEMENT SUPPORT**
- Insurance benefit verification
- Information about prior authorizations
- Guidance with appealing insurance denials or coverage restrictions

**ACCESS ASSISTANCE**
- Copay/Coinsurance assistance
- Free medication program
- Temporary access for insurance coverage delays
- Referrals to independent nonprofit organizations and foundations

**EDUCATION & SUPPORT**
- Access to a registered nurse, OCN®
- Educational information for your patients about their condition and Jakafi
- Patient Welcome Kit

**CONNECTION TO SUPPORT SERVICES**
- Referrals for transportation assistance
- Access to patient advocacy organizations for counseling and emotional support resources

Connect with IncyteCARES
For full program terms and eligibility, visit IncyteCARES.com or call 1-855-4-Jakafi (1-855-452-5234).

Jakafi is a registered trademark of Incyte Corporation.
©2016, Incyte Corporation. All rights reserved. RUX-1887 08/16
**PATIENT ASSISTANCE**

**myAbbVie Assist Patient Assistance**

MyAbbVie Assist believes that people who need AbbVie medicines should be able to get them. MyAbbVie Assist provides free medicines to qualifying patients. Patients may be eligible to receive free Lupron Depot if they:

- Have been prescribed Lupron Depot
- Have limited or no health insurance coverage
- Live in the United States
- Are being treated by a licensed U.S. healthcare provider on an outpatient basis.

If patients have insurance, the program will review their qualifying financial need based on a combination of insurance coverage, household income, and out-of-pocket medical expenses.

If patients would like to apply, they should work with their healthcare provider to submit a program application. Download the application [here](https://www.abbvie.com/patients/patient-assistance/program-qualification/lupron-depot-program-selection.html), follow the instructions on the first page, and submit all requested information via fax to 1.866.483.1305.

Upon review of a completed application, the program will notify the prescriber and patient about eligibility. If approved, it will ship the medication to the prescriber’s office. Call 1.800.222.6885 to request refills. This program is part of the AbbVie Patient Assistance Foundation, a separate legal entity from AbbVie. Contact myAbbVie Assist at 1.800.222.6885, Monday through Friday, for additional assistance.

**REIMBURSEMENT ASSISTANCE**

**Lupron Depot Support Plus**

With Support Plus, providers will receive:

- Patient benefit investigations
- Precertification and prior authorization management
- Reimbursement support
- Claims appeal assistance.

Whether it’s Medicare Advantage or private insurance, Lupron Depot Support Plus supports providers and their office by helping to manage the procurement process. Contact your AbbVie sales representative to learn more about how to access the Support Plus Program or call 1.800.621.1020.
PATIENT ASSISTANCE

Advancing Patient Support
Dedicated case managers can serve as a single point of contact and are there every step of the way—to help patients get started and stay on Zynlonta.

To enroll patients, complete and submit the enrollment form online (portal.trialcard.com/adchub/) or download the form (advancingpatientsupport.com/hcp/) and submit it via fax to 1.855.915.3005 or via email to support@advancingpatientsupport.com. Once enrolled, patients will receive a welcome call from the program.

For any questions, call 1.855.690.0340, Monday through Friday, 8:00 AM to 8:00 PM EST.

Commercial Co-Pay Program
If eligible, commercially insured patients can be enrolled in the co-pay program. They may pay as little as $0 per dose. The maximum co-pay assistance program benefit per patient, per calendar year, is $25,000. Enrolled patients are responsible for all co-pays and any other balances not covered by the program.

To enroll patients, complete and submit the enrollment form online (portal.trialcard.com/adchub/) or download the form (advancingpatientsupport.com/hcp/) and submit it via fax to 1.855.915.3005 or via email to support@advancingpatientsupport.com. Once enrolled, patients will receive a welcome call from the program.

For any questions, call 1.855.690.0340, Monday through Friday, 8:00 AM to 8:00 PM EST.

Patient Assistance Program
Patients who are uninsured or underinsured could receive Zynlonta for free if they meet the criteria for the patient assistance program. For more information on eligibility, call 1.855.690.0340, Monday through Friday, 8:00 AM to 8:00 PM EST.

REIMBURSEMENT ASSISTANCE

Advancing Patient Support
Advancing Patient Support offers the following services to help patients and healthcare providers:

Benefits investigation:
A summary of benefits will be provided to help healthcare providers and their patients better understand their insurance coverage and out-of-pocket costs.

Prior authorization/precertification:
The program can help determine if a prior authorization or precertification is needed for patients and can provide guidance and support throughout the process.

Appeals/claims support:
The program provides guidance on coding and billing, the appeals process, and can help answer any questions that may arise.

To enroll patients, complete and submit the enrollment form online (portal.trialcard.com/adchub/) or download the form (advancingpatientsupport.com/hcp/) and submit it via fax to 1.855.915.3005 or via email to support@advancingpatientsupport.com. Once enrolled, patients will receive a welcome call from the program.

For any questions, call 1.855.690.0340, Monday through Friday, 8:00 AM to 8:00 PM EST.
Amgen, Inc.

Oncology-related products: Aranesp® (darbepoetin alfa) injection, Blincyto® (blinatumomab) for injection, Imlugic® (talimogene laherparepvec) suspension for injection, Kanjinti™ (trastuzumab-anns) for injection, Kypolis® (carfilzomib) for injection, Lumakras™ (sotorasib) tablets, Mvasi™ (bevacizumab-awwb) injection, Neulasta® (pegfilgrastim) injection, Neulasta® Onpro® (pegfilgrastim) injection kit, Neupogen® (filgrastim) injection, Nplate® (romiplostim) injection, Prolia® (denosumab) injection, Riabni™ (rituximab-arrx) injection, Sensipar® (cinacalcet) tablets, Vectibix® (panitumumab) for injection, Xgeva® (denosumab) injection

Patient and Reimbursement Assistance Websites
amgenassist360.com
amgenfirststep.com

PATIENT ASSISTANCE

Amgen Assist 360™
Amgen Assist 360 is a single place for patients, caregivers, and healthcare professionals to go to find the support, tools, and resources most important to them. Patients are connected with an Amgen nurse navigator, who serves as a single point of contact and who can help patients find resources that are most important to them. Nurse navigators are only available to patients that are prescribed certain products. Nurse navigators are there to support, not replace, patients’ treatment plan and do not provide medical advice, nursing, or case management services. Amgen 360 can:
• Connect healthcare professionals to a reimbursement counselor or schedule a visit with a field reimbursement specialist.
• Find financial support options for any insurance type.
• If patients have questions about their Amgen medication, Amgen Assist 360 can help them get the answers they need.

For more information and enrollment forms by medication name, visit https://www.amgenassist360.com/hcp/ or call 1.888.4ASSIST (1.888.427.7478), Monday through Friday, 9:00 AM to 8:00 PM EST.

Amgen FIRST STEP™ Program
Amgen offers this program to help eligible commercially insured patients pay for their out-of-pocket prescription costs, including deductible, coinsurance, and co-payment.

Patient eligibility requirements:
• Patients must be prescribed one or more qualifying Amgen products.
• Patients must have private commercial health insurance that covers medication costs for the qualifying Amgen product(s).
• Patients must not be a participant in any federal, state, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs, the Department of Defense, or TriCare.
• Patients may not seek reimbursement for value received from the Amgen First Step Program from any third-party payers, including flexible spending accounts or healthcare savings accounts.

Other restrictions may apply. Amgen reserves the right to revise or terminate this program, in whole or in part, without notice at any time.

Program covers out-of-pocket medication costs for the qualifying Amgen product(s) only. Program does not cover any other costs related to office visit or administration of the Amgen product. Patient is responsible for costs above the maximum benefit. Call 1.888.427.7478 to ask a First Step representative to help you
understand the relevant maximum program benefit(s), which reset each calendar year.

To confirm patient eligibility and enroll in the program, visit amgenfirststep.com/register-card or call 1.888.427.7478, Monday through Friday, 9:00 AM to 8:00 PM EST.

**Independent Nonprofit Programs**

For patients with government insurance, like Medicare, Amgen Assist 360 can refer patients to independent nonprofit patient assistance programs that may be able to help them afford the co-pay costs for their prescribed medicine(s). For help, call 1.888.4ASSIT (1.888.427.7478).

**Amgen Safety Net Foundation**

Amgen Safety Net Foundation (https://www.amgensafetynetfoundation.com/) is a nonprofit patient assistance program sponsored by Amgen that helps qualifying patients access Amgen medicines at no cost or more qualifying Amgen products. Patient may be able to receive Amgen medications at no cost if they meet the following eligibility requirements:

- Have lived in the United States or its territories for six months or longer
- Satisfy income eligibility requirements
- Are uninsured or their insurance plan excludes the Amgen medicine or its generic/biosimilar.

Certain Medicare Part D patients with product coverage who cannot afford their out-of-pocket costs may be eligible. It is required that they are able to demonstrate:

- Inability to afford the medicine
- Ineligibility for Medicaid or Medicare’s low-income subsidy (Extra Help)

- Have satisfied all payer guidelines and prior authorization requirements prior to applying for assistance
- Do not have any other financial support options.

To apply, visit amgensafetynetfoundation.com/how-to-apply.html, select the appropriate medication, fill out and sign the Patient Application, and fax the completed application to 1.866.549.7239.

Once a completed application and any requested supporting documents have been received and processed, the patient and provider will be notified of the enrollment decision. Eligible patients are enrolled for a period up to 12 months. To re-enroll in Amgen Safety Net Foundation, patients must submit a new application.

For questions, call 1.888.762.6436, Monday through Friday, 8:00 AM to 8:00 PM EST.

**REIMBURSEMENT ASSISTANCE**

**Amgen Assist 360™**

Amgen reimbursement counselors can assist with submitting, storing, and retrieving benefit verifications for anyone currently on an Amgen product. Connect with an Amgen reimbursement counselor on the phone (1.888.427.7478) or schedule a visit with an Amgen field reimbursement specialist. Visit amgenassist360.com/hcp/patient-support/amgen-access-specialist for more information.

Visit the benefit verification center for tools, information, and support. To begin, choose the applicable Amgen product at www.amgenassistonline.com.

For more information, call 1.888.4ASSIT (1.888.427.7478), Monday through Friday, 9:00 AM to 8:00 PM EST.
PATIENT ASSISTANCE

Astellas Pharma Support Solutions℠

Astellas Pharma Support Solutions offers access and reimbursement support to help patients overcome challenges to accessing Astellas products. To enroll in Padcev, Xospata, or Xtandi Support Solutions, visit astellaspharmasupportsolutions.com, select the appropriate medication, and follow the patient enrollment process.

Astellas Patient Assistance Program

The Astellas Patient Assistance Program provides Xtandi or Xospata at no cost to patients who meet the program eligibility requirements. The patient may be eligible if they meet the following criteria:

- Patient is uninsured or has insurance that excludes coverage for Xtandi or Xospata.
- Patient has a verifiable shipping address in the United States.
- Patient has been prescribed Xtandi or Xospata for an FDA-approved indication.
- Patient meets program financial eligibility requirements.

To enroll a patient in the Astellas Patient Assistance Program, complete the Xtandi or Xospata Support Solutions enrollment process, including the program application submitted through the medication-specific prescriber portal or faxed to the number on the form. If the patient is eligible, the patient and provider will be notified, and the prescription will be shipped directly to the patient’s home.

Xospata Support Solutions℠

Xospata Support Solutions (astellaspharmasupportsolutions.com/products/xospata/index.aspx) offers access and reimbursement support to help patients access Xospata. It provides information regarding patient healthcare coverage options and financial assistance information that may be available to help patients with financial needs. To speak with a dedicated access specialist, call 1.844.632.9272, Monday through Friday, 8:30 AM to 8:00 PM EST.

Xospata Quick Start+℠ Program

The Xospata Quick Start+ Program provides a one-time, seven-day supply of Xospata at no cost to eligible patients who experience an insurance-related delay. Overnight shipping is offered directly to the patient. To be eligible, patients must:

- Have prescription drug insurance
- Be new to Xospata therapy
- Have been prescribed Xospata for an FDA-approved indication
- Have experienced an insurance-related access delay.

To enroll, fill out the appropriate section during the Xospata Support Solutions patient enrollment process (https://astellaspharmasupportsolutions.com/products/xospata/patient_enrollment_process.aspx).

Xospata Patient Savings Program

The Xospata Patient Savings Program is for eligible patients who have commercial prescription insurance. The Program parameters are as follows:

- Patients pay as little as $0 per prescription
- A patient will be enrolled in the program for a 12-month period
- There are no income requirements.

The program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program, including, but not limited to Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TriCare, Puerto Rico government insurance, or any state patient or pharmaceu-
Healthcare providers can begin the enrollment process on behalf of their patients at https://www.activateorthecard.com/xospatasavings/. Providers should let patients know they will receive an email to attest to the program’s terms and conditions. Patients will then receive additional communications via email to confirm program enrollment and provide instructions for use. For more information or help enrolling, call 1.855.221.3493.

**Xtandi Support Solutions**

Xtandi Support Solutions (astellaspharmasupportsolutions.com/products/xtandi/index.aspx) offers access and reimbursement support to help patients overcome challenges to accessing Xtandi. It provides information regarding patient healthcare coverage options and financial assistance options that may be available to help patients with financial needs. To speak with a dedicated access specialist, call 1.855.8XTANDI (1.855.898.2634), Monday through Friday, 8:00 AM to 8:00 PM EST.

**Xtandi Quick Start+ Program**

The Xtandi Quick Start+ Program provides a one-time, 14-day supply of Xtandi at no cost to new, eligible patients who experience a delay in insurance coverage. Overnight shipping is offered directly to the patient. Patient eligibility for the program includes:
- Have prescription drug insurance
- Be new to Xtandi therapy
- Have experienced an insurance-related access delay
- Have been prescribed Xtandi for an FDA-approved indication.

To enroll, fill out the appropriate section during the Xtandi Support Solutions patient enrollment process (https://astellaspharmasupportsolutions.com/products/xtandi/patient_enrollment_process.aspx).

**Xtandi Patient Savings Program**

The Xtandi Patient Savings Program is for eligible patients who have commercial prescription insurance. The program parameters are as follows:
- Patients can pay as little as $0 per prescription
- Patients will be enrolled in the program for a 12-month period
- There are no income requirements.

The program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program, including, but not limited to, Medicaid, Medicare, Medigap, Department of Defense, Veterans Affairs, TriCare, Puerto Rico government insurance, or any state patient or pharmaceutical assistance program. Healthcare providers can begin the enrollment process on behalf of their patients at https://www.activateorthecard.com/xtandi savings/. Providers should let patients know they will receive an email to attest to the program’s terms and conditions. Patients will then receive additional communications via email to confirm program enrollment and provide instructions for use. For more information or help enrolling, call 1.855.217.8311.

**PADCEV Co-Pay Assistance Program**

The PADCEV Co-Pay Assistance Program is for eligible patients who have private commercial health insurance and are not insured by any federal or state healthcare program, including, but not limited to, Medicare, Medicaid, TriCare, or Veterans Affairs (VA). Under this program:
- Patients pay as little as $5 per dose
- A patient will be enrolled in the program for a 12-month period
- Patients may save up to a maximum of $25,000 per calendar year
- There are no income requirements.

This offer is not valid for cash-paying patients. PADCEV Support Solutions can evaluate eligibility and enroll patients in the PADCEV Co-pay Assistance Program. For more information, contact PADCEV Support Solutions at 1.888.402.0627.

**PADCEV Patient Assistance Program**

The PADCEV Patient Assistance Program provides PADCEV at no cost to uninsured patients who meet the program eligibility requirements. PADCEV Support Solutions will evaluate a patient’s eligibility for the program. Patients may be eligible if they:
- Do not have insurance or have insurance that excludes coverage for PADCEV
- Have a verifiable shipping address in the United States
- Have been prescribed PADCEV for an FDA-approved indication
• Meet the program financial eligibility requirements.

To enroll, complete the program enrollment form (https://padcev.aspnpromgrams.com/Resources.aspx), including all signatures, and either upload it through the prescriber portal (padcev.aspnpromgrams.com/) or fax it to 1.877.747.6843. If the patient is eligible for the program, Padcev Support Solutions will notify the provider and the patient.

REIMBURSEMENT ASSISTANCE

Astellas Pharma Support Solutions

Benefits Verification
Astellas Pharma Support Solutions offers benefits verification assistance to evaluate a patient’s insurance coverage for Xtandi, Xospata, or Padcev. After performing a benefits verification, a summary of benefits will be provided that includes:
• The patient’s insurance coverage for the specific medication
• Requirements for prior authorization, step edit, or other coverage restrictions, if any
• Cost-sharing responsibility, including the deductible, coinsurance or co-payment, and out-of-pocket maximums
• A list of specialty pharmacies that participate in the patient’s insurance plan for the specific medication, if applicable.

Astellas Pharma Support Solutions will initiate the benefits verification upon receipt of the specific medication’s patient enrollment form. Once it is complete, a summary of benefits will be sent.

Prior Authorization
Astellas Pharma Support Solutions can provide prior authorization (PA) assistance when a patient’s insurer requires PA approval. After determining that a PA is required, the program will obtain the appropriate PA form and transfer basic patient and healthcare provider information to the required PA form. It will then be sent to the healthcare provider to review, complete, and sign. Astellas Pharma Support Solutions will follow up with the insurer to confirm receipt, check status, and obtain the outcome.

Denial Appeals
If the patient’s insurer denies a prior authorization request, Astellas Pharma Support Solutions can assist the healthcare provider with an appeal for a denied prior authorization request. Astellas Pharma Support Solutions will determine if any additional documentation is required by the patient’s insurer, inform the healthcare provider of what information is needed and where to send the appeal, and track and inform the healthcare provider of the appeal’s status.

For more information, visit https://astellaspharmasupportsolutions.com/ and select the prescribed medication to find contact the medication-specific contact information.
Oncology-related products: Calquence® (acalabrutinib) capsules, Faslodex® (fulvestrant) injection, Imfinzi® (durvalumab) injection for intravenous use, Iressa® (gefitinib) tablets, Lynparza® (olaparib) tablets, Tagrisso® (osimertinib) tablets

PATIENT ASSISTANCE

AstraZeneca Patient Savings Programs
The goal of the AstraZeneca Patient Savings Programs is to assist eligible patients with their out-of-pocket costs. Most eligible patients will pay $0 per month and may have access to up to a maximum limit per year, depending on the specific medication. There are no income requirements to participate in these programs.

Patients are ineligible if prescriptions are paid by any state or other federally funded programs, including, but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), or TriCare, or where prohibited by law. Eligibility rules apply. Offer is invalid for claims and transactions more than 120 days from the date of service.

How the Programs Work:
1. Patients may have an out-of-pocket cost for an AstraZeneca specialty product.
2. If patients meet the eligibility requirements, healthcare professionals can enroll patients into the Patient Savings Program via the online enrollment portal. The links to the portal for each product can be found at: astraZenecaspecialtysavings.com.
3. A Patient Savings Program account will be created for the eligible patient. Once enrolled, patient-specific account information will be presented in the portal for immediate use.
4. The patient will pay a set amount of their out-of-pocket costs, based on the product. The pharmacy or provider will use the Patient Savings Program to cover the balance, up to the program maximum.

For more information about eligibility and details on these programs, visit astraZenecaspecialtysavings.com or call AstraZeneca Access 360 at 1.844.ASK.A360 (1.844.275.2360), Monday through Friday, 8:00 AM to 8:00 PM EST.

AstraZeneca Access 360™
The AstraZeneca Access 360 program provides personal support to help streamline access and reimbursement for select AstraZeneca medicines. Access 360 provides:
• Pharmacy coordination
• Reimbursement support
• Patient affordability.

To learn more about the AstraZeneca Access 360 program, call 1.844.ASK.A360 (1.844.275.2360), Monday through Friday, 8:00 AM to 8:00 PM EST or visit www.MyAccess360.com.

The AZ&Me™ Prescription Savings Program
The AZ&Me Prescription Savings Program is designed to help qualifying patients without insurance and those in Medicare who are still having trouble affording their AstraZeneca medications. There are two programs:
• AZ&Me Prescription Savings program for people without insurance.
• AZ&Me Prescription Savings program for people with Medicare.

There is a shared application process for the AZ&Me Prescription Savings Program for people without insurance and the AZ&Me Prescription Savings Program for people with Medicare, and the same application is used for both programs. To apply for the program, patients and providers may either call 1.800.AZandMe (1.800.292.6363) or visit azandmeapp.com to begin.
the enrollment process online. For an updated list of the medications available through the AZ&Me Prescription Savings Program, please visit the eligibility page (www.azandmeapp.com/eligibility.html#hcp).

Eligibility Requirements:
- Patient must be a resident of the United States.
- Patient must not be currently receiving prescription drug coverage under a private insurance or government program (excluding Medicare), or receiving any other assistance to help pay for medicine.
- Patient’s annual income must be at or below a certain level.

If the patient is a Medicare Beneficiary, they must not be eligible for or enrolled in Low Income Subsidy (LIS) for Medicare Part D.

The following items must be submitted in order to complete the patient application:
- A completed application, signed and dated by the patient and prescriber.
- A completed prescription on page three of the application.

Please note that faxed applications must be sent from a provider’s office in order for the prescription to be processed.

For more information, please visit azandmeapp.com or call 1.800.AZandME (1.800.292.6363).

Independent Patient Assistance Foundations
Assistance may be available through independent foundations such as those listed on the Access 360 website (https://www.myaccess360.com/irressa-gefitinib/patient-affordability.html#). Foundations can provide a variety of assistance types, like co-pay, transportation, premium, patient education, etc.

REIMBURSEMENT ASSISTANCE

AstraZeneca Access 360™
Access 360 can assist providers and patients with:
- Benefit investigation
- Prior authorization support
- Claims and appeal process support.

For more information, call 1.844.ASK.A360 (1.844.275.2360), Monday through Friday, 8:00 AM to 8:00 PM EST or visit myaccess360.com.
**Bayer HealthCare Pharmaceuticals, Inc.**

Oncology-related products: Aliqopa™ (copanlisib) for injection, Nexavar® (sorafenib) tablets, Nubeqa® (darolutamide) tablets, Stivarga® (regorafenib) tablets, VitraKi® (larotrectinib), Xofigo® (radium Ra 223 dichloride) injection

**Patient and Reimbursement Assistance Websites**
- nubeqa-us.com
- xfigohcp.com/access/overview-and-availability
- zerocopaysupport.com
- aliqopa-us.com/access-and-reimbursement/arc-program/
- hcp.vitrakvi-us.com/access/
- hcp.nexavar-us.com/Resources/REACH-Financial-Support/

**PATIENT ASSISTANCE**

**Xofigo Access Services**
Xofigo Access Services provides a variety of services to support access to Xofigo.

**Xofigo Patient Assistance Program**
Xofigo Access Services may provide Xofigo free of charge to eligible patients who are uninsured or who are insured but do not have coverage for Xofigo. Eligibility criteria include:
- Financial criteria based on adjusted gross household income (documentation of income is required)
- Residency in the United States, including the District of Columbia, Puerto Rico, Guam, or the U.S. Virgin Islands.

To enroll, complete the Patient Support Request Form (https://www.xfigohcp.com/access/patient-financial-assistance), including the signed patient authorization, and fax it to 1.855.963.4463. Registered providers can also submit an application for patient assistance via the secure Xofigo Access Services Provider Portal at xfigoaccessonline.com/.

For more information, call 1.855.6XOFIGO (1.855.696.3446), Monday through Friday, 9:00 AM to 7:00 PM EST.

**$0 Commercial Co-pay Assistance Program**
Patients may be eligible for co-payment/coinsurance assistance if they have a private commercial plan that covers Xofigo. Patients approved for assistance will not have to pay anything to access Xofigo. If patients have public insurance (e.g., Medicare or other government payors, such as the Department of Veterans Affairs and Department of Defense), patients are not eligible. Eligibility criteria include:
- Patient has private commercial insurance.
- Patient resides in the United States, including the District of Columbia, Puerto Rico, Guam, or the U.S. Virgin Islands.

To apply, fax a completed Patient Support Request Form (https://www.xfigohcp.com/access/xofigo-cost), including the signed patient authorization, to Xofigo Access Services at 1.855.963.4463. Once approved, patients will receive an approval letter with a commercial co-pay/coinsurance identification (ID) card.

**Independent Co-Pay/Coinsurance Assistance Foundations**
If patients need assistance with cost-share requirements for Xofigo, they may be eligible for co-pay or coinsurance assistance through an independent co-pay/coinsurance assistance foundation. If co-pay assistance needs are identified,
an access counselor can provide information about any available foundation. The foundations determine patients’ eligibility for co-pay or coinsurance assistance based on their own criteria. Contact the program at 1.855.696.3446 for more information.

**Access Services by Bayer™**
Access Services by Bayer is a free support program available to eligible patients who have been prescribed Nexavar, Nubeqa, Stivarga, or Vitrakvi. The program provides patients with information about their therapy, helps them evaluate their financial assistance options, and offers education and support to healthcare professionals. Access Services by Bayer service counselors can provide:

- Reimbursement assistance
- Alternate coverage research for the uninsured or underinsured
- $0 Co-Pay program assistance for eligible, commercially insured patients
- Referrals to charitable foundations that may be able to help patients with government-sponsored insurance (such as Medicare, Medigap, Medicaid, VA/DoD health plans, and TriCare) with out-of-pocket costs
- Referrals to the Bayer U.S. Patient Assistance Foundation.

For more information, call 1.800.288.8374 or visit the prescribed medication’s website.

**Oncology $0 Co-Pay Program**
For eligible, commercially insured patients prescribed Nexavar or Stivarga, the zero dollar co-pay program allows patients to fill their prescription with no out-of-pocket costs. Patients can receive up to $25,000 in savings with no monthly maximum. To be eligible patients must:

- Be a United States resident
- Be over 18-years-old
- Currently have commercial health insurance for a portion of their prescription drug cost
- Not be enrolled in any federal or state subsidized healthcare program that covers a portion of their prescription drug costs, including Medicare (such as Medicare Part D prescription drug benefit), Medicaid, TriCare, or any other federal or state healthcare plan, including pharmaceutical assistance programs.

Enroll online at zeroCopaySupport.com by clicking on the specific medication. For questions about the co-pay program, call 1.866.581.4992.

**Vitrakvi $0 Co-Pay Program**
Eligible, commercially insured patients may have no co-pay for Vitrakvi, subject to a max amount of $25,000 per year, per patient. The program is for commercially insured patients using Vitrakvi for an approved FDA indication, and it does not cover costs for changes associated with administering Vitrakvi® or patient visits. Offer is valid only for patients treated in the United States, including Puerto Rico, Guam, and U.S. territories. Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible.

Enroll patients into the program by completing the Bayer Patient Support Request Form (https://hcp.vitrakvi-us.com/support-and-resources/access) and fax it to 1.800.390.1826. For questions about the program, call 1.647.245.5637.

**Nubeqa $0 Co-Pay Program**
Eligible patients may pay as little as $0 and save up to $25,000 per year. Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. Annual auto-enrollment that helps avoid gaps in therapy. No income requirements.

Apply online at: https://www.nubeqacopayprogram.com/. For questions or to enroll over the phone, call 1.800.288.8374.

**Nubeqa Free Trial Program**
The Nubeqa free trial program provides a one-month supply of Nubeqa at no cost to patients who meet the program eligibility requirements and agree to the terms and conditions. To be eligible, patients must reside in the United States or Puerto Rico and be a new patient not currently using Nubeqa or who previously received Nubeqa through the free trial program. For more information please call, 1.800.288.8374.

**Independent Charitable Organizations**
Access Services by Bayer may be able to help patients with government-sponsored insurance (such as Medicare, Medigap, Medicaid, VA/DoD health plans, and TriCare) with out-of-pocket costs. Patient Access Specialists can verify your coverage for the prescribed Bayer product and provide information about any available foundations.

**Bayer U.S. Patient Assistance Foundation**
The Bayer U.S. Patient Assistance Foundation (https://www.patientassistance.bayer.us/en/) is a charitable organization that helps eligible patients get Bayer prescription medicine at no cost. To be eligible for the Bayer U.S. Patient Assistance Foundation free drug program, patients must:
• Live in the United States or Puerto Rico
• Meet certain income limits
• Not have insurance, or have coverage for their Bayer prescription medication.

To apply, complete the enrollment form (https://www.patientassistance.bayer.us/en/resources) and fax it to 1.866.575.6568. Contact the program at 1.866.228.7723, Monday through Friday, 9:00 AM to 6:00 PM EST.

Aliqopa Resource Connections
The ARC patient support program offers comprehensive access, reimbursement support, and patient assistance services, including:
• The Bayer U.S. Patient Assistance Foundation for qualified uninsured or underinsured patients. Bayer U.S. Patient Assistance Foundation is a charitable organization that helps eligible patients get Bayer prescription medicine at no cost.
• The Temporary Patient Assistance Program for patients whose coverage is delayed or who experience a temporary lapse in coverage for Aliqopa.
• The Aliqopa $0 Co-Pay Program for eligible patients with commercial insurance. Patients must not be enrolled in a government-sponsored program and must meet certain other eligibility criteria to qualify for this program. If approved, the patient may pay as little as $0, with a maximum benefit of $25,000 per year.
• Referrals to independent assistance foundations for publicly insured patients and those requiring travel assistance.

To enroll in the ARC Program, fax the completed enrollment form (https://www.hcp.aliqopa-us.com/access-and-reimbursement/arc-program/) to 833.427.2329. For more information, call 833.ALIQOPA (833.254.7672), Monday through Friday, 9:00 AM to 7:00 PM EST.

REIMBURSEMENT ASSISTANCE

Xofigo Access Services
Xofigo Access Services assists healthcare professionals with:
• Insurance benefits verifications
• Billing and coding guidance.

To access these services, call 1.855.6XOFIGO (1.855.696.3446) 9:00 AM to 7:00 PM EST, Monday through Friday. You can also access these services online 24/7 through the Xofigo Access Services Provider Portal (www.xofigoaccessonline.com/).

Access Services by Bayer™
Call an Access Services by Bayer financial counselor for benefit verification and prior authorization, denial, and appeal information at 1.800.288.8374.

Visit the prescribed medication’s website for more information.

Aliqopa Resource Connections
The ARC patient support program offers comprehensive access, reimbursement support, and patient assistance services, including:
• Insurance benefit verifications
• Prior authorization information (physician office must submit prior authorization)
• Claims appeal information
• Claims status
• Billing and coding information
• Payer policy information.

For more information, call 833.ALIQOPA (833.254.7672), Monday through Friday, 9:00 AM to 7:00 PM EST or visit https://www.hcp.aliqopa-us.com/access-and-reimbursement/arc-program/.
BeiGene

Oncology-related product: Brukinsa™ (zanubrutinib) capsules

Patient and Reimbursement Assistance Website
brukinsa.com/patient-support

PATIENT ASSISTANCE

myBeiGene®
The myBeiGene program is a comprehensive patient support program designed to provide appropriate information and assistance to patients. MyBeiGene program services, include:

• Assisting with insurance verification and prior authorization support
• Co-pay as little as $0/prescription for commercially insured patients
• Bridge supply for insurance coverage delays
• Free product for uninsured and underinsured patients (Certain financial and eligibility criteria apply)
• Education and support
• Connections to third-party advocacy organizations.

Complete the online form (www.brukinsa.com/hcp/mybeigene-patient-enrollment) to enroll in myBeiGene or fax the completed Patient Enrollment Form (brukinsa.com/enrollment-form.pdf) to 1.877.828.5593.

Oncology nurse advocates are available Monday through Friday from 8:00 AM to 8:00 PM EST at 1.833.BeiGene (1.833.234.4363) to provide information and answer any questions regarding the myBeiGene patient support program.

Co-Pay Assistance
Eligible, commercially insured patients may have a co-pay as little as $0 per prescription. There is no patient income requirement. The program is subject to an annual benefit limit of $25,000. Patients are ineligible if prescriptions are payable by any state or federally funded programs, including, but not limited to, Medicare, Medicaid, Veterans Affairs (VA), or Tricare, or where prohibited by law. Eligibility criteria and restrictions apply.

Bridge Supply
Eligible patients may receive a 30-day supply of medication (for on-label use only) in cases of a coverage delay lasting longer than five days. Eligibility criteria and restrictions apply.

For more information and questions, call 1.833.BeiGene (1.833.234.4363), Monday through Friday, 8:00 AM to 8:00 PM EST.

REIMBURSEMENT ASSISTANCE

myBeiGene®
The myBeiGene program is a comprehensive patient support program designed to provide appropriate information and assistance to patients, including assistance with:

• Insurance verification
• Prior authorization support.

For more information, call 1.833.BeiGene (1.833.234.4363), Monday through Friday, 8:00 AM to 8:00 PM EST.
Oncology-related product: Abecma™ (idecabtagene vicleucel) suspension for IV infusion

Patient and Reimbursement Assistance Website
abecmahcp.com/abecma-support/

PATIENT ASSISTANCE

Cell Therapy 360®
Bristol Myers Squibb’s Cell Therapy 360 program supports patients and caregivers throughout their treatment journey, from enrollment through the initial post-infusion monitoring period, with referral resources, patient support navigators, logistical support, financial support, and wearable technology for post-infusion monitoring. Eligibility requirements may apply.

For healthcare providers at certified treatment centers, the program enrollment form can be received by contacting a dedicated cell therapy account manager, calling 1.888.805.4555, or accessing the Cell Therapy 360 Scheduling Portal at: celltherapy360.com/enroll-for-support/. For physical copies of the enrollment form, submit it, along with copies of the front and back of the patient’s insurance card, via fax to 1.866.588.6829.

Co-Pay Assistance
Through the co-pay program, Cell Therapy 360 will cover up to $10,000 of out-of-pocket costs for Abecma. It covers expenses for Abecma only.

Patients must be commercially or privately insured. The program is not available for patients who are enrolled in Medicare, Medicaid, TriCare, the Veterans Affairs (VA), or any other federal or state healthcare program. The program does not cover the costs of any other healthcare provider charges or any other treatment costs. Patients are responsible for non-drug-related out-of-pocket costs. Bristol Myers Squibb reserves the right to rescind, revoke, or amend this program without notice. Additional eligibility requirements may apply.

REIMBURSEMENT ASSISTANCE

Cell Therapy 360®
Cell Therapy 360 offers access confirmation, including benefit verification, prior authorization, and/or single case agreement (if required). Call 1.888.805.4555 for 24/7 on-call assistance.

Cell Therapy 360 Patient Assistance Program
Patients may be eligible for the Cell Therapy 360 patient assistance program if they are uninsured or have insurance that excludes coverage for Abecma and have financial need. Eligible patients must have a household income of no more than 600 percent of the federal poverty level. Additional eligibility requirements may apply.
**Oncology-related product:** Ayvakit™ (avapritinib) tablets

**Patient and Reimbursement Assistance Website**

*yourblueprint.com/hcp/

---

**PATIENT ASSISTANCE**

**YourBlueprint™**

YourBlueprint facilitates access and reimbursement, including:

- Comprehensive benefits verification
- Assistance with prior authorization, appeals, and formulary exceptions
- Connecting patients with financial assistance options
- Access to temporary treatment programs for patients who have a delay or lapse in insurance coverage.

To enroll, complete the enrollment form online (https://yourblueprint.com/hcp/) or in writing. Downloadable enrollment forms should be submitted to YourBlueprint via fax to 1.866.370.3082 or email to info@yourblueprint.com. Once the completed enrollment form is submitted, the patient’s case manager will contact the healthcare professional by phone to confirm enrollment and discuss next steps based on the services requested.

To speak with a dedicated case manager, call 1.888.BLUPRNT (1.888.258.7768), Monday through Friday, 8:00 AM to 8:00 PM EST.

**Co-Pay Assistance Program**

This program helps eligible, commercially insured patients reduce their out-of-pocket costs (co-pay, coinsurance, or deductible) to as little as $0 per month. Patients must have commercial insurance with coverage for their prescription. Uninsured or cash paying patients are not eligible. Electronic enrollment is required. Offer is not available to patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, such as patients enrolled in Medicare Part D and patients whose prescription is paid for by Medicare, Medicaid, Medigap, CHAMPUS, Department of Defense (DoD), TriCare, Veterans Affairs (VA), Children’s Health Insurance Program (CHIP), the Indian Health Service, or a state pharmaceutical assistance program. Blueprint Medicines reserves the right to rescind, revoke, or amend the program and discontinue support at any time without notice.

To be evaluated for assistance, complete and submit the enrollment form (https://yourblueprint.com/hcp/financial-assistance/) via fax to 1.866.370.3082 or email to info@yourblueprint.com.

**Independent Charitable Foundations**

Case managers can provide contact information for independent charitable foundations that might be able to assist patients. These foundations are not associated with Blueprint Medicines and establish their own rules and application processes. Blueprint Medicines does not endorse any particular foundation.
Uninterrupted Access
YourBlueprint offers the following no cost options to eligible patients who need assistance accessing their Blueprint Medicines therapy while awaiting an insurance coverage determination or while transitioning between doses. These programs include:

• **QuickStart Program:** This program offers a no cost 15-day supply of therapy to newly prescribed patients who have an insurance coverage delay. Eligible patients may receive three refills pending insurance coverage. The program is available to patients with private/commercial or government insurance experiencing delays in coverage. Patients must be new to therapy and enrollment in YourBlueprint is required.

• **Coverage Interruption Program:** This program provides a no cost 15-day supply of treatment to eligible patients already on therapy who face a temporary interruption in insurance coverage. Eligible patients may receive three refills pending insurance coverage. Patients must be on therapy and enrollment in YourBlueprint is required.

• **Ayvakit Dose Exchange Program:** This program allows patients who have a change in their dose of Ayvakit to exchange remaining medication for the new dose. To apply to this program, complete the Ayvakit dose exchange form ([https://yourblueprint.com/wp-content/uploads/AYVAKIT-Dose-Exchange-Form.pdf](https://yourblueprint.com/wp-content/uploads/AYVAKIT-Dose-Exchange-Form.pdf)) and submit it to YourBluePrint via fax to 1.866.370.3082 or email to info@yourblueprint.com.

To speak with a dedicated case manager, call 1.888.BLUPRNT (1.888.258.7768), Monday through Friday, 8:00 AM to 8:00 PM EST.

REIMBURSEMENT ASSISTANCE

**YourBlueprint™ Benefits Verifications**
Case managers can conduct a benefits verification to determine patients’ health insurance coverage and out-of-pocket costs. After verifying coverage, the program will provide a summary of benefits to the provider’s office over the phone, as well as fax. For the patient, it can call to review the summary of benefits verbally, and upon request, mail a copy to the patient.

**Prior Authorization**
Case managers can support patients through the process of managing a prior authorization requirement. Here is what to expect:

• First, YourBlueprint will coordinate with patients’ insurer to gather the prior authorization requirements, including the payer specific documents.

• A case manager will then contact the provider’s office to help guide them through the submission process and provide the necessary documents to complete, including a documentation checklist.

• After the provider’s office submits the prior authorization request, upon request, YourBlueprint can track the progress and communicate the status of a prior authorization to you.

**Appeals**
In the event of a prior authorization denial, case managers can assist with an appeal of the payer’s decision via a request for reconsideration by providing:

• Additional guidance on types of information to include

• A documentation checklist

• A sample letter of medical necessity and/or a sample letter of appeal.

For more information, visit yourblueprint.com/hcp or call 1.888.BLUPRNT (1.888.258.7768), Monday through Friday, 8:00 AM to 8:00 PM EST.
Bristol Myers Squibb

Oncology-related products: Abraxane® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), Empliciti® (elotuzumab) for injection, Idhifa® (enasidenib) tablets, Inrebic® (fedratinib) capsules, Istodax® (romidepsin) for injection, Onureg® (azacitidine) tablets, Opdivo® (nivolumab) injection for intravenous use, Pomalyst® (pomalidomide) capsules, Reblozyl® (luspatercept-aamt) for injection, Revlimid® (lenalidomide) capsules, Sprycel® (dasatinib) tablets, Thalomid® (thalidomide) capsules, Vidaza® (azacitidine for injection), Yervoy® (ipilimumab) injection for intravenous use

Patient and Reimbursement Assistance Website
bmsaccesssupport.bmscustomerconnect.com/

PATIENT ASSISTANCE

BMS Access Support®
Bristol Myers Squibb (BMS) is committed to helping appropriate patients get access to BMS medications by providing access and reimbursement support services. BMS Access Support offers reimbursement and patient financial assistance. For more information, call the BMS support center at 1.800.861.0048, Monday through Friday, 8:00 AM to 8:00 PM EST.

BMS Oncology Co-Pay Assistance Program
This program is designed to assist eligible, commercially insured patients who have been prescribed select BMS medications with out-of-pocket deductibles, co-pays, or co-insurance requirements. To be eligible, patients must have commercial (private) insurance that covers the prescribed BMS medication but does not cover the full cost, and patients must live in the United States or Puerto Rico. Patients may not be participating in any state or federal healthcare program, including Medicaid, Medicare, Medigap, CHAMPUS, TriCare, Veterans Affairs (VA), or Department of Defense (DoD), or any state, patient, or pharmaceutical assistance program. Patients who move from commercial (private) insurance to a state or federal healthcare program will no longer be eligible. If patients have purchased their prescription insurance through a Health Exchange (also known as a Health Insurance Marketplace or Small Business Health Options Program [SHOP] Marketplace), they are currently eligible.

Program benefits and limits include:
• For patients prescribed Abraxane or Reblozyl, the program will cover the co-pay for each dose, up to a maximum of $10,000 per BMS medication during a calendar year.
• For patients prescribed Empliciti, Opdivo, Yervoy, or Opdivo plus Yervoy, they must pay the first $25 of the co-pay for each dose of a BMS medication covered. The program will cover the remainder of the co-pay, up to a maximum of $25,000 per BMS medication during a calendar year. (For clarification, if a patient is prescribed two BMS medications in combination, the maximum is $50,000.) Patients are responsible for any costs that exceed the $25,000 maximum.
• For patients prescribed Idhifa, Inrebic, Onureg, Pomalyst, Revlimid, or Thalomid, they may pay as little as $10 per one-month supply, subject to a maximum benefit of $15,000 per calendar year (excluding certain dispensing costs).
• For patients prescribed Sprycel, they may pay as little as $0 per 30-day supply, up to a maximum of $15,000 per calendar year.

The program may apply retroactively to out-of-pocket expenses that occurred within 120 days prior to the date of the enrollment. The enrollment period is one calendar year, and patients must enroll by December 31, 2021.
Enroll patients online (https://www.activatethecard.com/6288portal/) or download, complete, and fax the specific medication’s enrollment form (https://www.bmsaccesssupport.bmscustomerconnect.com/) to the number listed on the form.

**Independent Charitable Foundations**

Patients insured through federal healthcare programs are not eligible for co-pay assistance programs sponsored by Bristol Myers Squibb. BMS Access Support can make a referral to independent charitable foundations offering support for your specific patient. Contact BMS Access Support at 1.800.861.0048 for details.

**Bristol Myers Squibb Patient Assistance Foundation**

The Bristol Myers Squibb Patient Assistance Foundation (BMSPAF) is an independent, charitable organization that helps eligible patients who need temporary help obtaining their prescribed BMS medicines. Patients may be eligible for BMSPAF if they:

- Do not have insurance coverage for the prescribed medication listed on the website (https://www.bmspaf.org/#home).
- Live in the United States, Puerto Rico, or U.S. Virgin Islands.
- Are being treated by a U.S. licensed prescriber.
- Are being treated with the medicine as an outpatient.
- Are prescribed a BMS medicine for cancer (even if patients’ income is higher than the program’s limits).

Other eligibility criteria may apply. Healthcare professionals can download and complete the application on its website (https://www.bmspaf.org/apply). You can also call 1.800.736.0003 to have an application mailed or faxed. For any questions, call 1.800.736.0003, Monday through Friday, 8:00 AM to 8:00 PM EST.

**REIMBURSEMENT ASSISTANCE**

**BMS Access Support®**

Bristol Myers Squibb (BMS) is committed to helping appropriate patients get access to BMS medications by providing access and reimbursement support services.

**Benefits Reviews**

BMS can review patient coverage for their medication, and reviews are typically completed within a median time of 24 hours. For enrolled patients, benefits may also be reverified.

**Prior Authorization Assistance**

BMS Access Support is ready to assist by providing information about the prior authorization (PA) process. A BMS Access Support care coordinator can:

- Conduct benefits review, obtaining information about any PA requirement
- Call the payer to obtain PA details
- Fax summary of benefits to provider.

**Appeals Assistance**

If the patient’s insurer has denied coverage, the denial may be appealed. BMS Access Support may be able to assist by providing information about the appeals process.

To start a benefits review, visit https://www.bmsaccesssupport.bmscustomerconnect.com/ and select the prescribed medication. For more information, call the BMS support center at 1.800.861.0048, Monday through Friday, 8:00 AM to 8:00 PM EST.
Oncology-related product: Udenyca® (pegfilgrastim-cbqv) injection

Patient and Reimbursement Assistance Website
coheruscomplete.com

PATIENT ASSISTANCE

Coherus COMPLETE™
Coherus Complete provides a suite of patient support services and programs designed to assist with patient access.

Coherus COMPLETE Co-Pay Assistance Program
Coherus Complete offers a co-pay assistance program that covers out-of-pocket expenses related to Udenyca for commercially insured patients. Eligible patients qualify for $0 out-of-pocket costs for each Udenyca dose, subject to a $15,000 maximum annual benefit per enrollment period. The program has an 180-day lookback period. No physical co-pay card is required. Electronic co-pay claims submission through office billing software.

To be eligible for the co-pay assistance program patients:
  • Must be prescribed Udenyca for a medically appropriate use
  • Must have commercial health insurance that covers the medication costs of Udenyca
  • Must not be covered by any federal, state, or government-funded healthcare program, such as Medicare, Medicaid, Medicare Advantage, Medicare Part D, Veterans Affairs, the Department of Defense, or TriCare
  • Must not seek reimbursement amount received from Coherus from any third-party payers, including flexible spending accounts or healthcare savings accounts.

Patients with commercial insurance who have received Udenyca in the past 6 months may be eligible. To enroll, visit copay.coheruscomplete.com to log into the portal and apply.

Patient Assistance Program
Patients with no insurance may be eligible for financial support for Udenyca through the patient assistance program. Patient eligibility criteria:
  • Uninsured, functionally underinsured, or Medicare patients that demonstrate financial hardship and cannot afford their move “cost-” up to previous line-sharing obligation
  • Must meet all eligibility requirements to qualify
  • United States resident and must physically reside in the U.S. or U.S. territory
  • Be under the care of a U.S. licensed provider with an established practice located in the U.S.
  • Do not have any other financial support options
  • Diagnosis and dosing must be consistent with FDA-approved prescribing information for Udenyca
  • Adjusted annual household income of less than or equal to 500 percent of the federal poverty level
  • Must receive treatment in the outpatient setting incident to the prescribing physician’s professional services.

Patients with government insurance, including Medicare, Medicaid, VA, DOD, TriCare, or any other insurance that is federally or state-funded, can be provided Udenyca at no cost through the patient assistance program. Patients must meet program eligibility criteria and be considered functionally underinsured. For more information, visit https://coheruscomplete.com/financial-assistance/medicare.

Enroll patients online at https://coheruscomplete.com/financial-assistance/uninsured. For additional information, call 1.844.4.UDENCYA (1.844.483.3692).

Charitable Foundations
Coherus Complete may also be able to help patients find financial support through charitable foundations. Patient access specialists can
research alternative coverage options for patients. When funding becomes available, healthcare professionals will receive email notifications alerting them to available funds from charitable foundations. Patients must be enrolled in Coherus Complete.

REIMBURSEMENT ASSISTANCE

Coherus COMPLETE™
For reimbursement assistance, contact Coherus Complete at 1.844.483.3692, your Coherus field reimbursement manager, or individual payers for payer-specific information.
PATIENT ASSISTANCE

Daiichi Sankyo Access Central™

Daiichi Sankyo Access Central provides support and information to help patients access Turalio, which is available through Biologics. Fax the Patient Enrollment Form (https://dsiaccesscentral.com/hcp/turalio) and the patient’s prescription directly to Biologics at 1.800.823.4506 to enroll.

Turalio Co-Pay Program

Eligible patients may pay as little as $0 per prescription, with a maximum benefit of $25,000 per calendar year. Patients must have commercial insurance coverage. There are no income requirements for eligibility. Patients participating in government healthcare insurance programs are not eligible, including patients participating in Medicare, Medicaid, Medigap, TriCare, Veterans Affairs, Department of Defense, or any state-funded programs. In order to continue receiving co-pay assistance, patients must reapply for the program each calendar year. Patients can enroll up to 30 days after their first Turalio treatment and utilize a retroactive enrollment period for assistance on dates of service that took place prior to enrollment. The practice or patient must call an Access Central coordinator for assistance on retroactive enrollment.

There are two simple ways to enroll:
1. Fill out and fax the Patient Enrollment Form (https://dsiaccesscentral.com/hcp/turalio/financial-help/copay) to Biologics at 1.800.823.4506, and Biologics will complete the enrollment process for eligible patients.
2. Patients may also be enrolled online at: turalio.copaysavingsprogram.com/.

If patients are eligible, Biologics will enroll them and call practices so that they can inform their patients of their enrollment. An Access Central coordinator may call practices to address any issues with the co-pay assistance enrollment process. For questions about eligibility or the enrollment process, call Biologics at 1.800.850.4306.

Patient Assistance Program

The Turalio Patient Assistance Program may provide Turalio at no cost for financially eligible patients who are uninsured or underinsured. Patients must have been denied coverage, are uninsured, or are functionally uninsured (denied prior authorization, formulary exclusion). Additional terms and conditions apply. Medicare enrollees may be eligible for this program if they are unable to meet their out-of-pocket costs for Turalio and meet the required income criteria.

To enroll, complete the Patient Enrollment Form (https://dsiaccesscentral.com/hcp/turalio/financial-help/pap) and fax it to 1.833.471.9988 for patients’ eligibility to be assessed. The enrollment process can also be started over the phone by calling 1.866.437.4669.

Third-Party Foundations

For patients with government insurance (such as Medicare or Medicaid), there are third-party organizations that may provide help with medication costs. Call an Access Central Coordinator for more information on third-party organizations at 1.866.437.4669.

Turalio QuickStart Program

Patients experiencing a five-day delay in getting their prescription may be eligible for the Turalio QuickStart Program. Eligible patients can receive a 14-day prescription at no cost. When filling out the Patient Enrollment Form (https://dsiaccesscentral.com/hcp/turalio/coverage-access/quickstart), com-
Completing the optional QuickStart prescription section will help expedite this process. To be eligible, patients must:

- Be new to Turalio
- Have commercial or government insurance
- Be experiencing a coverage delay of five or more business days after submission of a completed prior authorization.

Additional terms and conditions apply. Please note that QuickStart prescriptions cannot be shipped until both the physician and patient have completed the REMS requirements, including signing the REMS Patient Enrollment Form (https://dsiaccesscentral.com/hcp/turalio/coverage-access/quickstart).

REIMBURSEMENT ASSISTANCE

**Daiichi Sankyo Access Central™**

Daiichi Sankyo Access Central provides support and information to help patients access Turalio, which is available through Biologics. Fax the Patient Enrollment Form (dsiaccesscentral.com/hcp/turalio) and patients’ prescription directly to Biologics at 1.800.823.4506. Upon receiving the form, Biologics will be able to:

- Conduct a benefits investigation
- Help complete the prior authorization
- Assist with enrollment into the Turalio Co-Pay Program for eligible, commercially insured patients
- Refer uninsured patients who may be eligible for the Turalio Patient Assistance Program to Daiichi Sankyo Access Central
- Provide healthcare professionals with a summary of benefits when requested.

Biologics is equipped to answer questions about Turalio prescriptions and patient support by calling 1.800.850.4306.
**PATIENT ASSISTANCE**

**ENHERTU4U**
Support options are available to help patients who have been prescribed Enhertu access their treatment. Enroll today for help with:
- Affordability options
- Coding and reimbursement
- Distribution
- Field reimbursement manager.

**ENHERTU Patient Savings Program**
The goal of the Enhertu Patient Savings Program is to remove cost as a barrier for eligible commercial patients by assisting with their out-of-pocket costs. Eligible patients may pay as little as $0 per Enhertu prescription, up to $26,000 per calendar year. The annual benefit can be used for the cost of the drug itself and may also cover up to $100 in infusion costs per administration. There are no income requirements to participate in the program. Patients who are residents of Massachusetts, Michigan, Minnesota, or Rhode Island are not eligible for infusion assistance.

Patients may be eligible for this program they are insured by commercial insurance and their insurance does not cover the full cost of the prescription. Patients who are enrolled in a state or federally funded prescription insurance program are not eligible. This includes patients enrolled in Medicare Part B, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DoD) programs or TriCare, and patients who are Medicare-eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees.

If patients meet eligibility requirements, they can be enrolled online (enhertusavings.com/auth/login) or by calling 1.833.ENHERTU (1.833.364.3788). For assistance on enrolling patients or for questions, call 1.833.364.3788.

**Patient Assistance Program**
This program is designed to help qualifying uninsured, underinsured, or Medicare patients who are having financial difficulty affording their medication. The program provides Enhertu to qualifying patients at no cost. To be eligible for the program, patients must:
- Be a resident of the United States
- Not have insurance, private or government, that covers Enhertu
- Not be receiving any other assistance to help pay for Enhertu
- Have an annual income at or below a certain level.

If patients are a Medicare beneficiary:
- They must not be eligible for or enrolled in Low Income Subsidy (LIS) for Medicare Part D.
- They must have spent at least three percent of their annual household income on prescription medicines in the current year.

If patients have experienced a life-changing event in the past year, and their financial documentation does not accurately reflect their current situation, they are encouraged to apply to the Enhertu Patient Assistance Program. They may still meet the criteria to enroll.

To enroll in the Enhertu Patient Assistance Program, complete the enrollment form (enhertu4u.com/hcp/affordability.html) and fax it to 1.833.904.1851. Once patients are enrolled in the program, a Product Request Form (www.enhertu4u.com/hcp/affordability.html) must be completed for each prescription and refill to ensure accuracy of weight-based dosing of Enhertu.
For more information, call 1.833.ENHERTU (1.833.364.3788), Monday through Friday, 9:00 AM to 6:00 PM EST.

**Independent Foundations**
Assistance may be available through independent foundations. Foundations can provide a variety of assistance types: co-pay, transportation, premium, patient education, etc. These foundations are not associated with AstraZeneca or Daiichi Sankyo; specific details and eligibility requirements can be found directly at the foundations’ websites.

**REIMBURSEMENT ASSISTANCE**

**ENHERTU4U**
**Benefit Verification and Prior Authorization Assistance**
Specialists can help with benefit verification, prior authorization assistance, and pharmacy research and coordination. To request support for your patient, please complete and sign pages one and three of the patient enrollment form (https://www.enhertu4u.com/hcp/access.html#enroll-nav) and fax it to 1.866.760.5917. A signature is required from both prescriber and patient. You can also call 1.833.ENHERTU (1.833.364.3788) to enroll patients over the phone.

Upon receiving a completed enrollment form, ENHERTU4U will complete the benefit verification within a business day and provide the healthcare professional’s office with the prior authorization requirements and required forms to obtain insurance approval for treatment. Once the prior authorization is submitted, the program will follow up with the patient’s insurance company to ensure that they receive a coverage decision. Patients will be assessed for a temporary free supply if they experience a coverage delay of greater than five business days.

**Coding and Appeals**
Coding and appeals support are available through ENHERTU4U. In some cases, payers may deny an initial claim for Enhertu. Fax a completed enrollment form and the explanation of benefits with reason for denial to 1.866.760.5917 for assistance.

If a claim is denied, the program will provide the specific appeals requirements. You will need to provide a formal letter appealing the denial to the payer. For more information, call 1.833.ENHERTU (1.833.364.3788).
**PATIENT ASSISTANCE**

**Eisai Assistance Program**
The Eisai Assistance Program can provide information to patients and healthcare professionals about coverage for Eisai medicines, as well as information about programs that may help eligible patients afford their medication. Depending on patients’ financial situation and clinical status, resources may be available to help with patients’ costs for their Eisai prescribed medicine.

**Eisai Patient Assistance Program**
Eisai has established the Patient Assistance Program for patients who need help paying for Lenvima. This program provides medications at no cost to uninsured and financially burdened patients who meet program eligibility criteria.

To enroll, complete the Lenvima Eisai Assistance Program Enrollment Form ([https://www.eisaireimbursement.com/hcp/lenvima/documents-and-resources](https://www.eisaireimbursement.com/hcp/lenvima/documents-and-resources)), and fax it to 1.855.246.5192. For more information, call 1.866.61.EISAI (1.866.613.4724), Monday through Friday, 8:00 AM to 8:00 PM EST.

Eisai reserves the right, at its sole discretion, to discontinue the Patient Assistance Program or change the qualifications at any time. All patient information remains confidential. Product supply for the program depends upon availability.

**$0 Co-Pay Program**
Eligible, commercially insured patients prescribed Halaven or Lenvima may pay as little as $0 per month. Depending on patients’ insurance plan, they could have additional financial responsibility for any amounts over Eisai’s maximum liability. Limits vary depending on the Eisai medication prescribed. Limits include:
- For patients prescribed Halaven, the co-pay program provides up to $18,000 per year to assist with out-of-pocket costs.
- For patients prescribed Lenvima, the co-pay program provides up to $40,000 per year to assist with out-of-pocket costs.

The program is not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, Medigap, VA, DoD, or TriCare.


For patients prescribed Halaven, the completed enrollment form ([eisaireimbursement.com/-/media/Files/XRay/Halaven/Halaven-0Copay-Enrollment-Form.pdf](https://eisaireimbursement.com/-/media/Files/XRay/Halaven/Halaven-0Copay-Enrollment-Form.pdf)) must be submitted by fax to 1.844.745.2350.

If the patient is determined to be eligible, they will be sent a welcome letter and a card. This card should be given to the provider’s office so that it can be used to process the virtual debit card payment.
Lenvima Does Exchange Program
There may be times healthcare professionals need to dose reduce a patient during the course of treatment due to adverse reaction before the patient has finished their current supply of Lenvima. Through the Lenvima Dose Exchange Program, eligible patients that require a dose reduction can exchange up to 15 unused doses for the same number of doses at the reduced dose strength at no additional cost.

The program allows patients to exchange unused 20mg doses for 14mg doses when a healthcare professional has directed a dose reduction based on the prescribing information.

Complete the Lenvima Dose Exchange enrollment form (https://www.eisaireimbursement.com/hcp/lenvima/patient-support) and fax—along with a prescription—to Sonexus at 855.246.3192.

REIMBURSEMENT ASSISTANCE

The Eisai Assistance Program
For patients prescribed Halaven, Eisai can provide information to patients and healthcare professionals about coverage for Halaven, including billing and coding information. Call 1.866.61.EISAI (1.866.613.4724) Monday through Friday, 8:00 AM to 8:00 PM EST, for questions.

For Lenvima, specialists will complete a full benefit investigation to understand patients’ insurance coverage for Lenvima. Call 1.866.61.EISAI (1.866.613.4724) or visit www.eisaireimbursement.com/hcp/lenvima/accessing-lenvima for more information and to enroll patients.
PATIENT ASSISTANCE

Lilly Oncology Support Center
Through the Lilly Oncology Support Center, Lilly strives to offer personalized treatment support for eligible patients prescribed a Lilly Oncology product. For those who qualify, it can help with:

- Understanding patients’ insurance coverage
- Review of financial-assistance options, including savings card programs and independent patient-assistance foundations
- For some products, it provides dedicated, personalized support through every step of treatment.

Lilly Oncology Infused Products Co-Pay Program
Commercially insured qualifying patients could pay as little as $0 (depending on the product) for their prescribed medication. There are no income requirements. There is a $25,000 annual maximum benefit. To be eligible, patients must:

- Have been prescribed one of the following Lilly Oncology medicines covered by the program—Alimta, Cyramza, Erbitux, or Portrazza
- Have commercial insurance that covers the prescribed Lilly Oncology medicine, but does not cover the full cost
- Be 18 years of age or older
- Be receiving the prescribed medicine for an FDA-approved use
- Be residents of the United States or Puerto Rico.

Patients may not be participating in any state or federal healthcare program, including, without limitation, Medicaid, Medicare, Medigap, DoD, VA, TriCare, or any state patient, or pharmaceutical assistance program; patients who move from commercial insurance to a state or federal healthcare program will no longer be eligible. For enrolled patients, a claim for reimbursement must be submitted within 180 days of infusion to receive program benefits. The program may provide support for doses with a date of service that falls within 120 days prior to the date the application is received by the program.

To enroll patients into the program, download and print the Infused Products Enrollment Form (lillyoncologysupport.com/assets/pdf/patient_assistance_program_application.pdf). Complete and fax the form to 1.877.366.0585.

Independent Patient Assistance Program Foundations
The Lilly Cares Foundation, Inc., a separate nonprofit organization, offers a patient assistance program to help qualifying patients receive Lilly medications at no cost. For more information about Lilly Cares, please visit LillyCares.com.

Lilly Oncology Support Center can also provide information about a number of independent patient assistance programs that may be able to help eligible patients. These foundations are not affiliated with Eli Lilly and Company and have been established and are operated independently. Funding availability changes weekly, so contact a Lilly Oncology Support Center representative at 1.866.472.8663 for the most recent updates.
Verzenio Continuous Care™
Verzenio Continuous Care provides various forms of support and information to help patients access Verzenio, which may include the following:
• Benefits investigation support
• Co-pay savings and other financial support
• Ongoing support
• Field reimbursement support.

The Verzenio Continuous Care Program is not a guarantee of coverage. Terms and conditions apply for all programs. To enroll, complete and fax the Enrollment Form (verzenio.com/assets/pdf/hcp_enrollment_form.pdf) to 1.855.545.5957. In order to process the requested services, Verzenio Continuous Care will require two patient signatures and a prescriber signature. Not signing the enrollment form will result in an incomplete submission and a delay in requested services.

For any questions, call Lilly Oncology Support Center at 1.844.VERZENIO (1.844.837.9364), Monday through Friday, 8:00 AM to 10:00 PM EST.

Verzenio Savings Card
Eligible, commercially insured patients pay as little as $0 a month. Subject to a monthly cap of wholesale acquisition cost plus usual and customary pharmacy charges and a separate annual cap set at Lilly’s sole discretion. Patients are responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial insurance coverage or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TriCare, or any state patient or pharmaceutical assistance program. Card activation is required.

Digital cards can be downloaded online at: verzenio.com/hcp/savings-support.

MyRightDose
This dose exchange program may simplify midcycle dose reductions for patients and at no cost to them. Additional terms and conditions apply. To be eligible for the MyRightDose program, patients must:
• Return their unused pills in the provided pre-addressed envelope and according to the instructions provided by MyRightDose
• Be 18 years of age or older
• Be residents of the United States or Puerto Rico
• Be prescribed Verzenio for an FDA-approved indication.

To apply for this program, complete the Dose Exchange Program Enrollment Form (https://www.myrightdose.com/assets/pdf/MyRightDose_Enrollment_Form.pdf). Fax the completed form with prescriber signature to 1.833.557.2417, Monday through Friday, 9:00 AM to 6:00 PM EST or visit verzenio.com.

Retevmo Savings Card
Eligible, commercially insured covered patients pay as little as $0 a month. Offer is good for up to 12 months until Dec. 31, 2021. Patients must have coverage for Retevmo through their commercial drug insurance to pay as little as $0 for a 30-day supply of Retevmo, subject to a monthly cap of wholesale acquisition cost plus usual and customary pharmacy charges, and a separate annual cap set at Lilly’s sole discretion. Participation in the program requires a valid patient HIPAA authorization. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TriCare/CHAMPUS, or any state patient or pharmaceutical assistance program.

To apply for the Retevmo Savings Card, visit retevmo.com/savings-support#savings-card or call 1.866.472.8663, Monday through Friday, 8:00 AM to 10:00 PM EST to request a savings card.
Retevmo Interim Access Program
The Retevmo Interim Access Program may provide a temporary supply of Retevmo at no cost to insured, eligible patients who have been prescribed Retevmo for the first time and are experiencing a delay in their insurance coverage decision. This program is not available to patients whose insurers have made a final determination to deny the patient coverage for Retevmo. If a denial is received after the initial five business days have passed and appeal rights are being pursued, or if there is a persistent coverage delay, the patient, under appropriate circumstances, may be eligible for up to three additional 15-day supplies of Retevmo.

MyRightDose
This dose exchange program may simplify midcycle dose changes for patients. It ships the appropriate dose directly to patients’ homes in as early as 48 hours and at no cost to them. Additional terms and conditions apply. To enroll patients, complete the MyRightDose Enrollment Form (retevmo.com/assets/pdf/dose-exchange-enrollment-form.pdf), and fax it with the prescriber’s signature to 1.844.372.9043. For more information, call 1.833.290.2175, Monday through Friday, 9:00 AM to 6:00 PM EST, or visit retevmo.com.

REIMBURSEMENT ASSISTANCE
Lilly Oncology Support Center
Through the Lilly Oncology Support Center, Lilly strives to offer individualized treatment support for eligible patients prescribed a Lilly Oncology product. For those who qualify, Lilly Oncology can help with reimbursement (eligibility determinations, benefits investigation, prior authorization assistance, and appeals information).

For questions or more information, call 1.866.472.8663, Monday through Friday, 8:00 AM to 10:00 PM EST.

Verzenio Continuous Care™
Once enrolled in the Verzenio Continuous Care Program, patients will have access to a benefits investigation.

Benefits Investigation
The program helps patients understand their coverage options, locate the appropriate pharmacy, and identify their lowest possible out-of-pocket cost.

For any questions, call Lilly Oncology Support Center at 1.844.VERZENIO (1.844.837.9364), Monday through Friday, 8:00 AM to 10:00 PM EST.

Retevmo Savings & Support
Retevmo Savings & Support can provide insurance and coverage assistance. A benefits investigation helps eligible, enrolled patients understand their coverage options, locate the appropriate specialty pharmacy, and identify their lowest possible out-of-pocket cost, and a field reimbursement manager helps patients access prescribed Lilly FDA-approved medicines. For more information, call the Lilly Oncology Support Center at 1.866.472.8663, Monday through Friday, 8:00 AM to 10:00 PM EST.
PATIENT ASSISTANCE

CoverOne®

CoverOne provides patient access and reimbursement support services to help eligible patients gain appropriate access to Bavencio in the United States.

CoverOne recognizes that each patient’s situation is different and is dedicated to helping them one at a time. For more information, contact 844.8COVER1 (844.826.8371), Monday through Friday, 8:00 AM to 8:00 PM EST.

When Bavencio is used in combination with axitinib, questions related to reimbursement and access for axitinib may be referred to Pfizer Oncology Together™ at www.pfizeroncologytogether.com/hcp.

Patient Assistance Program

CoverOne includes a patient assistance program that provides Bavencio at no charge for patients who meet certain income, insurance (i.e., uninsured), and residency eligibility criteria. To determine patient eligibility, providers should complete a CoverOne Enrollment Form on the CoverOne Enrollment Portal (coverone.com/en/portal/log-in.html) or fax the downloadable form to 1.800.214.7295 prior to treatment.

Patient assistance is not applied retroactively. A CoverOne representative will notify patients and healthcare professionals as soon as possible with patients’ eligibility determination.

NOTE: The CoverOne patient assistance program is a philanthropic program for patients in need and is not contingent on any past or future commercial sale.

Co-Pay Assistance Program

CoverOne provides co-pay assistance for privately insured Bavencio patients with co-pay/coinsurance responsibilities who meet the program eligibility criteria. Enrolled patients may be eligible to pay as little as a $0 co-pay for each treatment for Bavencio, up to a maximum of $30,000 per year. Once the annual co-pay assistance limit is reached, enrolled patients are responsible for paying all co-pays and any balance not covered by CoverOne.

Healthcare professionals may submit an application for co-pay assistance for their privately-insured patients by submitting an enrollment form through the CoverOne Enrollment Portal (https://www.coverone.com/en/portal/log-in.html) or by faxing a completed Enrollment Form to 1.800.214.7295. CoverOne is not permitted to offer co-pay assistance to any claims covered, paid or reimbursed, in whole or in part, by Medicaid, Medicare, or other federal or state healthcare programs. Full terms and conditions for co-pay assistance can be found at coverone.com.

Enrollment in the co-pay assistance program does not guarantee assistance. Whether an expense is eligible for the CoverOne Co-Pay Assistance benefit will be determined at the time the benefit is paid. Eligible co-pay expenses must be in connection with a separately paid claim for Bavencio administered in an outpatient setting, which is otherwise covered by a private or commercial insurance plan.

Oncology Navigation Center™

The EMD Serono Oncology Navigation Center™ (ONC) is a patient access and reimbursement support program available to help eligible patients gain appropriate access to Tepmetko. Its access navigators are committed to helping patients access Tepmetko, including:

- Reimbursement support

Oncology-related products: Bavencio® (avelumab) injection, Tepmetko® (tepotinib) tablets

Patient and Reimbursement Assistance Websites

coverone.com
tepmetko.com/us-en/home/cost-assistance.html
• Bridge program for new patients with insurance delays
• Co-pay assistance for privately insured patients
• Patient assistance program for eligible patients.

To enroll patients, complete and fax the enrollment form (https://www.oncnavigationcenter.com/en/home.html) to 1.844.501.0062. For questions, call 1.844.662.3631, Monday through Friday, 8:00 AM to 8:00 PM EST.

Co-Pay Assistance Program
The Oncology Navigation Center provides a Co-Pay Assistance Program to help privately insured patients who meet the program eligibility criteria with co-pay/coinsurance responsibilities. Enrolled patients may be eligible to pay as little as a $0 co-pay for each prescription of Tepmetko up to a maximum of $15,000 per year. Privately insured patients may apply for assistance by submitting an enrollment form (oncnavigationcenter.com/en/Oncology-Navigation-Center-Enrollment-Form.pdf).

Government insured patients, including Medicare Part D/Medicare Advantage and Medicaid beneficiaries, are not eligible for the Co-Pay Assistance Program. The program will notify patients of their eligibility determination as soon as possible.

Patient Assistance Program
ONC includes a patient assistance program that provides Tepmetko at no charge to patients who meet certain insurance (i.e., uninsured), income, and residency eligibility criteria. To determine patient eligibility, providers should complete and fax the ONC Enrollment Form (oncnavigationcenter.com/en/Oncology-Navigation-Center-Enrollment-Form.pdf) to 1.844.501.0062 prior to treatment.

An access navigator will notify healthcare professionals as soon as possible about the patient’s eligibility status. If eligible, the program will ship the free supply of Tepmetko to the patient.

Bridge Program
ONC has established a bridge program to assist eligible patients in accessing their initial prescription of Tepmetko free of charge in the event the patient’s insurer has not provided a coverage determination for at least five days, and the following criteria are met:
• Be a new patient
• Have received a prescription for Tepmetko
• Have an on-label diagnosis
• Be insured (i.e., a commercial insurer or a federal healthcare program)
• Have experienced a delay in a coverage determination of at least five business days

To apply, fax a completed ONC Enrollment Form (https://www.oncnavigationcenter.com/en/Bridge-Program.html) to 1.844.501.0062 to verify benefits or request assistance.

REIMBURSEMENT ASSISTANCE

CoverOne®
CoverOne will help healthcare professionals and patients understand the specific coverage and reimbursement guidelines for Bavencio. Reimbursement support services include:
• Insurance benefit verification
• Prior authorization assistance
• Information on relevant billing codes for Bavencio (HCPCS, CPT, ICD-10-CM, NDC)

Fax a completed ONC Enrollment Form (https://www.oncnavigationcenter.com/en/Reimbursement_support_services.html) to 1.844.501.0062 to verify benefits or request assistance. For questions, call 1.844.662.3631, Monday through Friday, 8:00 AM to 8:00 PM EST.

EMD Serono, Inc. and Pfizer, Inc. do not guarantee coverage and/or reimbursement for Bavencio. Coverage, coding, and reimbursement policies vary significantly by payer, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. Patients and healthcare professionals should always verify coverage, coding, and reimbursement guidelines on a payer and patient-specific basis.

Oncology Navigation Center™
Access navigators are available to help patients and their care teams understand how Tepmetko may be covered under each patient’s insurance/pharmacy benefits. Reimbursement support includes:
• Patient-specific benefit verification
• Formulary research – Medicare Part D, private payers, Medicaid
• Information on relevant billing codes
• Prior authorization assistance
• Appeals assistance.

Enroll patients through the CoverOne Enrollment Portal (www.coverone.com/en/portal/log-in.html), or fax a completed CoverOne Enrollment Form (www.coverone.com/en/Reimbursement_support_services.html) to 1.800.214.7295 to request services.
PATIENT ASSISTANCE

EpizymeNOW
To help facilitate access to Tazverik for patients with a valid prescription, EpizymeNOW Patient and Product Support can help patients understand their insurance coverage and identify any financial or product support that may be available. All patient support is subject to eligibility criteria and program terms and conditions.

To enroll patients in EpizymeNOW Patient and Product Support, complete the enrollment form (tazverik.com/Content/pdf/patient-support-form.pdf) by checking all support options for which patients’ are applying and fax the completed form to 1.833.437.1437. For more information, call 1.833.4EPINOW (1.833.437.4669), Monday through Friday, 9:00 AM to 6:00 PM EST.

Co-Pay Assistance Program
For patients with commercial (private) health insurance, they may be eligible to receive co-payment assistance to help reduce their out-of-pocket costs for Epizyme medications. Patients pay no more than $10 per co-payment amount per prescription fill, with an annual cap of $15,000. This offer is not valid for cash-paying patients or patients currently enrolled in Medicare, Medicaid, or any other federal or state healthcare program. Limitations apply. To be eligible, patients must:
• Currently have commercial (private) health insurance that covers Tazverik
• Not have primary or secondary insurance coverage under any state or federal health care program, including Medicare or Medicaid.
• Reside in the United States, including U.S. territories
• Have a valid prescription for Tazverik.

Healthcare professionals and pharmacy staff can enroll patients into the co-pay program online at: https://portal.trialcard.com/epizyme/.

Patient Assistance Program
Patients may be eligible to receive free medication if they are:
• Uninsured
• Underinsured (based on program eligibility criteria)
• Enrolled in the Medicare Part D benefit and have coverage for Tazverik, but are currently experiencing financial hardship (based on Epizyme’s review of appropriate supporting documentation).

To be eligible, patients must:
• Meet Epizyme’s financial eligibility requirements for enrollment in the patient assistance program based on income and other supporting financial documentation
• Reside in the United States, including U.S. territories
• Have a valid prescription for Tazverik
• Be currently uninsured or underinsured based on insurance information verification.

Quick Start Program
Patients may be eligible to receive their medication right away if they experience a delay in the authorization of prescription drug coverage greater than five business days and their doctor has determined there is an immediate medical need to start treatment with Tazverik. If eligible, a 15-day supply (up to 60 days) of Tazverik will be provided to patients until their prior authorization or coverage request is approved.

Bridge Supply Program
Patients may be eligible to receive a limited supply of free medication if they experience an unexpected change or disruption in their prescription drug coverage or supply (e.g., insurance provider requires a new or updated prior authorization or a change or loss of insurance).
REIMBURSEMENT ASSISTANCE

EpizymeNOW
EpizymeNOW can help patients understand their insurance coverage and identify any financial or product support that may be available. For more information, call 1.833.437.4669, Monday through Friday, 9:00 AM to 6:00 PM EST.
PATIENT ASSISTANCE

EASE Exelixis Access Services®

Exelixis Access Services (EASE) provides a variety of support to help patients get started on treatment as soon as possible. EASE can meet the unique needs of patients and practices at each step along the access journey. The program provides healthcare professionals and their eligible patients with access to a single point of contact—an EASE case manager—to assist with access to a variety of services and programs, including:

• The EASE Co-Pay Program that ensures eligible, commercially insured patients pay $0 per month, subject to a maximum benefit of $25,000 per year. Additional restrictions and eligibility rules apply. Patients with government insurance are excluded. Visit activatethecard.com/7311 to enroll eligible patients.
• The EASE Patient Assistance Program that helps eligible patients who cannot afford their drug costs receive their Exelixis medicines free of charge. Additional restrictions and eligibility rules apply.
• The Cabometyx Quick Start Program that provides free medicine to eligible patients who experience a payer decision delay of five days or more. Limited to on-label indications. Additional restrictions and eligibility rules apply.
• The 15-Day Free Trial Program that provides free medicine to eligible patients who experience a payer decision delay of five days or more. Limited to on-label indications. Additional restrictions and eligibility rules apply.
• The Cabometyx Dos Exchange Program that provides a free 15-day supply in the lower dose to help patients who require a dose reduction. Additional restrictions and eligibility rules apply. Patients are required to return any unused product.

To apply for these services, download and complete the appropriate medication-specific form (Cabometyx: https://www.cabometyxhcp.com/downloads/CABOMETYXEASEEnrollmentForm.pdf; Cometriq: www.cometriq.com/downloads/COMETRIQEASE_Enrollment_Form.pdf). Make sure to select the services for which patients are applying, and fax the completed form to 1.844.901.3273. Patients can also be enrolled into EASE services using CoverMyMeds® (www.covermymeds.com/main/). For more information, call 1.844.900.3273.

REIMBURSEMENT ASSISTANCE

EASE Exelixis Access Services®

At the provider’s request, EASE can provide support with:
• Benefits investigation
• Prior authorization assistance
• Appeals support and follow-up.

For more information, call 1.844.900.EASE (1.844.900.3273), Monday through Friday, 8:00 AM to 8:00 PM EST.

This description of the Exelixis Access Services program is for informational purposes only. Exelixis makes no representation or guarantee concerning reimbursement or coverage for any service or item. Information provided through the Exelixis Access Services program does not constitute medical or legal advice and is not intended to be a substitute for a consultation with a licensed healthcare provider, legal counsel, or applicable third-party payer(s). Exelixis reserves the right to modify the program at any time without notice.
Patient Assistance

Genentech Access Solutions
Genentech Access Solutions is a resource for access and reimbursement support after a Genentech medicine is prescribed. Enroll patients into the program online (https://genentech-prod.force.com/hcp/GNE_CM_PACT_Login#!/) or by going to https://www.genentech-access.com/hcp.html, selecting the prescribed medication, and downloading and completing the necessary forms. Fax the forms to the number listed on the forms.

Genentech Patient Foundation
The Genentech Patient Foundation gives free Genentech medicine to people who don’t have insurance coverage or who have financial concerns. Patients qualify if they:

• Are uninsured with incomes under $150,000

• Are insured with coverage for a Genentech medicine with incomes under $150,000

• Are insured with coverage for a Genentech medicine, with unaffordable out-of-pocket costs, who have pursued other forms of financial assistance, and with household size and income within certain guidelines. (Guidelines are available at www.gene.com/patients/patient-foundation/see-if-you-qualify).

If one of these situations applies, enroll patients online (https://genentech-prod.force.com/hcp/GNE_CM_PACT_Login#!/) or fax the completed enrollment forms (gene.com/patients/patient-foundation/apply-for-help) to 833.999.4363. The request will be processed within five business days upon receipt of the required forms, and the provider’s office will be contacted to discuss the application outcome and any next steps.

For more information, call 866.422.2377, Monday through Friday, 6:00 AM to 5:00 PM PST.

Genentech Oncology Co-Pay Assistance Program
This co-pay assistance program helps eligible patients pay for prescription medication costs. In order to qualify for the program, patients must meet the following criteria:

• Be covered by commercial or private insurance

• Receive a Genentech Oncology product for an FDA-approved indication

• Not participate in a federal or state-funded healthcare program, such as Medicare, Medicaid, Medigap, VA, DoD, or TriCare

• Be 18 years of age or older, or have a legal guardian 18 years of age or older to manage the program

• Live in and receive treatment in the United States or U.S. territories

Oncology-related products: Alecensa® (alectinib) capsules, Avastin® (bevacizumab) injection for IV use, Cotellic® (cobimetinib) tablets, Erivedge® (vismodegib) capsules, Gavreto® (pralsetinib) capsules, Gazyva® (obinutuzumab) injection, Herceptin® (trastuzumab) injection for intravenous use, Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk) injection, Kadcyla® (ado-trastuzumab emtansine) injection for intravenous use, Perjeta® (pertuzumab) for injection, Phesgo™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) subcutaneous injection, Polivy® (polatuzumab vedotin-piiq) injection for intravenous use, Rituxan® (rituximab), Rituxan Hycela® (rituximab and hyaluronidase human) injection for subcutaneous use, Rozlytrek® (entrectinib) capsules, Tarceva® (erlotinib) tablets (co-marketed with Astella Pharma US, Inc.), Tecentriq® (atezolizumab) injection for intravenous use, Venclexta® (venetoclax) tablets, Xeloda® (capecitabine) tablets, Zelboraf® (vemurafenib) tablets

Patient and Reimbursement Assistance Website

genentech-access.com
• Not be receiving assistance through the Genentech Patient Foundation or any other co-pay charitable organization.

There are no income requirements. Patients pay as little as $5 for their prescribed Genentech oncology product(s) with an annual benefit limit of $25,000 per product. The $5 co-pay applies to FDA-approved Genentech combination products. Retroactive requests for assistance may be honored for qualifying patients if the infusion or prescription fill occurred within 180 days prior to enrollment and the patient meets all eligibility criteria at the time of infusion. No physical card is needed; patients simply need their Member ID.

To get started, visit copayassistance now.com. For questions about this program, call 855.MY.COPAY (855.692.6729), Monday through Friday, 9:00 AM to 8:00 PM EST.

Referrals to Independent Co-pay Assistance Foundations
An independent co-pay assistance foundation is a charitable organization providing financial assistance to patients with specific disease states. Genentech Access Solutions offers referrals to independent co-pay assistance foundations for eligible patients who are commercially or publicly insured, including those covered by Medicare and Medicaid. Genentech does not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral.

To get started, visit genentech-access.com, select the prescribed medication, and follow instructions to apply for this assistance.

REIMBURSEMENT ASSISTANCE

Genentech Access Solutions Benefits Investigation
Genentech Access Solutions can conduct a benefits investigation (BI) to help determine if a Genentech medicine is covered, if prior authorizations are required, which specialty pharmacy the health insurance plan prefers, and if patient assistance might be needed. The potential outcomes of a BI are:
• Treatment is covered
• Prior authorization is required
• Treatment is denied.

Both the Prescriber Service Form and the Patient Consent Form must be received before Genentech Access Solutions can begin helping patients. Forms can be found by going to genentech-access.com, selecting the prescribed medication, and selecting the “Forms and Documents” option. They can be submitted via fax to the number listed on the form or online via My Patient Solutions (genentech-access.com/hcp/my-patient-solutions.html).

Prior Authorization Assistance
Genentech Access Solutions can help identify if a prior authorization is necessary and offer resources as healthcare professionals obtain it for patients. Both the Prescriber Service Form and the Patient Consent Form must be received before Genentech Access Solutions can begin helping patients.

If the request for a prior authorization is not granted, a field reimbursement manager or Genentech Access Solutions specialist can work with providers to determine next steps.

Appeals
If patients’ health insurance plan has issued a denial, a field reimbursement manager or Genentech Access Solutions specialist can provide resources as healthcare professionals prepare an appeal submission per patients’ plan requirements. If a plan issues a denial:
• The denial should be reviewed, along with the health insurance plan’s guidelines, to determine what to include in the patient’s appeal submission
• A field reimbursement manager or Genentech Access Solutions specialist has local payer coverage expertise and can help determine specific requirements for the patient.

Sample letters and additional considerations are available at genentech-access.com by selecting the prescribed medication and selecting the “Forms and Documents” section. Appeals cannot be completed or submitted by Genentech Access Solutions on providers’ behalf.

My Patient Solutions
My Patient Solutions is an online tool to help enroll patients in Genentech Access Solutions and manage service requests. Log in or register (www.genentech-access.com/ hcp/my-patient-solutions.html) with My Patient Solutions to:
• Enroll and re-enroll patients
• Communicate with a Genentech Access Solutions specialist
• See which service requests require action
• Co-pay assistance details
• View benefits investigation reports
• Follow up on prior authorizations or appeals
• Request benefits reverifications.

Account registration can be completed by one person for the entire practice and for multiple practice locations at https:// genentech-prod.force.com/hcp/GNE_ CM_PACT_Login#!/. For assistance, call 866.422.2377, Monday through Friday, 6:00 AM to 5:00 PM PST.
PATIENT ASSISTANCE

Trodelvy Access Support
Trodelvy access support is a patient access and reimbursement support program. It will help healthcare providers and their patients understand specific coverage and reimbursement guidelines for Trodelvy. Patient access support includes:
- Trodelvy savings program
- Gilead patient assistance program
- Referrals to independent third-party assistance organizations.

To enroll a patient, complete the enrollment form (https://trodelvy.com/pdf/Savings_Program_Enrollment.pdf) with the patient and fax it to 1.833.851.4344. For further information, contact the program at 1.844.TRODELVY (1.844.876.3358), Monday through Friday, 9:00 AM to 7:00 PM EST.

Trodelvy Savings Program
The savings program provides savings to commercially or privately insured patients on their out-of-pocket costs. Patients pay $0 out of pocket for Trodelvy, which includes co-pay and coinsurance up to $25,000 annually. Patients are responsible for cost share of treatments and office visits. This program does not support any claims covered, paid, or reimbursed, in whole or in part, by Medicaid, Medicare, or other federal or state healthcare programs.

Gilead Patient Assistance Program
Patients who are uninsured or underinsured may be eligible to obtain access to Trodelvy at no cost through the Gilead Patient Assistance Program. To qualify for assistance, patients must meet certain eligibility criteria. To determine patient eligibility, fax a completed program enrollment form (https://trodelvyhcp.com/pdf/Patient-Assistance-Enrollment-Form-TROT00102.pdf) to 1.833.851.4344.

A case manager will contact the provider’s office with determination of patient’s eligibility. For more information regarding the program, contact 1.844.TRODELVY (1.844.876.3358).

Third-Party Assistance Referrals
Trodelvy Access Support case managers can provide patients who are unable to afford their medication (including those with Medicare, Medicaid, or other government-sponsored insurance) with information about independent third-party organizations that may be able to help with the cost of treatment.

Healthcare professionals can call 1.844.TRODELVY (1.844.876.3358), option 4, for more information.

REIMBURSEMENT ASSISTANCE

Trodelvy Access Services
Trodelvy access support is a patient access and reimbursement support program. Reimbursement support services include:
- Coverage verification
- Prior authorization information
- Claims status information
- Billing and coding information
- Alternate assistance options.

For further information, contact the program at 1.844.TRODELVY (1.844.876.3358), Monday through Friday, 9:00 AM to 7:00 PM EST.
Together with GSK Oncology
Together with GSK Oncology offers patients and healthcare professionals a variety of access and reimbursement services for all GSK oncology products—all in one place.

To enroll, complete the enrollment form for the prescribed medication (www.togetherwithgskoncology.com/hcp-resources/). Select the requested services from the program and complete all patient and prescriber information. Make sure that both the patient and prescriber sign the form. Fax the completed form, plus copies of the patient’s medical and pharmacy insurance cards, to the number listed on the form.

Together with GSK Oncology will contact the prescriber’s office by the next business day—and will conduct a summary-of-benefits call with the patient within two business days.

For more information, call 1.844.4.GSKONC (1.844.447.5662), Monday through Friday, 8:00 AM to 8:00 PM EST.

Co-pay Program
Eligible, commercially insured patients could pay as little as $0 for their medicine. Terms and conditions apply.

Patients may be eligible based on general criteria below:
- Have a commercial medical or prescription insurance plan or are uninsured
- Are a resident of the United States (including the District of Columbia, Puerto Rico, and the U.S. Virgin Islands)
- Are not eligible for or enrolled in a government funded program.

If the patient is approved, the Together with GSK Oncology Commercial Co-pay Program may help with patient’s cost share for a GSK oncology product and the cost of administration, up to $100 per administration for IV products, up to a program total of $26,000 annually. Residents of Massachusetts, Michigan, Minnesota, or Rhode Island are not eligible for reimbursement of administration fees. Eligibility in the program is for one year. Patients must apply for co-pay assistance each year that they wish to participate in the program.

Patient Assistance Program
Uninsured patients who meet eligibility requirements may access medication free of charge through this patient assistance program. Medicare patients who meet program requirements may also be eligible for the program.

To qualify for the patient assistance program, patients must:
- Live in one of the 50 states, District of Columbia, Puerto Rico, or U.S. Virgin Islands
- Meet one of these criteria:
  - Uninsured
  - Have private commercial insurance but have no coverage (medical or pharmacy) for the product as demonstrated to the program through the defined appeals process criteria (please contact program for details)
- Not be currently receiving prescription drug coverage through a

Oncology-related products: Blenrep (belantamab mafodotin-blmf) for injection, Jemperli (dostarlimab-gxly) injection, Zejula® (niraparib) capsules

Download and complete the medication-specific Together with GSK Oncology enrollment form (https://www.togetherwithgskoncology.com/hcp-resources/) with your patient to submit for approval. Healthcare providers can also begin the enrollment process online (https://copayapplication.com/twgo/#).
government program (excluding Medicare), which includes Medicaid, VA, DOD or TriCare benefits
• Not be eligible for Puerto Rico’s Government Health Plan Mi Salud, or have applied and been denied
• Meet certain income eligibility requirements. Patients whose income exceeds the program eligibility maximum will be provided the opportunity to demonstrate that their eligible medical expenses bring them within the income eligibility criteria (please contact program for details).

For more information, call 1.844.4GSKONC (1.844.447.5662).

Quick Start and Bridge Program
For patients experiencing delay in coverage for Zejula at first dispense (Quick Start), or coverage interruptions while already on treatment (Bridge), download and fill out the Zejula enrollment form (www.togetherwithgskoncology.com/hcp-resources/zejula/). Fax the completed form to 1.800.645.9043.

REIMBURSEMENT ASSISTANCE

Together with GSK Oncology
For healthcare professionals—and their patients—Together with GSK Oncology offers:
• Patient-specific benefits investigation
• Prior authorization and appeals support
• Claims assistance.

Together with GSK Oncology can provide practices with assistance for claims submissions, including providing examples of forms and sample letters, outlining payer-specific information.

For more information, call 1.844.4GSKONC (1.844.447.5662), Monday through Friday, 8:00 AM to 8:00 PM EST.
PATIENT ASSISTANCE

G1 to One™
G1 to One is your single source for access and affordability solutions. It offers a suite of solutions to common access and reimbursement hurdles, such as:

- Initiating benefits verification for patient coverage and out-of-pocket responsibilities
- Providing payer-specific guidance for prior authorizations and appeals to address patient needs
- Offering solutions for insurance-related delays
- Connecting patients, regardless of insurance type, to appropriate resources that can address high deductibles, co-pays/coinsurance, or even a lack of coverage.

Patient must express need and meet certain eligibility requirements. To enroll patients, complete and submit the enrollment for (https://www.cosela.com/pdf/G1_to_One_Enrollment_Form.pdf) by faxing it to 1.833.329.4121. Call the program with questions at 1.833.G1toOne (1.833.418.6663), Monday through Friday, 8:00 AM to 8:00 PM EST or email enroll@G1toOne.com.

G1 Commercial Co-Pay Program
The G1 Commercial Co-pay Program is designed to support commercially insured patients who are eligible. Patients may be able to receive financial support for medication costs. Patient must be prescribed Cosela for a medically appropriate use and have commercial health insurance that covers the medication costs. Patients are not eligible if they are enrolled in any federal or state subsidized healthcare program that covers a portion of the prescription drug costs, including Medicare (such as Medicare Part D prescription drug benefit or a Medicare Advantage plan), Medicaid, TriCare, or any other federal or state healthcare plan, including pharmaceutical assistance programs, or where prohibited by law. The program only covers the out-of-pocket cost of Cosela and does not cover any administrative or office visit costs. Cash paying patients are not eligible for this offer.

Enroll patients into the co-pay program online (https://portal.trialcard.com/g1portal/).

REIMBURSEMENT ASSISTANCE

G1 to One™
G1 to One offers a suite of solutions to common access and reimbursement hurdles, such as benefits verification for patient coverage and out-of-pocket responsibilities. Submitting the completed enrollment form will initiate a benefits investigation that includes coverage status, prior authorization requirements, and patient out-of-pocket costs. This information will be provided to the healthcare provider. Enrollment into the program does not guarantee benefits.

To enroll patients, complete and submit the enrollment for (https://www.cosela.com/pdf/G1_to_One_Enrollment_Form.pdf) by faxing it to 1.833.329.4121. Call the program with questions at 1.833.G1toOne (1.833.418.6663), Monday through Friday, 8:00 AM to 8:00 PM EST or email enroll@G1toOne.com.
PATIENT ASSISTANCE

IncyteCARES
IncyteCares helps eligible patients access their prescribed Incyte medications and offers information and resources that provide extra support during treatment. Its team is available to patients and their caregivers by phone every weekday. It helps eligible patients with:

- Reimbursement support
- Delivery coordination
- Financial assistance options
- Temporary access for coverage delays
- Connection to support services
- Education and helpful resources.

To enroll, complete and submit the medication-specific enrollment form at incytecares.com or through the online portal at the medication specific website (https://hcp.incytecares.com/). Completed hard-copy forms should be faxed to the number indicated on the form. Once an eligible patient is enrolled for Jakafi, an IncyteCares representative will call to:

- Review coverage and costs for the prescribed medication
- Coordinate patients’ prescription and monthly delivery with an appropriate specialty pharmacy
- Offer financial assistance options for which the patient may be eligible
- Explain other resources and support available to the patient during treatment.

For Pemazyre, Biologics will conduct a benefits verification and contact patients to coordinate delivery of the filled prescriptions. For additional help, call 1.855.452.5234, Monday through Friday, 8:00 AM to 8:00 PM EST for patients prescribed Jakafi. Call 1.866.708.8806, Monday through Friday, 8:00 AM to 8:00 PM EST for patients prescribed Pemazyre.

Co-Pay/Coinsurance Program
Eligible patients can receive their medication for as little as $0 per month, subject to monthly and annual limits. To qualify, patients must:

- Have commercial or private prescription drug coverage
- Be a resident of the United States or a U.S. territory
- Have a valid prescription for an Incyte medication for an FDA-approved or compendia-recognized use.

Patients insured under federal or state government prescription drug programs—including Medicare Part D, Medicare Advantage, Medicaid, or TriCare—are not eligible. Patients without prescription drug coverage are also not eligible. Amount of savings for the purchase of Jakafi will not exceed $11,977 per month and $25,000 per year. Amount of savings on Pemazyre will not exceed $9,000 per claim and $25,000 per year.

For patients prescribed Jakafi, enroll them into IncyteCares online at: https://sservices.trialcard.com/Coupon/incyte/. For patients prescribed Pemazyre, contact IncyteCares at 1.866.708.8806 to enroll patients or go online at: https://portal.trialcard.com/pemazyre/.

Patient Assistance Program
The IncyteCares Patient Assistance Program helps eligible patients who do not have prescription drug insurance or who have trouble affording their co-pay. Eligible patients can receive medication free of charge. Terms of program may change at any time.

To qualify, patients must:

- Be confirmed as eligible for and enrolled in IncyteCares
- Be a resident of the United States or a U.S. territory
- Have a valid prescription for
an Incyte medication for an
FDA-approved use or a clinical
compendia-listed use approved for
coverage by Medicare
• Meet certain household size and
annual income criteria.

Medicare Part D patients may
be eligible by meeting additional
criteria and program require-
ments, including but not limited
to earning less than 600 percent
of the federal poverty limit. Within
two business days of receiving
the enrollment form, patients are
notified of “conditional approval”
for the program. This allows them
to receive free medication for 90 days.
Full approval is only granted once
income information is submitted
and confirmed. Terms and condi-
tions apply. To enroll patients, visit
the prescribed medication’s website
(https://hcp.incytecares.com/) to
enroll online or download and fax
the appropriate enrollment form.

Temporary Access Program
Eligible patients receive a free
short-term supply of medication.
If a patient’s prescription drug
insurer requires more than a
three-day wait for determining
coverage approval, IncyteCares may
be able to provide a free short-term
supply of the prescribed Incyte medi-
cation in the meantime. No purchase
contingencies or other obligations
apply. To qualify, patients must:
• Be confirmed as eligible for and
enrolled in IncyteCares
• Have commercial or private
prescription drug coverage or a
healthcare exchange plan
• Be a resident of the United States
or a U.S. territory
• Have a valid prescription for
an Incyte medication for an
FDA-approved use
• Provide proof of the coverage
delay. This may be a notice

providers or patients receive from
the insurance company.

Patients insured under federal or
state government prescription drug
programs, including Medicare Part
D, Medicare Advantage, Medicaid,
or TriCare, are not eligible. Patients
without prescription drug coverage
are also not eligible.

Independent Foundations
Patients may be eligible for help with
medication, treatment-related travel,
and other costs.

If patients do not qualify for the
IncyteCares Co-pay/Coinsurance
Program or patient assistance
program, IncyteCares may be
able to provide information about
other organizations or independent
foundations that may offer help.
Some assist with medication costs,
transportation or lodging expenses
related to treatment, or counseling
services, offered at reduced or no
cost. Eligibility and availability
of these assistance programs are
determined by the individual
organizations.

RIEMBURSEMENT
ASSISTANCE

IncyteCARES
IncyteCares’ mission is to help
eligible patients access their pre-
scribed medications and to offer
information and resources that
provide support during treatment.

For eligible patients prescribed
Pemazyre, IncyteCares can
provide benefits verification and
as-needed prior authorization or
appeal support. For patients pre-
scribed Jakafi, IncyteCares can
review patients’ coverage and
costs. For more information, call
1.866.708.8806 for patients pre-
scribed Pemazyre or 1.855.452.5234
for patients prescribed Jakafi.
PATIENT ASSISTANCE

IPSEN CARES®
The Ipsen Cares (Coverage, Access, Reimbursement and Education Support) serves as a central point of contact between patients, caregivers, doctors’ offices, insurance companies, and specialty pharmacies. The program is staffed by dedicated patient access specialists who can assist in a variety of ways:
• Reimbursement assistance
• Co-pay assistance program for eligible patients
• Patient assistance program
• Adherence programs
• Communications with providers and patients
• Specialty pharmacy network.

Providers can help patients enroll in three ways:
1. Through the online provider portal at https://ipsencaresportal.biologicsinc.com/Account/Login.
2. By printing a medication-specific downloadable PDF (https://www.ipsencares.com/) to be filled out and faxed to 1.888.525.2416.
3. By calling a patient access specialist at 866.435.5677, Monday through Friday, 8:00 AM to 8:00 PM EST.

Once a completed enrollment form is received, a patient access specialist will conduct a benefits verification to review patients’ out-of-pocket costs associated with the Ipsen medication. Additional support offerings for which patients may be eligible will be discussed at that time.

IPSEN CARES Co-pay Assistance Program
Most eligible patients with private insurance pay no co-pay, subject to a maximum annual benefit of $20,000. For Somatuline Depot, the program exhausts after 13 injections, or a maximum annual benefit of $20,000, whichever comes first. Cash-pay patients are eligible to participate in the program. For cash-pay patients, the maximum co-pay benefit amount per prescription is $1,666.66, subject to the annual maximum of $20,000 in total. Patients must enroll every 12 months from date of acceptance to receive a continued benefit.

Patients are not eligible for co-pay assistance through Ipsen Cares if they are enrolled in any state or federally funded programs for which drug prescriptions or coverage could be paid in part or in full, including, but not limited to, Medicare Part B, Medicare Part D, Medicaid, Medigap, VA, DoD, or TriCare (collectively, “Government Programs”), or where prohibited by law. For more information, visit www.ipsencares.com/ or call 866.435.5677.

Patient Assistance Program
The patient assistance program is designed to provide Ipsen medications at no cost to eligible patients. Patients may be eligible to receive free medication if they are experiencing financial hardship, have no insurance coverage, and received a prescription for on-label use of an Ipsen medication. Eligibility does not guarantee approval for participation in the program.

To qualify, patients must:
• Be uninsured or functionally uninsured
• Have a valid prescription for an Ipsen product.
• Be a United States resident
• Be experiencing financial hardship.

Providers can help patients enroll in three ways:
1. Through the online provider portal at https://ipsencaresportal.biologicsinc.com/Account/Login.
2. By printing a medication-specific downloadable PDF (https://www.ipsencares.com/) to be filled out and faxed to 1.888.525.2416.
3. By calling a patient access specialist at 866.435.5677.
REIMBURSEMENT ASSISTANCE

IPSEN CARES®
Ipsen Cares offers the following reimbursement assistance services:

- **Benefits Verification:** Ipsen Cares verifies patients’ coverage, restrictions (if applicable), and co-payment/coinsurance amounts.
- **Prior Authorization:** Ipsen Cares provides information on documentation required by payers on prior authorization specifics and makes recommendations for next steps based on payer policy.
- **Appeals Information:** Ipsen Cares provides information on the payer-specific processes required to submit a level I or a level II appeal, as well as provides guidance as needed throughout the process.

Visit ipsencares.com for more information or call 866.435.5677, Monday through Friday, 8:00 AM to 8:00 PM EST.

### 2021 Poverty guidelines as of January 13, 2021*

<table>
<thead>
<tr>
<th>PERSONS IN FAMILY/HOUSEHOLD</th>
<th>POVERTY GUIDELINE</th>
</tr>
</thead>
<tbody>
<tr>
<td>For families/households with more than 8 persons, add $4,540 for each additional person.</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>$12,880</td>
</tr>
<tr>
<td>2</td>
<td>$17,420</td>
</tr>
<tr>
<td>3</td>
<td>$21,960</td>
</tr>
<tr>
<td>4</td>
<td>$26,500</td>
</tr>
<tr>
<td>5</td>
<td>$31,040</td>
</tr>
<tr>
<td>6</td>
<td>$35,580</td>
</tr>
<tr>
<td>7</td>
<td>$40,120</td>
</tr>
<tr>
<td>8</td>
<td>$44,660</td>
</tr>
</tbody>
</table>

* Federal poverty level amounts are higher in Alaska and Hawaii.
PATIENT ASSISTANCE

Janssen CarePath
Janssen CarePath is the one source for access, affordability, and treatment support for patients. Janssen CarePath helps verify insurance coverage for patients, provides reimbursement information, helps find financial assistance options for eligible patients, and provides ongoing support to help patients start and stay on prescribed Janssen medications.

Eligible patients can be enrolled through the Janssen CarePath provider portal at janssencarepathportal.com. For questions, call 877.CarePath (877.227.3728), Monday through Friday, 8:00 AM to 8:00 PM EST.

Janssen CarePath Savings Program
The Janssen CarePath Savings Program can help eligible patients save on their out-of-pocket costs for their Janssen medicine(s). Depending on their health insurance plan, savings may apply toward co-pay, coinsurance, or deductible.

This program is only available to individuals using commercial or private health insurance for their Janssen medication, including plans available through state and federal healthcare exchanges. This program is not available to individuals who use any state or federal government-funded healthcare program to cover a portion of medication costs, such as Medicare, Medicaid, TriCare, Department of Defense, Veterans Administration. Janssen CarePath Savings Program is based on medication costs only and does not include costs to give treatment. There is no income requirement.

Savings for Janssen medicines, include:
• For Balversa, eligible patients will pay $5 per fill with a $25,000 maximum program benefit per calendar year.
• For Darzalex, Darzalex Faspro, and Yondelis, eligible patients will pay $5 per dose with a $20,000 maximum program benefit per calendar year.
• For Erleada, eligible patients will pay $0 per month with a $15,000 maximum program benefit per calendar year or one-year supply, whichever comes first.
• For Rybrevant, eligible patients will pay $5 per infusion with a $26,000 maximum program benefit per calendar year.
• For Zytiga, eligible patients pay $10 per month with a $12,000 maximum program benefit per calendar year or one-year supply, whichever comes first.

To learn more about the Janssen CarePath Savings Program, including full eligibility requirements, visit www.janssencarepath.com/hcp, select the prescribed medication, and see affordability options. For patients prescribed Balversa, visit www.balversa.com/support-resources/cost-support for more information.

Other Affordability Options
For patients using government-funded healthcare programs or without health coverage, Janssen CarePath can provide information about other resources that may be able to help patients with their out-of-pocket medication costs.

Independent co-pay assistance foundations have their own rules for eligibility. Janssen has no control...
over these independent foundations and can only refer patients to a foundation that supports their disease state. Janssen does not endorse any particular foundation.

**Johnson & Johnson Patient Assistance Foundation**

The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, nonprofit organization that is committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies. To see if patients might qualify for assistance, please contact a JJPAF program specialist at 800.652.6227, Monday through Friday, 9:00 AM to 6:00 PM EST, or visit the foundation website at [www.JJPAF.org](http://www.JJPAF.org).

**REIMBURSEMENT ASSISTANCE**

**Janssen CarePath**

Navigating payer processes may seem complicated at times. Janssen CarePath can provide informational resources that may be able to help.

**Benefits Investigation Support**

Janssen CarePath provides benefits information that may help patients get the Janssen treatments providers may be considering for them.

**Prior Authorization, Exceptions, and Appeals**

There are three primary categories of requests:
- Prior authorizations
- Coverage determinations (including exception requests)
- Appeals.

Janssen CarePath provides resources to help your practice better understand and manage payer processes. The provider portal ([https://www.janssencarepathportal.com/ProviderSelfRegister](https://www.janssencarepathportal.com/ProviderSelfRegister)) allows healthcare professionals to enroll eligible patients into the program, start benefits investigations and prior authorizations, and view the Savings Program transactions. For more information, call 877.227.3728, Monday through Friday, 8:00 AM to 8:00 PM EST.
**PATIENT ASSISTANCE**

**JazzCares™**
The JazzCares Program is sponsored by Jazz Pharmaceuticals to help improve access to Jazz products for appropriate patients. Dedicated JazzCares can:
- Help patients understand their insurance coverage.
- Help patients with paying for their medication.
- Offers a free drug program for eligible patients.

Enroll patients online via the prescribed medicine’s website (http://jazzcares.com/hcp) or call 1.833.533.5299. Patients prescribed Zepzelca can be enrolled into JazzCare online (https://jazzcares.com/patients/zepzelca/).

For more information, call 1.888.533.5299, Monday through Friday, 8:00 AM to 8:00 PM EST.

**Savings Card**
This program is only available for certain Jazz products, and it provides eligible, commercially insured patients with assistance for out-of-pocket costs, subject to an annual maximum. Eligible patients prescribed Vyxeos or Zepzelca may pay as little as $10 per prescription. For more information, call JazzCares at 1.888.533.5299.

**Free Drug Program**
Eligible patients who are uninsured or who are deemed uninsured due to lack of coverage for their prescribed medicine may receive their Jazz product at no cost. Subject to financial and residency eligibility criteria. To apply for this assistance, visit https://jazzcares.com/hcp/ and select the prescribed medication from the list to download the medicine-specific enrollment form and fax to the number listed.

**Other Financial Assistance Options**
JazzCares can also refer patients to other financial assistance.

**REIMBURSEMENT ASSISTANCE**

**JazzCares™**
To help patients understand their insurance coverage, Jazz Cares can:
- Investigate benefits and verify patients’ coverage
- Provide prior authorization and appeals support

Oncology-related products: Defitelio® (defibrotide sodium) injection, Erwineaze® (asparaginase Erwinia chrysanthemi) for injection, Vyxeos® (daunorubicin and cytarabine) liposome for injection, Zepzelca® (lurbinectedin) for injection

Patient and Reimbursement Assistance Website
jazzcares.com/hcp
PATIENT ASSISTANCE

KaryForward®

KaryForward is a patient support program dedicated to providing assistance and resources to patients and their caregivers for Karyopharm medications, including insurance coverage, financial assistance, and resources and support.

All support and programs are subject to eligibility requirements. Enroll patients online (https://www.karyforward.com/hcp) or fax the completed enrollment form (https://www.karyforward.com/pdf/KaryForward%20Enrollment%20Form.pdf) to 1.833.589.1603. For more information, call 1.877.KARY4WD (1.877.527.9493), Monday through Friday, 8:00 AM to 8:00 PM EST.

Xpovio Co-pay Program

This offer allows eligible patients with commercial insurance to pay as little as $5 per prescription, with a maximum of $8,000 per month and an annual cap of $25,000. The program will cover the co-pay costs of the Karyopharm Therapeutics product only. Patients must meet the following criteria to enroll:

- United States or U.S. territory residency
- Patient has commercial (private) insurance that covers Xpovio

Patients are not eligible if they are uninsured or if they participate in any federal or state healthcare program, including without limitation Medicare, Medicaid, TriCare, and Veterans Health Administration. This offer is not valid for cash-paying patients, where Xpovio is not covered by patients’ commercial insurance, or where the plan reimburses patients for the entire cost of the medication. Karyopharm Therapeutics reserves the right to rescind, revoke, amend, or terminate this offer or the program in its entirety at any time.

To enroll patients in the program, apply online at https://portal.trialcard.com/xpovio/ or download and complete the KaryForward Enrollment Form (https://www.karyforward.com/pdf/KaryForward%20Enrollment%20Form.pdf), check the “Copay Program” box, and fax the form to 1.833.589.1603.

KayForward Patient Assistance Program

Patients who are uninsured or underinsured may be eligible to receive Karyopharm medications at no cost. In order to be eligible for the program, patients must:

- Be a resident of the United States or its territories and be under the care of a licensed healthcare professional authorized to prescribe, dispense, and administer medicine in the U.S.
- Be uninsured or underinsured or lack coverage for the prescribed therapy.

To enroll patients in KayForward Patient Assistance Program, download and complete the Enrollment Form (https://www.karyforward.com/pdf/KaryForward%20Enrollment%20Form.pdf), mark the “Patient Assistance Program” box, and fax the completed form to 1.833.589.1603.

Alternate Sources of Coverage

If patients do not meet the eligibility criteria for the co-pay program or patient assistance program, KaryForward may be able to help identify alternate sources of coverage. To get started, download and complete an enrollment form (https://www.karyforward.com/pdf/KaryForward%20Enrollment%20Form.pdf) or call KaryForward at 1.877.KARY4WD (1.877.527.9493), Monday through Friday, 8:00 AM to 8:00 PM EST.

QuickStart Program

This program enables providers to initiate Karyopharm medications.
according to prescribing information for patients who experience a delay in insurance coverage. Patients may be eligible for this program if circumstances exist, including but not limited to patient safety, when:

• There is an inability to verify insurance coverage within five business days.
• A healthcare professional determines the patient needs urgent access to the Karyopharm medication.

**Bridge Program**
This program enables healthcare professionals to provide eligible patients an emergency supply of a Karyopharm medication at no cost if they experience an unexpected disruption in therapy exceeding five business days and if a provider determines that it is medically necessary for the patient to continue therapy without interruption.

**Dose Exchange Program**
KaryForward’s Dose Exchange Program can help healthcare professionals make necessary adjustments to patient’s Xpovio dose mid-cycle. For additional refills, a new prescription will need to be submitted to the patient’s specialty pharmacy or an in-office dispensing site. Patients can be enrolled into the program online at: [https://www.karyforward.com/hcp](https://www.karyforward.com/hcp).

**REIMBURSEMENT ASSISTANCE**

**KayForward**
Get assistance navigating the insurance process, including:

• **Insurance verification**, including benefits, deductibles, and co-pay or coinsurance
• **Prior authorization assistance**, including identifying plan-specific requirements and providing information about the process

• **Coding and billing assistance**, including providing information on the prescribed therapy and the respective regimen
• **Claims management and appeals assistance**, including providing information about the appeals process if a denial is received.

To get started, fax a completed enrollment form ([https://www.karyforward.com/pdf/KaryForward%20Enrollment%20Form.pdf](https://www.karyforward.com/pdf/KaryForward%20Enrollment%20Form.pdf)) to 1.833.589.1603 or call KaryForward at 1.877.KARY4WD (1.877.527.9493), Monday through Friday, 8:00 AM to 8:00 PM EST.
Kite Konnect™
Kite Konnect provides a vital link of support to patients, caregivers, and healthcare professionals. From patient identification to follow-up, it helps facilitate treatment and maintain a critical connection to care, including:
• **Patient enrollment:** Register a patient for therapy if you are a healthcare professional.
• **Reimbursement support:** Help with benefits investigation, claims appeals information, and potential sources of support for eligible and underinsured patients.
• **Logistics support:** Learn about potential resources for transportation and housing assistance.
• **Ongoing commitment:** Kite Konnect case managers are available to support healthcare professionals and patients throughout the CAR-T treatment journey.

For healthcare professionals at authorized treatment centers, start by enrolling patients for therapy using the Kite Konnect Hospital Portal: https://kitekonnect.force.com/s/. For the most up-to-date information and additional details, call Kite Konnect at 1.844.454.5483.
PATIENT ASSISTANCE

Merck Access Program
The Merck Access Program may be able to help answer questions about access and support, including:
• Benefit investigations, prior authorizations, and appeals
• Insurance coverage for patients
• Co-pay assistance for eligible patients
• Referral to the Merck Patient Assistance Program for eligibility determination
• Reimbursement.

To enroll, visit merckaccessprogram.com/hcp/, select the prescribed medication, and use the online portal (merckaccessportal.com/merck/) or complete the appropriate enrollment form that can be signed and submitted electronically. For hard copy forms, print and fax the completed form to the number listed on it. A program representative will contact the patient and provider.

For further assistance, call 855.257.3932, Monday through Friday, 8:00 AM to 8:00 PM EST.

Merck Co-Pay Assistance Program
The Merck Co-pay Assistance Program offers assistance to eligible, privately insured patients who need help affording the out-of-pocket costs for their medication. Once enrolled, patients prescribed Keytruda will pay the first $25 of their co-pay per infusion, subject to a maximum co-pay assistance program benefit of $25,000 per patient, per calendar year. Co-pay assistance may be available for patients who:
• Are a resident of the United States (including Puerto Rico)
• Have private health insurance that covers the prescribed, eligible Merck medicine under a medical benefit program
• Have been prescribed the prescribed, eligible Merck medicine for an FDA-approved indication
• Meet all other criteria of the program.

If the patient is ineligible for this program, they may be able to get help from an independent co-pay assistance foundation. A representative can provide information about independent foundations that are able to provide financial support to patients who do not qualify for the Merck Co-Pay Assistance Program. Each independent foundation has its own eligibility criteria and application process. For more information, visit www.merckaccessprogram-keytruda.com/hcp/the-merck-copay-assistance-program/ and contact the patient and provider office.

The Merck Co-pay Assistance Program is not valid for patients covered under a government program, as that term is defined in the terms and conditions. The program is not valid for uninsured patients.

To enroll, visit www.merckaccessprogram-keytruda.com/hcp/the-merck-copay-assistance-program/ and a program representative will contact the patient and provider office.

Oncology-related products: Emend® (aprepitant) capsules, Emend® (fosaprepitant dimeglumine) for injection, Intron® A (interferon alfa-2b, recombinant) for injection, Keytruda® (pembrolizumab) injection, Ontruzant® (trastuzumab-dttb) for injection, Zolinza® (vorinostat) capsules

Vaccine: Gardasil®9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
The Organon Access Program
The Organon Access Program can help answer questions about insurance coverage for Ontruzant, what options may be available for co-pay assistance, and eligibility for referrals to the Organon Patient Assistance Program. If requesting a referral to the patient assistance program, include a prescription for Ontruzant in the patient’s program application.

Enroll patients into the program online (organonaccessprogram-ontruzant.com/hcp/enroll-now). To enroll over the phone or for questions, call 844.326.2986, Monday through Friday, 8:00 AM to 8:00 PM EST.

Organon Co-Pay Assistance Program
Eligible patients must pay the first $5 of co-pay per administration of Ontruzant, subject to a maximum benefit per patient, per calendar year of $25,000. To be eligible, patients must:
• Must be prescribed Ontruzant for an FDA-approved indication
• Must have private health insurance that provides coverage for the cost of Ontruzant under a medical benefit plan.

The program is not valid for uninsured patients or those who are covered under Medicaid, Medicare, a Medicare Part D or Medicare Advantage plan, TriCare, CHAMPUS, Puerto Rico Government Health Insurance Plan, or any other state or federal medical or pharmaceutical benefit program or pharmaceutical assistance program.

Merck Helps™
Merck provides certain medicines and adult vaccines for free to people who do not have prescription drug or health insurance coverage and who, without assistance, cannot afford their Merck medicines and vaccines. If patients need help paying for their medicines or adult vaccines, the Merck Patient Assistance Program may be able to help.

Merck Patient Assistance Program
This private and confidential program provides certain medicines free of charge to eligible individuals, primarily the uninsured who, without assistance, could not afford needed Merck medicines. Individuals who don’t meet the insurance criteria may still qualify for the Merck Patient Assistance Program if they attest that they have special circumstances of financial and medical hardship, and their income meets the program criteria. A single application may provide for up to one year of medicine free of charge to eligible individuals and an individual may reapply as many times as needed.

Eligibility criteria include:
• Patient must be a United States resident and have a prescription for a Merck product from a healthcare provider licensed in the United States.
• Patient does not have insurance or other coverage for their prescription medicine.
• Patient cannot afford to pay for their medicine.

Specific income requirement amounts can be found at www.merckhelps.com/. Select the prescribed medication to see qualifications. If patients do not meet the prescription drug coverage criteria, their income meets the program criteria, and there are special circumstances of financial and medical hardship that apply to their situation, you can request that an exception be made. Patients do not have to be a U.S. citizen.

To apply, patients and providers must complete the Enrollment Form for the specific Merck medication. Visit merckhelps.com and search for the specific medication, download and complete the medication’s enrollment form, and mail completed forms to the address listed at the top. For assistance, call 800.727.5400.

REIMBURSEMENT ASSISTANCE

Merck Access Program Benefit Investigations
The Merck Access Program can contact insurers to request coverage and benefits information. Visit the specific Merck product site for additional resources.

Prior Authorizations
If a prior authorization is required, or for assistance in understanding if a prior authorization is required, the Merck Access Program may be able to help. The prior authorization checklist and sample letter can help healthcare professionals understand the documents and information that may be helpful when seeking a prior authorization. As always, providers should check for payer-specific requirements.

Appeals
The program may be able to help healthcare professionals understand the information appeal submission. The appeal checklist and sample appeal letter can help you to understand the documents and infor-
information that may be helpful when filing an appeal. As always, check for payer-specific requirements.

For any questions, call 855.257.3932, Monday through Friday, 8:00 AM to 8:00 PM EST.

The Organon Access Program
The program can answer questions about:
• Benefit investigations
• Billing and coding
• Co-pay assistance for eligible patients
• Prior authorizations and appeals
• Referrals to the patient assistance program
• Product distribution.

Enroll patients into the program online (organonaccessprogram-truzant.com/hcp/enroll-now). To enroll over the phone or for questions, call 844.326.2986, Monday through Friday, 8:00 AM to 8:00 PM EST.
PATIENT ASSISTANCE

My MISSION Support
The My MISSION Support program cares about making sure eligible patients get the help they need to start treatment. Whether a patient is uninsured or has challenges with out-of-pocket costs through their insurance plan, My MISSION Support has a variety of programs that may be able to assist.

Enroll patients online (https://www.mymissionsupport.com/enroll#follow-these-easy-steps) or send the completed downloadable enrollment form via fax to 866.870.6241 or via email to access@MyMissionSupport.com. Once the enrollment form is submitted, a My MISSION Support program specialist will work with patients to provide patient-specific support.

For any questions, call 855.421.6172, Monday through Friday, 8:00 AM to 8:00 PM EST.

Co-pay Assistance Program
Commercially insured patients taking Monjuvi may be able to receive assistance through the My MISSION Support Co-Pay/Coinsurance Assistance Program. If eligible, patients may pay as little as $0 for Monjuvi, up to $25,000 per calendar year, to help with their out-of-pocket costs.

In order to be eligible for the co-pay program, patients:
• Must have commercial insurance
• Must not have Medicare, Medicaid, or other government insurance
• Must meet certain guidelines set forth in the program’s terms and conditions.

To enroll in the program, please complete the following sections of the My MISSION Support enrollment form (www.mymissionsupport.com/enroll#follow-these-easy-steps):
• Sections 1 through 4 regarding co-pay support and patient- and insurance-specific information
• Sections 5 and 7 regarding physician information and signature
• Sections 9 and 10 regarding patient signature and consent.

Submit the form online, fax it to 866.870.5241, or email it to access@mymissionsupport.com.

Co-pay Assistance Program
Commercially insured patients taking Monjuvi may be able to receive assistance through the My MISSION Support Co-Pay/Coinsurance Assistance Program. If eligible, patients may pay as little as $0 for Monjuvi, up to $25,000 per calendar year, to help with their out-of-pocket costs.

In order to be eligible for the co-pay program, patients:
• Must have commercial insurance
• Must not have Medicare, Medicaid, or other government insurance
• Must meet certain guidelines set forth in the program’s terms and conditions.

To enroll in the program, please complete the following sections of the My MISSION Support enrollment form (www.mymissionsupport.com/enroll#follow-these-easy-steps):
• Sections 1 through 4 regarding co-pay support and patient- and insurance-specific information
• Sections 5 and 7 regarding physician information and signature
• Sections 9 and 10 regarding patient signature and consent.

Submit the form online, fax it to 866.870.5241, or email it to access@mymissionsupport.com.
Independent Support Organizations
Patients with coverage for Monjuvi through Medicare (either through Medicare Advantage or traditional Medicare), Medicaid, or other government-sponsored insurance may be eligible for support through independent third-party foundations. My Mission Support can provide contact information for independent third-party organizations that may be able to assist patients with the following:
• Deductibles
• Co-pays/coinsurance
• Insurance premiums
• Treatment-related costs, such as transportation, home care and child care.

Eligibility requirements are determined solely by the independent foundation and assistance availability will vary by organization. For more information, call 855.421.6172, Monday through Friday, 8:00 AM to 8:00 PM EST.

REIMBURSEMENT ASSISTANCE
My MISSION Support
The My Mission Support program is a resource for healthcare providers for access and reimbursement support for their patients. Its field access and reimbursement managers can provide assistance to support access to Monjuvi. Program specialists can help research patient-specific benefits and answer any questions related to coding and coverage for Monjuvi.

In the event of a claim denial, My Mission Support can research the denial reason and assist healthcare providers in the preparation of an appeal submission. Once the appeal is submitted, program specialists can follow up with the insurer until a coverage determination is made.

Enroll patients online (https://www.mymissionsupport.com/enroll#follow-these-easy-steps) or send the completed downloadable enrollment form via fax to 866.870.6241 or via email to access@MyMissionSupport.com. To find out more, call 855.421.6172, Monday through Friday, 8:00 AM to 8:00 PM EST.
PATIENT ASSISTANCE

**Viatris Advocate™**
A team of dedicated patient access specialists is available to answer calls and address concerns or questions regarding:
- Reimbursement support
- Financial support
- Field reimbursement support
- Alternate coverage identification.

Enroll patients into Viatris Advocate online via the provider portal (https://www.viatrisadvocateportal.com/via_pp/login/#/), or fax the completed patient enrollment form (https://www.fulphila.com/-/media/fulphilacom/pdf/patient_enrollment.pdf?la=en) to 833.247.2756. For assistance or additional information, call 833.695.2623, Monday through Friday, 9:00 AM to 8:00 PM EST.

**Viatris Advocate™ Co-Pay Assistance Program**
The program can be used to reduce the amount of an eligible patient’s out-of-pocket expenses for their prescribed Mylan medications. For patients prescribed Fulphila, the program can cover up to the full amount of the patient’s out-of-pocket expense per prescription, up to a maximum of $10,000 per 12-month period. For patients prescribed Ogivri, the program can cover up to the full amount of the patient’s out-of-pocket expense per prescription, subject to a maximum aggregate amount of $25,000 per 12-month period.

To be eligible, patients must:
- Be or have a guardian that is 18 years of age or older
- Be a resident of the United States or Puerto Rico
- Have commercial prescription drug insurance.

This co-pay assistance program is not valid for uninsured patients or commercially insured patients without coverage for the prescribed Mylan medication; not valid for patients who are covered in whole or in part by any state or federally funded healthcare program, including, but not limited to, any state pharmaceutical assistance program, Medicare (Part D or otherwise), Medicaid, Medigap, VA or DOD, or TriCare; not valid if the patient is Medicare eligible and enrolled in an employer-sponsored health plan or prescription benefit program for retirees; and not valid if the patient’s insurance plan is paying the entire cost of this prescription.

Patient Assistance Program
Patients without insurance coverage for their prescribed Mylan medicines who cannot afford their medication may be able to receive Mylan product(s) free of charge. Eligibility requirements apply based on residency, income, and other factors. Contact Viatris Advocate at 1.833.695.2623 for more information.

Alternate Coverage Identification
Viatris Advocate can help identify other resources, such as state programs or third-party charitable foundations, that may be able to assist patients.

REIMBURSEMENT ASSISTANCE

**Viatris Advocate™**
A team of dedicated patient access specialists is available to answer calls and address concerns or questions regarding:
- Coding and billing
- Benefit investigation
- Prior authorization/reauthorization assistance and tracking
- Coverage/claim appeal assistance and tracking
- Insurance coverage verification
- Field reimbursement support.
Patient Assistance Checklist for Uninsured Patients

- I have received the chemotherapy order written by the physician?  
  - YES  
  - NO  
  If no, list drug(s) below and continue on with checklist.

- Is a replacement drug program available?  
  - YES  
  - NO  
  If yes, identify drug and program:

- Does the patient qualify for this program?  
  - YES  
  - NO  
  If no, state reason(s) why:

- If yes, I have completed all the necessary forms and paperwork for the drug replacement program.  
  - YES  
  - NO  
  If no, state reasons why:

- Does the patient need drug(s) that are not available through a drug replacement program?  
  - YES  
  - NO  
  If yes, identify which drugs:

- Is Foundation funding assistance available for any of these drug(s)?  
  - YES  
  - NO  
  If yes, identify Foundation(s) and drug(s):

- I have completed all the necessary forms and paperwork for these Foundation funding program(s).  
  - YES  
  - NO  
  If no, state reasons why:

- Does the patient qualify for charity care within from my clinic, cancer center, hospital, or healthcare system?  
  - YES  
  - NO  
  If yes, identify program:

- I have completed all the necessary forms and paperwork necessary to apply for this charity care.  
  - YES  
  - NO  
  If no, state reasons why:

- Is there a balance or money owed related to treatment?  
  - YES  
  - NO  
  If yes, identify balance:

- If yes, I have worked with the patient and family to create a payment plan for the balance of his or her treatment costs.  
  - YES  
  - NO

Source: ACCC Financial Advocacy Network. accc-cancer.org/FAN
PATIENT ASSISTANCE

Patient Assistance Now Oncology (PANO)

PANO is the preferred first stop for access to Novartis Oncology Patient Support programs. Through one-on-one guidance with a dedicated case manager, patients will discover which Novartis Oncology Patient Support programs they are eligible to receive and may also be referred to other services.

Support for patients include:

- Information about financial assistance that may be available
- Patient support counselors who are able to provide information in more than 160 languages
- Patient navigators who provide one-on-one support specific to a patient’s Novartis medication
- Dedicated case managers with private extensions who can be contacted directly for updates on patients
- Insurance benefits verification, including information on prior authorizations and denial appeals
- A combination of PANO case managers and/or field reimbursement managers are available to help, depending on the complexity of a patient’s case.

To learn more about how PANO can help, call 1.800.282.7630, Monday through Friday, 9:00 AM to 8:00 PM EST.

Novartis Patient Assistance Foundation

This foundation may help provide access to Novartis medicines to patients experiencing financial hardship and/or have no third-party insurance coverage for their medicines. Please be advised that access to the medicines distributed through the Novartis Patient Assistance Foundation, Inc., is free of charge to all eligible patients.

To be eligible, patients must:

- Be a United States resident
- Provide proof of income that meets financial eligibility requirements
- Have limited or no prescription coverage. (Exceptions exist for individuals with limited prescription coverage.)

There are two ways to enroll in the program:

- Fill out the PANO Service Request Form online by visiting patient.novartisoncology.com/financial-assistance/PANO/.
- Download and complete the PANO Service Request Form (www.patient.novartisoncology.com/financial-assistance/PANO/), and fax the completed form to 1.888.891.4924.

To learn more about how the Novartis Patient Assistance Foundation can help, call 1.800.277.2254.

Oncology-related products: Adakveo® (crizanlizumab-tmca) for IV infusion, Afinitor® (everolimus) tablets, Exjade® (deferasirox) tablets for oral suspension, Femara® (letrozole) tablets, Gleevec® (imatinib mesylate) tablets, Jadenu® (deferasirox) tablets, Kisqali® (ribociclib) tablets, Kymriah® (tisagenlecleucel) suspension for IV infusion, Mekinist® (trametinib) tablets, Piqray® (alpelisib) tablets, Promacta® (el trombopag) tablets, Rydapt® (midostaurin) capsules, Sandostatin® (octreotide acetate) injection, Sandostatin® LAR Depot (octreotide acetate) for injectable suspension, Tabrecta™ (capmatinib) tablets, Tafinlar® (dabrafenib) capsules, Tasigna® (nilotinib) capsules, Tykerb® (lapatinib) tablets, Votrient® (pazopanib) tablets, Zometa® (zoledronic acid) for injection, Zykadia® (ceritinib) tablets

Patient and Reimbursement Assistance Websites

hcp.novartis.com/access
patient.novartisoncology.com/financial-assistance/
Universal Co-Pay Program

Novartis Oncology has made it easy for patients with private insurance to access financial support for their prescription co-pay costs on almost all Novartis Oncology medications.

Eligible, privately insured patients may pay $25 per month and Novartis will pay the remaining co-pay, up to $15,000 per calendar year, per product. Patients are responsible for any costs once the limit is reached in a calendar year. This program is not available for patients who are enrolled in Medicare, Medicaid, TriCare, VA, DoD, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend the program and discontinue support at any time without notice. Find out if a patient is eligible to enroll in the program by visiting Copay.NovartisOncology.com or by calling 1.877.577.7756.

Independent Charitable Foundations

If patients have government insurance, there may be financial assistance options available. To see a variety of independent charitable foundations that may be available to provide additional assistance, visit www.patient.novartisoncology.com/financial-assistance/government-insurance/.

The organizations and websites listed are independently operated and not managed by Novartis Pharmaceuticals Corporation. Novartis assumes no responsibility for any information they may provide.

Kymriah Cares®

Whether patients and providers have questions about Kymriah or insurance coverage, Kymriah Cares can help. The program can provide assistance with treatment center support, patient support, and coordination of care support.

To learn more, call 1.844.4KYMRIAH (1.844.459.6742) from 8:00 AM to 8:00 PM EST.

REIMBURSEMENT ASSISTANCE

Patient Assistance Now Oncology (PANO)

PANO is the preferred first stop for access to Novartis Oncology Patient Support programs. Through one-on-one guidance with a dedicated case manager, patients will discover which Novartis Oncology Patient Support programs they are eligible to receive and may also be referred to other services. Support for patients includes:

- Insurance benefits verification
- Information on prior authorization
- Information on denial appeals.

Get started today by submitting the PANO Service Request Form online (https://www.hcp.novartis.com/access/). To learn more call 1.800.282.7630, Monday through Friday, 9:00 AM to 8:00 PM EST.
PATIENT ASSISTANCE

On Course™
On Course provides insurance support and reimbursement information, as well as financial assistance, guidance, and understanding for patients.

To enroll patients in the program, complete the enrollment form (oncoursesupport.com/docs/Oncopeptides_ON_COURSE_Enrollment_Form_0221.pdf) in its entirety, including signatures from the patient and healthcare professional, and fax the completed form to 1.844.662.6737. For questions, call 1.844.300.ONCO (1.844.300.6626), Monday through Friday, 8:00 AM to 8:00 PM EST.

Co-Pay Card
Eligible patients with commercial insurance may pay as little as $5 per month, with an annual cap of $25,000; max amount is $8,000 per month. Other restrictions may apply. Patient must meet the following criteria to enroll:
• United States or U.S. territory residency.
• Patient has commercial (private) insurance that covers Pepaxto
• Pepaxto is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.

Patient is not eligible if they are uninsured or if they participate in any federal or state health care program, including without limitation Medicare, Medicaid, Tricare, Veterans Health Administration. This program is not valid for cash-paying patients, where Pepaxto is not covered by the patient’s commercial insurance, or where the plan reimburses patients for the entire cost of Pepaxto.

To enroll patients in the program, apply online (https://portal.trialcard.com/oncopeptides/melflufen/), or download and complete the Oncopeptides enrollment form (oncoursesupport.com/docs/Oncopeptides_ON_COURSE_Enrollment_Form_0221.pdf) in its entirety, select “Copay Assistance” in the first box, and fax the completed form to 1.844.662.6737.

REIMBURSEMENT ASSISTANCE

On Course™
On Course can work with practices and programs to help evaluate patients’ prescription insurance coverage options, including:
• Insurance benefits verification: The program will help research patients’ insurance benefits to determine their coverage.

Patient Assistance Program
On Course includes a patient assistance program for patients who do not have access to health insurance or for who’s insurance plan does not cover the entire cost of their medication. The program may be able to provide the prescribed medication at no cost. Some restrictions apply, and patients will need to meet certain eligibility criteria.

To enroll and determine patient eligibility, complete the enrollment form (oncoursesupport.com/docs/Oncopeptides_ON_COURSE_Enrollment_Form_0221.pdf) in its entirety, select “Patient Assistance Program (PAP)” in the first box, and fax the completed form to 1.844.662.6737. If patients are uninsured, make sure to fill out the “Evaluate for PAP Program” section, as well.
• **Prior authorization assistance:**
The program will partner with providers to manage the prior authorization process on behalf of your patients.

• **Claims management and appeals assistance:** If insurance denies a patient’s coverage, the program can assist with the appeals process.

Coding and billing information is also available on its website (https://oncoursesupport.com/health-care-professionals.html). For more information, call 1.844.300.ONCO (1.844.300.6626), Monday through Friday, 8:00 AM to 8:00 PM EST.
PATIENT ASSISTANCE

Pfizer Oncology Together™

At Pfizer Oncology Together, patient support is at the core of everything it does. It can help patients:

- Access their prescribed Pfizer Oncology medications
- Identify financial assistance options
- Connect patients to a dedicated care champion who can offer personalized support resources.

To enroll patients, providers can use the Provider Portal (https://www.pfizeroncologytogether-portal.com/) or download the Pfizer Oncology Together enrollment form (pfizeroncologytogether.com/enroll) and fax the completed form to 1.877.736.6506. For questions, call 1.877.744.5675, Monday through Friday, 8:00 AM to 8:00 PM EST. Visit pfizeroncologytogether.com for more information.

Pfizer Oncology Together Co-Pay Savings Program

Eligible, commercially insured patients may pay as little as $0 per month for their oral medications or per treatment for injectable medications through these co-pay savings programs. For oral products, patients may receive up to $25,000 in savings annually. For certain injectable products, the maximum annual patient savings range from $10,000 to $25,000.

Patients are not eligible for these programs if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TriCare, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. The co-pay card will be accepted only at participating pharmacies. For oral products, you may be able to submit a request for a rebate in connection to a program offer if your pharmacy does not participate. Pfizer reserves the right to rescind, revoke, or amend these programs without notice. For more information, call 1.877.744.5675 or visit www.pfizeroncologytogether.com.

Pfizer Patient Assistance Program

Eligible patients may receive up to a 90-day supply of Pfizer medication for free, while applying for Medicaid. If patients do not qualify for Medicaid, they may be able to
get a one-year supply of medication for free through the Pfizer Patient Assistance Program. Patients must meet eligibility requirements and reapply as needed.

To be evaluated for assistance through the Pfizer Patient Assistance Program, healthcare professionals and their patients must submit a completed enrollment form. Patients must also provide proof of income, such as the prior year’s tax return, a W2 form, or a paycheck stub. They also must:

• Have a valid prescription from a healthcare provider licensed in the United States or a U.S. territory for the Pfizer medication for which they are seeking
• Have no prescription coverage, or not enough coverage, to pay for their Pfizer medication
• Meet certain income limits, which are subject to change on an annual basis and will vary depending on household size
• Reside in the U.S. or a U.S. territory
• Not be treated in an inpatient setting of care, such as a hospital or nursing home.

The Pfizer Patient Assistance Program is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions.

If a patient is accepted into the Pfizer Patient Assistance Program, Pfizer will inform the healthcare professional by fax and phone and the patient by phone and letter. Uninsured patients may receive free medication for up to one calendar year, while underinsured patients are enrolled through the end of the calendar year. For more information, call 1.877.744.5675 or visit www.pfizeroncologytogether.com/.

Support from Independent Charitable Organizations
Pfizer will assist patients with searching for financial support that may be available from independent charitable foundations. These foundations exist independently of Pfizer and have their own eligibility criteria and application processes. Availability of support from the foundations is determined solely by the foundations.

Pfizer RxPathways®
Pfizer RxPathways connects eligible patients to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. Visit www.pfizerrxpathways.com/ to search by the prescribed medication’s name and see which available programs are right for patients.

REIMBURSEMENT ASSISTANCE

Pfizer Oncology Together™
If patients need access or reimbursement support for their prescribed Pfizer oncology medications, the following support is available:

• Benefits verification: Pfizer can conduct a benefits verification to determine patients’ health insurance coverage and out-of-pocket costs.
• Prior authorization assistance: Pfizer will coordinate with patients’ insurer to determine the prior authorization requirements, where and how to submit requests, and typical turnaround times. Pfizer will also follow up with the insurer on behalf of patients and track the progress and status.
• Appeals assistance: Pfizer can review the reasons for a denied claim and help with the appeals process by providing information on payer requirements.
• Online support: Log in to the provider portal (www.pfizeroncologytogether-portal.com/) to complete and submit an online enrollment form, view secure messaging, generate patient status reports, and access forms, tools and resources.

For any questions about a specific Pfizer Oncology product, a Pfizer Oncology account specialist can help provide detailed information. Find your local representative at https://www.pfizeroncologytogether.com/hcp/reimbursement-information#local-support. For more information and questions, call 1.877.744.5675, Monday through Friday, 8:00 AM to 8:00 PM EST.
PATIENT ASSISTANCE

Imbruvica By Your Side

Imbruvica By Your Side offers personalized support to help patients access and stay on track with their prescribed treatment. It has expanded its offerings to include:

- Connections with field access specialists who work with providers’ offices to help patients navigate insurance reimbursement
- Patient support ambassadors who provide individualized support with patients and encourages them to contact their care team for guidance around any health concerns
- Resources that help patients better understand how to maintain their treatment as prescribed
- Tools that help patients track their treatment and support them throughout the journey to navigate pain points and stay on track with their prescribed treatment.

Any patients that were enrolled in the YOU&i™ program have been automatically enrolled in Imbruvica By Your Side.

Learn more about the financial support available for patients with and without insurance. By Your Side ambassadors connect patients with insurance specialists to learn about access to Imbruvica, find affordability support options, and sign up for information and resources to support them along their treatment journey.

Enroll patients in this program online (https://imbruvicahcp.com/by-your-side-enrollment-form/) or by downloading the enrollment form (https://imbruvicahcp.com/patient-support-program/) and faxing it to 1.800.752.5896 To learn more about this program, call 1.888.YourSide (1.888.968.7743), Monday through Friday, 8:00 AM to 8:00 PM EST.

Imbruvica Co-Pay Program

Eligible patients may pay as little as $10 per prescription of Imbruvica until the maximum limit of $24,600 per calendar year is reached. The program is available to patients with commercial prescription coverage who meet eligibility criteria. The Imbruvica Co-Pay Card cannot be used by patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs, including Medicare Part D, Medicare Advantage Plan, Medicaid, Medigap, VA, DOD, and TriCare, or where prohibited by law or the patient’s health insurance provider.

Independent Charitable Organizations

For patients with federally funded Medicare, Medicaid, or commercial insurance, financial assistance may be available from independent charitable organizations. Contact information for such independent charitable organizations is available upon request. Independent charitable organizations have their own rules for eligibility. Imbruvica By Your Side has no control over these independent charitable organizations.

Dose Exchange Program

The Imbruvica By Your Side Dose Exchange Program is available to facilitate a dose reduction if providers decide to adjust patients’ doses before they have finished their current pack of Imbruvica. Patients may qualify for the program if they meet each of the requirements:

- Patients must have remaining pills from a current prescription for an FDA-approved indication for Imbruvica.
- Patients must return their remaining pills.

Instructions for return will be provided with a pre-addressed envelope for patients to return any unused quantity of the oncology-related product: Imbruvica® (ibrutinib) capsules.
previous strength. To enroll patients, download, sign, and fax the enrollment form (https://imbruvicahcp.com/dose-exchange-prescription-enrollment-form.pdf), to 1.800.752.5896.

REIMBURSEMENT ASSISTANCE

Imbruvica By Your Side
The Imbruvica By Your Side program connects you with field access specialists who work with providers’ offices to help patients navigate insurance reimbursement. Enroll patients in this program online (https://imbruvicahcp.com/by-your-side-enrollment-form/) or by downloading the enrollment form (https://imbruvicahcp.com/patient-support-program/) and faxing it to 1.800.752.5896.

To learn more about the services available and for questions, call 1.888.YourSide (1.888.968.7743), Monday through Friday, 8:00 AM to 8:00 PM EST.
PATIENT ASSISTANCE

LIBTAYO Surround®

LIBTAYO Surround® offers patient support that facilitates access to medication when patients need assistance with out-of-pocket costs. The program will help investigate patients’ eligibility in the following programs:

- Commercial co-pay program
- Patient assistance program. For more information call, 1.877.LIBTAYO (1.877.542.8296), option 1, Monday through Friday, 8:00 AM to 8:00 PM EST.

Commercial Co-pay Program

Eligible patients with commercial insurance may pay as little as $0 for Libtayo, which includes any product-specific co-pay, coinsurance, and insurance deductibles—up to $25,000 in assistance per year. There is no income requirement to qualify for the program.

This program is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, Veterans Affairs/Department of Defense, TriCare, or similar federal or state programs. This program is not a debit card program and does not cover or provide support for supplies, procedures, or any physician-related service associated with Libtayo. General non–product-specific co-pays, coinsurance, or insurance deductibles are not covered. Additional program conditions apply.

To be eligible:

- Patients must be insured by a commercial health plan that requires a co-payment, coinsurance, and/or deductible amount for Libtayo.
- Patients must be residents of the United States or its territories or possessions.
- Patients must be at least 18 years of age.
- Patients must be prescribed Libtayo for an FDA-approved indication.

There are two ways to enroll patients in the co-pay program:

- Download the LIBTAYO Surround Enrollment Form (https://www.libtayohcp.com/libtayo-surround-enrollment#enroll-content) in English or Spanish and fax the completed form to 1.833.853.8362.
- Physician offices can also apply on patients’ behalf via the provider portal (https://www.libtayosurroundportal.com/libtayoprovider/s/login/?ec=302&startURL=%2Flibtayoprovider%2F)

Patient Assistance Program

Eligible patients who meet income requirements and are uninsured, lack coverage for Libtayo, or have Medicare Part B with no supplemental insurance coverage may receive Libtayo at no cost. Patients must have an annual gross household income that does not exceed the greater of $100,000 or 500 percent of the federal poverty level. Enroll patients via the provider portal or Libtayo Surround enrollment form (https://www.libtayohcp.com/libtayo-surround-enrollment#enroll-content).

Identification of Alternate Sources of Funding

Patients without insurance coverage or patients with inadequate insurance coverage who need assistance with out-of-pocket medication costs may be eligible for alternate funding sources for Libtayo.

For more information, call LIBTAYO Surround at 1.877.LIBTAYO (1.877.542.8296).
Nurse Support
Patients can contact a LIBTAYO Surround nurse advocate 24/7 to receive the following additional support throughout their treatment journey:
- Information on patient advocacy groups and local support organizations, transportation services, and travel and lodging
- General patient education
- Appointment reminders.

REIMBURSEMENT ASSISTANCE

LIBTAYO Surround®
LIBTAYO Surround provides access and reimbursement support to help patients receive their medication as quickly as possible. Upon receipt of a LIBTAYO Surround enrollment form, a LIBTAYO Surround reimbursement specialist may be able to provide several types of assistance, including:
- Benefits investigation
- Prior authorization assistance to review and explain payer requirements
- Appeal assistance when prior authorizations are denied
- Claims assistance to address questions as healthcare providers prepare claims and to review the status of claims with patients’ health insurers.

Enroll patients online using the provider portal or fax the completed enrollment form (https://www.libtayohcp.com/libtayo-surround-enrollment#enroll-content) to 1.833.853.8362. For more information, call 1.877.LIBTAYO (1.877.542.8296), option 1, Monday through Friday, 8:00 AM to 8:00 PM EST.
PATIENT ASSISTANCE

Sandoz One Source®
Sandoz One Source provides comprehensive patient support services designed to help simplify and support patient access. Available services include:
- Product replacement program
- Commercial co-pay program
- Independent foundation information
- Patient assistance program
- Reimbursement support.

To enroll, download and complete the enrollment form (https://www.ziextenzo.com/sites/ziextenzo_com/files/2020-11/ZIEXTENZO-Sandoz-One-Source-Enrollment-Form.pdf) and fax the completed form to 1.844.726.3695.

For more information, call 1.844. SANDOZ1 (1.844.726.3691), Monday through Friday, 8:00 AM to 8:00 PM EST.

Commercial Co-Pay Program
The Sandoz One Source Commercial Co-Pay Program supports eligible, commercially insured patients with their out-of-pocket costs for Zarxio or Ziextenso. There are no income requirements. The virtual co-pay card ensures that patients have immediate access to their benefits.

Patients may pay $0 out-of-pocket for the first dose or cycle and for subsequent doses or cycles up to a maximum benefit of $10,000 annually. Patients’ prescription must be for an approved indication. This program is for insured patients only; cash-paying or uninsured patients are not eligible.

Patients are not eligible if prescription for Ziextenso or Zarxio is paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TriCare, or private indemnity plans that do not cover prescription drugs, or HMO insurance plans that reimburse the patient for the entire cost of their prescription drugs, or where prohibited by law. The program may apply to out-of-pocket expenses that occurred within 120 days prior to the date of the enrollment. Patients can be enrolled online via the savings portal (https://qv.trialcard.com/one source-hub#/app/layout/home).

Product Replacement Program
As a supplement to the Sandoz returns policy, Sandoz Once Source offers a simple product replacement process for spoiled Zarxio or Ziextenso products under the following circumstances:
- Product was mishandled, dropped, or broken
- There was an admixture error
- Product was inappropriately stored or refrigerated, or was frozen
- Product was reconstituted but not administered due to an unforeseen patient condition or because the patient missed the appointment.

Contact Sandoz One Source at 1.844.SANDOZ1 (1.844.726.3691) to request a replacement product.

REIMBURSEMENT ASSISTANCE

Sandoz One Source®
Sandoz One Source provides services designed to help simplify and support patient access. Available services include:

Oncology-related products: Zarxio® (filgrastim-sndz) subcutaneous or intravenous injection, Ziextenso® (pegfilgrastim-bmez) injection

Patient and Reimbursement Assistance Websites
zarxio.com/resources/patient-support/
ziextenzo.com/hcp/patient-services.html
• Benefit investigations
• Prior authorization support
• Appeals support
• Coding and billing support.

To enroll, download and complete the enrollment form (https://www.ziextenzo.com/sites/ziextenzo_com/files/2020-11/ZIEXTENZO-Sandoz-One-Source-Enrollment-Form.pdf) and fax the completed form to 1.844.726.3695.

For more reimbursement information, call 1.844.SANDOZ1 (1.844.726.3691), Monday through Friday, 8:00 AM to 8:00 PM EST.
PATIENT ASSISTANCE

CareASSIST®
CareASSIST offers resources and support for eligible patients prescribed Sanofi Genzyme oncology medications, including:
• Access and reimbursement
• Financial assistance
• Resource support.

To enroll, download the Enrollment Application (https://www.sanoficareassist.com/hcp/) and fax the completed form to 1.855.411.9689. Healthcare professionals can also enroll patients through the online portal (CareASSISTProviderPortal.com). For any questions or assistance, call 1.833.WE+CARE (1.833.930.2273), Monday through Friday, 9:00 AM to 8:00 PM EST.

CareASSIST Copay Program
Eligible patients with commercial insurance may pay as little as $0 for their Sanofi Genzyme medicines, including any product-specific co-pay, coinsurance, and insurance deductibles—up to $25,000 in assistance per year. To be eligible, patients must:
• Have commercial or private insurance, which includes state or federal employee plans and health insurance exchanges
• Be residents of the United States or its territories or possessions.

There is no income requirement to qualify for this program. Eligible patients will remain enrolled in the program for 12 months dating from the time of approval. Patients will be evaluated for continued eligibility on an annual basis. As appropriate, their enrollment will be renewed. Other conditions apply.

To get started, download and print a CareASSIST application (https://www.sanoficareassist.com/hcp/). Make sure the “CareASSIST Copay Program” box in Section 1 is checked and fax the completed application to 1.855.411.9689. The application process can also be started by calling 1.833.WE+CARE (1.833.930.2273) where a CareASSIST patient access specialist will assist with the next steps, or healthcare professionals can enroll patients through the online portal (CareASSISTProviderPortal.com).

CareASSIST Patient Assistance Program
For patients who meet program eligibility requirements for financial assistance through CareASSIST, medication can be provided at no cost through the CareASSIST Patient Assistance Program. In order to be eligible, patients must meet the following requirements:
• Patient must be a resident of the United States or its territories or possessions and be under the care of a licensed healthcare provider authorized to prescribe, dispense, and administer medication in the U.S.
• Patient must have no insurance coverage or lack coverage for the prescribed therapy
• Patients with Medicare Part B with no supplemental insurance coverage may be eligible
• Patient must have an annual household income that does not exceed the greater of $100,000 or 500 percent of the current Federal Poverty Level.

Approved patients may remain enrolled for up to 12 months. Patients with Medicare Part B with no supplemental insurance coverage who qualify for the CareASSIST Patient Assistance Program will need to reapply at the beginning of each calendar year. To get started, download and print a CareASSIST application (https://www.sanofi careassist.com/hcp/). Make sure the
“CareASSIST Patient Assistance Program” box in Section 1 is checked and fax the completed application to 1.855.411.9689. The application process can also be started by calling 1.833.WE+CARE (1.833.930.2273) where a CareASSIST patient access specialist will assist with the next steps, or healthcare professionals can enroll patients through the online portal (CareASSISTProviderPortal.com).

Alternate Sources of Coverage
CareASSIST may be able to identify sources of coverage for patients who are uninsured or lack coverage, or who need assistance with their out-of-pocket medication costs.

Through CareASSIST, a patient access specialist may be able to:
- Identify potential alternate coverage programs and explain their benefits
- Answer questions about the application process for such programs
- Provide the contact information for such programs.

Possible alternate coverage sources include Medicaid, state health exchanges, state pharmaceutical assistance programs, and independent charitable foundations.

For more information, call 1.833.WE+CARE (1.833.930.2273).

REIMBURSEMENT ASSISTANCE

CareASSIST®
CareASSIST patient access specialist can help evaluate insurance coverage and identify options for patients, which includes the following services:
- Insurance verification, including benefits, deductibles, and co-pay or coinsurance: Full benefit verification is specific to the prescribed therapy from Sanofi Genzyme and the patient’s insurance plan
- Prior authorization assistance: Patient access specialists identify plan-specific requirements and can provide information about the process
- Coding and billings assistance: Information on the prescribed therapy and the respective regimen. Field reimbursement managers are available to assist with complex reimbursement questions
- Claims management and appeals assistance: Patient access specialists can provide information about the appeals process if a denial is received.

There may be additional independent support services available to patients that a CareASSIST patient access specialist can help determine, including:
- Clinical support services
- Food and nutrition programs
- Transportation assistance
- Health supply/cosmetic aids
- Patient advocacy support
- Home care services support.

To learn more, call 1.833.WE+CARE (1.833.930.2273), Monday through Friday, 9:00 AM to 8:00 PM EST.
PATIENT ASSISTANCE
Seagen Secure®
Seagen Secure works with practices and patients to get them enrolled and started on their Seagen therapy quickly. Once patients are enrolled, Seagen Secure will help patients understand their insurance coverage and financial assistance options. A case manager can assist with any coverage or financial issues, including:

- Benefits investigation
- Appeal assistance
- Commercial out-of-pocket assistance program
- Uninsured and underinsured patient assistance.

For more information about Seagen Secure, call 855.4SECURE (855.473.2873), Monday through Friday, 8:00 AM to 8:00 PM EST.

Patient Assistance Program
Case managers can provide eligible uninsured and underinsured patients their Seagen therapy free of charge. Patients must meet eligibility requirements.

To enroll, complete the medication-specific Healthcare Provider Request Form and Patient Authorization Form (seagensecure.com) and fax the completed forms to 855.557.2480. To enroll over the phone, call 855.4SECURE (855.473.2873).

Commercial Out-of-Pocket Assistance
Case managers can offer patients enrollment in the commercial out-of-pocket assistance program, designed to lower out-of-pocket costs for each prescription. Patients must meet eligibility requirements.

Enroll patients online using the program portal (https://www.seagensecuresavings.com/). Healthcare professionals can also enroll patients by completing the medication-specific Healthcare Provider Request Form and Patient Authorization Form (seagensecure.com) and faxing the completed forms to 855.557.2480. To enroll over the phone, call 855.4SECURE (855.473.2873).

REIMBURSEMENT ASSISTANCE
SeaGen Secure®
Once patients are enrolled in Seagen Secure, they will be assigned a dedicated case manager who can assist with any coverage or financial issues, like benefits investigation and appeal assistance.

Benefits Investigation
Case managers will help determine coverage, evaluate prior authorization requirements or other restrictions, and determine patients’ financial responsibility.

Appeal Assistance
If a patient’s insurer denies a prior authorization request and you want to appeal, case managers can identify the appropriate steps.

Contact Seagen Secure by calling 855.4SECURE (855.473.2873), Monday through Friday, 8:00 AM to 8:00 PM EST.
PATIENT ASSISTANCE

Yonsa Support®
Yonsa Support is a comprehensive resource for patients taking Yonsa. These services include:
- **Co-Pay Program**: The program helps eligible, commercially insured patients access their Yonsa prescriptions.
- **Patient Assistance Program**: Patients who are underinsured or uninsured may be eligible to receive free medication. To get patients started with the program, complete and submit the program application (https://yonsarx.com/pdfs/Form.pdf).

For any questions about Yonsa Support, call 1.855.44YONSA (1.855.449.6672) Monday through Friday, 8:00 AM to 8:00 PM EST.

Co-Pay Program
Eligible, commercially insured patients may pay as little as $10 for each fill of a Yonsa prescription, subject to a maximum annual benefit of $15,000 per calendar year. To participate in this program, patients must have commercial health insurance and be a resident of the United States, Puerto Rico, Guam, or the Virgin Islands. Patients are ineligible for the program if they are covered under Medicaid, Medicare, Medicare Part D, Medicare Advantage plan, TriCare, or Champus, or those with no insurance.

Patients can activate the co-pay card by visiting www.activatethecard.com/7436.

Patient Assistance Program
Patients who are underinsured or uninsured may be eligible to receive free medication. To get patients started with the patient assistance program, download and complete the Odomzo Support Patient Assistance Program Application (https://www.odomzo.com/hcp/financial-assistance). Fax the completed and signed form to 1.877.872.6575. Income documentation is required, and the program is subject to terms and conditions. For questions, call 1.844.5.ODOMZO

Odomzo Support™
Odomzo Support helps eligible patients access Odomzo. For any questions, call 1.844.5.ODOMZO (1.844.563.6696), Monday through Friday, 8:00 AM to 8:00 PM EST.

Co-Pay Program
Eligible, commercially insured patients may pay as little as $10 a month for an Odomzo prescription, subject to a maximum annual benefit of $15,000 per calendar year. To participate in this program, patients must have commercial health insurance and be a resident of the United States, Puerto Rico, Guam, or the Virgin Islands. Patients are ineligible for the program if they are covered under Medicaid, Medicare, Medicare Part D, Medicare Advantage plan, TriCare, or Champus, or those with no insurance.

Patients can activate the co-pay card by visiting www.activatethecard.com/7436.

Patient Assistance Program
Patients who are underinsured or uninsured may be eligible to receive free medication. To get patients started with the patient assistance program, download and complete the Odomzo Support Patient Assistance Program Application (https://www.odomzo.com/hcp/financial-assistance). Fax the completed and signed form to 1.877.872.6575. Income documentation is required, and the program is subject to terms and conditions. For questions, call 1.844.5.ODOMZO

Oncology-related products: Odomzo® (sonidegib) capsules, Yonsa® (abiraterone acetate) tablets
(1.844.563.6696), Monday through Friday, 8:00 AM to 8:00 PM EST.

REIMBURSEMENT ASSISTANCE

Yonsa Support®
Yonsa Support is a comprehensive resource for patients taking Yonsa. Sun Pharma and CoverMyMeds are working together to expedite the prior authorization process. For more information, contact CoverMyMeds at 1.866.452.5017.

Odomzo Support™
Sun Pharma and CoverMyMeds are working together to expedite the prior authorization process to help patients receive their Odomzo therapy as prescribed. For more information, contact CoverMyMeds at 1.866.452.5017.
PATIENT ASSISTANCE

Taiho Oncology Patient Support™
Accessing treatments can be challenging at times. Taiho Oncology Patient Support offers personalized services to give patients, caregivers, and healthcare professionals the help they need in getting started with Taiho Oncology products. This includes insurance verification, help with medication costs, and treatment plan support.

Co-pay Assistance Program
Eligible patients may pay $0 per treatment cycle. Patients may be eligible if they:
• Have commercial prescription insurance coverage
• Reside within the United States, Puerto Rico, or U.S. territories
• Use a specialty pharmacy or hospital outpatient pharmacy
• Receive medication from a doctor’s office.

Patients are not eligible for the co-pay program if they are reimbursed under Medicaid, a Medicare drug benefit program, TriCare, or other state or federal programs. To determine patient eligibility, go to TaihoOncologyCopay.com or call 844.TAIHO.4U (844.824.4648).

Patient Assistance Program
The patient assistance program can provide financial assistance to eligible patients who have insufficient or no prescription insurance. Eligible patients may receive Taiho Oncology products at no cost based on assistance, financial, and medical criteria.

Alternate Funding Support
Taiho Oncology Patient Support can also refer eligible, public- or government-insured patients to nonprofit foundations for co-pay or other assistance. Taiho Oncology does not influence or control the decisions of these co-pay assistance foundations. Each foundation has its own criteria for patient eligibility. Taiho Oncology cannot guarantee financial assistance once a patient has been referred.

There are three ways to enroll in Taiho Oncology Patient Support:
• Complete the Patient Enrollment Form (www.taihopatientsupport.com/how-to-enroll), Spanish enrollment forms are available online, and fax the form to 1.844.287.2559.
• Complete the enrollment forms online and upload them to the healthcare professional portal (https://taihooncologyhcp.caremetx.com/account/logon/support).

• Call 1.844.TAIHO.4U (1.844.824.4648), Monday through Friday, 8:00 AM to 8:00 PM EST.

Once enrolled, healthcare professionals can expect a Taiho Oncology Patient Support reimbursement specialist to confirm the patient’s enrollment and share next steps. Patients can expect a welcome to the program and explanation of their insurance benefits for their prescribed Taiho Oncology product.

REIMBURSEMENT ASSISTANCE

Taiho Oncology Patient Support™
The Taiho Oncology Patient Support program simplifies access for those who have been prescribed a Taiho Oncology product as part of their treatment. Just a phone call away, it can help determine insurance coverage, coordinate prescriptions, and more.

Access and Reimbursement Support
The program can help patients understand their insurance coverage and/or out-of-pocket responsibility through benefit verifications, determine prior authorization requirements of the insurance

Oncology-related products: Inqovi® (decitabine and cedazuridine) tablets, Lonsurf® (trifluridine and tipiracil) tablets

Patient and Reimbursement Assistance Website
taihopatientsupport.com
company, and assist with appeals if coverage is denied.

**Pharmacy Coordination**
The Taiho Oncology Patient Support program can also triage patients’ prescriptions, coordinate prescriptions with the specialty pharmacy, self-dispensing practice, or hospital outpatient pharmacy, and communicate regularly with patients about prescription status.

To enroll, complete the Patient Enrollment Form (www.taihopatient support.com/financial-support), Spanish forms are available online, and fax it to 1.844.287.2559.
Or healthcare professionals can complete the enrollment forms online and upload them to the portal (https://taihooncologyhcp. caremetx.com/). For help, call 1.844.TAIHO.4U (1.844.824.4648).
PATIENT ASSISTANCE

**Takeda Oncology Here2Assist™**

Takeda Oncology Here2Assist is a comprehensive support program committed to helping patients navigate coverage requirements, identify available financial assistance, and connect with helpful resources throughout their treatment.

To enroll, download the Takeda Oncology Here2Assist Enrollment Form ([here2assist.com/pdf/Takeda_Oncology_Here2Assist_Enrollment_Form.pdf](http://here2assist.com/pdf/Takeda_Oncology_Here2Assist_Enrollment_Form.pdf)), and fax the completed and signed form with a copy of the patient’s insurance card and prescription to 1.844.269.3038. Prescription is only valid if received by fax.

After the patient’s enrollment form is received and processed, a Takeda Oncology Here2Assist case manager will conduct a benefits verification to determine the patient’s prescription coverage and potential out-of-pocket costs. A summary of coverage will be provided to the provider’s office within two business days. For more information, call 1.844.817.6468, Monday through Friday, 8:00 AM to 8:00 PM EST. or visit [here2assist.com/patient/home](http://here2assist.com/patient/home).

**Takeda Oncology Co-Pay Assistance Program**

For patients with commercial insurance concerned about their out-of-pocket costs for Alunbrig, Iclusig, or Ninlaro, the Takeda Oncology Co-Pay Assistance Program may be able to help. Patients could pay as little as $10 per prescription with an annual maximum benefit of $25,000.

This offer cannot be used if patients are a beneficiary of, or any part of their prescription is covered or reimbursed by: (1) any federal or state healthcare program (Medicare, Medicaid, TriCare, Veterans Administration, Department of Defense, etc.), including a state or territory pharmaceutical assistance program, (2) the Medicare Prescription Drug Program (Part D), or if patients are currently in the coverage gap, Medicare Advantage Plans, Medicaid Managed Care or Alternative Benefit Plans under the Affordable Care Act, or Medigap, or (3) insurance that is paying the entire cost of the prescription. Patients must be at least 18 years old. Additional terms and conditions apply.

To enroll, visit [takedaoncologycopay.com](http://takedaoncologycopay.com) or call Takeda Oncology Here2Assist case manager at 1.844.817.6468.

**Takeda Oncology Patient Assistance Program**

If patients do not have insurance or the prescribed medication is not covered by their insurance, they may be eligible to receive their medication at no cost through this program. To be eligible for the Patient Assistance Program, patients must meet certain financial and insurance coverage criteria.

To apply for the Patient Assistance Program, work with your patient to complete and submit a Patient Assistance Program Application ([here2assist.com/pdf/Takeda_Oncology_Patient_Assistance_Program_Enrollment_Form.pdf](http://here2assist.com/pdf/Takeda_Oncology_Patient_Assistance_Program_Enrollment_Form.pdf)) and a valid prescription for their medication. Original signatures are required. Fax the completed and signed application form along with a valid prescription to Takeda Oncology Here2Assist at 1.844.269.3038.

If the patient qualifies, they may be enrolled for up to one year. Upon
enrollment, a Takeda Oncology Here2Assist case manager will notify the patient and their healthcare provider. A one-month supply of their medication will be delivered to the patient at no cost. Each month, a Takeda Oncology Here2Assist case manager will confirm with patients and their providers that they are still being treated and are eligible to receive another month’s supply of medication.

**RapidStart Program**
If patients experience a delay in insurance coverage determination of at least five days, they may be eligible to receive a one-month supply of their medication at no cost. To enroll patients in the RapidStart Program, a completed Takeda Oncology Here2Assist Enrollment Form must be on file, and a RapidStart Request Form must be completed and submitted (drug-specific forms are available at here2assist.com/patient/home).

**Velcade Reimbursement Assistance Program**
From finding financial assistance to understanding their disease, Tekeda Oncology Here2Assist can provide the information needed throughout patients’ treatment. Case managers can connect patients and providers to personalized support for Velcade. Call to speak to a case manager at 1.844.817.6468, option 2, Monday through Friday, 8:00 AM to 8:00 PM EST or visit www.Here2Assist.com.

---

**REIMBURSEMENT ASSISTANCE**

**Takeda Oncology Here2Assist™**
Here2Assist can help with:
- Benefits verification
- Prior authorizations
- Payer denials.

The program does not complete forms, file claims, or appeal claims for callers. It cannot guarantee success in overturning a payer denial.

To enroll, download the Takeda Oncology Here2Assist Enrollment Form (here2assist.com/pdf/Takeda_Oncology_Here2Assist_Enrollment_Form.pdf) and fax the completed and signed form along with a copy of the patient’s insurance card and prescription to 1.844.269.3038. Prescription is only valid if received by fax. Call 1.844.817.6468, option 2, Monday through Friday, 8:00 AM to 8:00 PM EST, for more information.

**Velcade Reimbursement Assistance Program**
Tekeda Oncology Here2Assist can provide the information needed throughout patients’ treatment. Case managers can connect patients and providers to personalized support for Velcade. Call to speak to a case manager at 1.844.817.6468, option 2, Monday through Friday, 8:00 AM to 8:00 PM EST. Or visit www.Here2Assist.com.
PATIENT ASSISTANCE

TerSera Support Source
TerSera is committed to help remove the financial and access barriers that so often get in the way of patients who are prescribed Zoladex and Varubi.

Co-Pay Assistance
Eligible, commercially insured and cash paying patients pay as little as $0 of their co-pay or coinsurance amount. For Varubi, the card carries a $200 max cap per fill and a maximum benefit of $2,000 per calendar year. For Zoladex, the card carries a maximum benefit of $2,000 per calendar year. Eligible cash paying patients will receive up to $300 off each one-month supply of Zoladex. Patients are not eligible if prescriptions are paid by any state or other federally funded programs, including, but not limited to, Medicare or Medicaid, Medigap, VA, DOD, or TriCare, or where prohibited by law. Visit activate thecard.com/7526 to enroll for Zoladex, or visit activatethecard.com/7774 to enroll for Varubi. For questions regarding the Varubi or Zoladex co-pay card, call 1.844.864.3014, Monday through Friday, 8:00 AM to 8:00 PM EST.

TerSera Therapeutics Patient Assistance Program
TerSera is committed to helping eligible patients access Zoladex or Varubi through the Patient Assistance Program. If patients qualify, they may get free TerSera medicine for up to one year. TerSera will send an application for renewal once patients’ enrollment ends. Medicines can be sent to patients’ homes or their doctor’s office; most medicines are sent in a 90-day supply. Patients may qualify for the program if they:
- Are a United States resident, or a Green Card or Work Visa holder
- Meet certain household income limits
- Do not have prescription drug coverage that helps pay for their TerSera medicines.

To apply for patients prescribed Zoladex, complete the Patient Assistance Program enrollment form (zoladexhcp.com/pdf/patient-assist-enroll_form.pdf) and fax the completed form to 855.836.3066. For more information, call 1.844.965.2339.

To apply for patients prescribed Varubi, download the enrollment form (documents.tersera.com/varubi/VarubiEnrollmentForm.pdf) and fax the completed form to 1.855.836.3066. For more information, call 1.855.686.8725, Monday through Friday, 8:00 AM to 8:00 PM EST.

REIMBURSEMENT ASSISTANCE

TerSera Support Source
TerSera Support Source is committed to providing services that streamline the approval process, including prior authorization information and appeals support.

Visit terserasupportsource.com for more information.

Oncology-related products: Varubi® (rolapitant) tablets, Zoladex® (goserelin acetate implant)
PATIENT ASSISTANCE

Teva Cares Foundation
The Teva Cares Foundation is a group of patient assistance programs created to make a positive difference in the lives of patients and their families. For decades, Teva has been working through its patient assistance programs to improve patient access to medication and ensure that cost is not a barrier to treatment. Teva’s commitment to patients provides certain Teva medications at no cost to patients in the United States who meet certain insurance and income criteria. To determine if your patient qualifies, review the Teva Cares Foundation Patient Assistance Programs eligibility requirements for the prescribed medication online at tevatures.org/doiqualify or call 1.877.237.4881, Monday through Friday, 9:00 AM to 8:00 PM EST. Then download the appropriate enrollment application for the prescribed medication and fax the completed form to 877.438.4404.

If a patient does not meet the eligibility requirements for the Teva Cares Foundation Patient patient assistance programs, Teva may offer a reimbursement assistance program or other type of program to assist them. For more information, call 888.TEVA.USA (888.838.2872). Some patients may be eligible for assistance from other programs. For a listing of these other assistance programs go to tevatures.org/otherresources/.

REIMBURSEMENT ASSISTANCE

CORE
The reimbursement and insurance process can be complicated. Comprehensive Oncology Reimbursement Expertise (CORE) is available to help eligible patients, their caregivers, and healthcare professionals navigate the reimbursement process. CORE offers a range of services, including:

• Benefit verification and coverage determination
• Precertifications/prior authorization support
• Coverage guidelines and claims investigation assistance
• Support through the claims and appeals process

Download the CORE enrollment form at tevacore.com/resources and fax it to 866.676.4073. For questions, call 1.888.587.3263, Monday through Friday, 9:00 AM to 6:00 PM EST or visit TevaCORE.com.
PATIENT ASSISTANCE

TG Patient Support™
TG Patient Support is a comprehensive program that provides information and support to help patients navigate the reimbursement process and understand their treatment with Ukoniq, including:
• Insurance support
• Financial support programs
• Educational support.

Contact a TG Patient Support case manager by calling 1.877.TGTXPSP (1.877.848.9777), Monday through Friday, 8:00 AM to 8:00 PM EST.

TG Co-Pay Assistance Program
Patients with commercial or private insurance may be eligible to receive Ukoniq for as little as $5 per prescription. This program is not available for patients who are enrolled in Medicare, Medicaid, Medigap, TriCare, VA, DoD, the Government Health Insurance Plan available in Puerto Rico, or any other state or federally funded health care program. Medicare-eligible patients who are enrolled in a government subsidized retiree prescription drug plan are also ineligible for the program.

Eligibility for the program is based on the calendar year. Patients must apply for co-pay assistance each year that they wish to participate in the program. Enroll patients online at: https://www.tgcommercialcopayprogram.com/.

Patient Assistance Program
Patients with no insurance coverage or who are underinsured and meet financial eligibility criteria may be able to receive Ukoniq free of charge. Patients must meet certain eligibility criteria to qualify for the program. Eligible patients must be uninsured or underinsured with an annual family gross income equal to or less than 600 percent of the current federal poverty level. To enroll, download and complete the TG Patient Support enrollment form (https://ukoniq.com/patientsupport), and fax it to 1.877.778.1329.

Independent Charitable Organization Support
For patients with state or federally funded insurance coverage, including Medicare or Medicaid, TG Therapeutics can provide a list of financial assistance options from independent charitable organizations. For more information, call TG Patient Support at 1.877.848.9777.

Quick Start and Bridge Supply
Patients with a five-day delay or lapse in insurance coverage may be eligible to receive a 15-day supply of Ukoniq to prevent prolonged delays or interruptions in therapy. To enroll, download and complete the TG Patient Support enrollment form (https://ukoniq.com/patientsupport), and fax it to 1.877.778.1329.

REIMBURSEMENT ASSISTANCE

TG Therapeutics is committed to helping patients get access to its medications. The program can help with benefits investigations, including:
• Verifying patients’ insurance benefits for Ukoniq, including their co-pay or coinsurance responsibility.
• Verifying if a prior authorization is required and the insurance plan’s process for submitting a prior authorization.
• Follow up by a case manager with the payer on the status of the prior authorization.
To enroll, download and complete the TG Patient Support enrollment form (https://ukoniq.com/patientsupport), and fax it to 1.877.778.1329. Contact a TG Patient Support case manager by calling 1.877.TGTXPSP (1.877.848.9777), Monday through Friday, 8:00 AM to 8:00 PM EST.
PATIENT ASSISTANCE

Adaptive Biotechnologies understands that each patient’s situation is unique. It is committed to providing guidance and support during each step of the insurance process. That’s why it offers the Adaptive Assist Patient Support Program: to help facilitate access to clonoSEQ testing services for patients with lymphoid cancer who could benefit from the clinical insights provided by measurable residual disease testing. The Adaptive Assist Patient Support Program is a comprehensive reimbursement support program to support patients for the duration of their measurable residual disease testing by:

- Aiding patients to understand the billing process and potential out-of-pocket costs
- Assisting with prior authorizations for all incoming clinical orders
- Appealing for the maximum benefits and lowest out-of-pocket cost
- Assisting with out-of-pocket costs after coverage.

For questions, call the program at 1.855.236.9230, Monday through Thursday, 9:00 AM to 7:00 PM EST, and Friday, 9:00 AM to 5:00 PM EST.

Patient Support Program
Adaptive Biotechnologies is committed to providing financial assistance opportunities to qualified clonoSEQ patients with a demonstrated financial need.

To be eligible for enrollment, a patient must meet all of the following criteria:
- Be a United States citizen or legal resident age 18 years or older; patients under the age of 18 are eligible but require the application form to be signed by a parent or legal guardian
- Be uninsured or have insurance that does not cover the full cost of clonoSEQ testing
- Meet financial need requirements based on the patient’s income and the number of persons in their household or sum of medical expenses as a percentage of household income
- Call 1.855.236.9230 to enroll in five minutes over the phone, or submit a completed and signed application form (www.clonoseq.com/adaptive-assist/), including acknowledgment of the requirement to submit a tax return, W-2, pay stub, or other comparable document demonstrating financial need if and when requested by Adaptive Technologies. If applicable, a sum of eligible medical expenses, including medications and/or test receipts may be required.

Neither the application nor the Patient Support Program constitute a contract. Adaptive Biotechnologies retains the right to change the program in whole or part at any time in the exercise at its sole discretion.

Adaptive Biotechnologies will send a notification letter indicating final program eligibility determination within 10 working days following receipt of a fully completed and signed application. An incomplete form may result in delays to processing and/or enrollment. For more information or to enroll over the phone, call 1.855.236.9230 or visit clonoseq.com/adaptive-assist.

REIMBURSEMENT ASSISTANCE

Adaptive Assist™
Adaptive Assist offers out-of-pocket estimates for patients and caregivers needing to determine the potential out-of-pocket costs via a benefits investigation prior to order submission. It will also evaluate all orders for the need for prior authorization and follow up as needed.

Oncology-related products: clonoSEQ® Assay (for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia.)
To enroll in the Adaptive Assist program, call 1.855.236.9203 or download and complete the program application (http://www.clonoseq.com/adaptive-assist/). Call 1.855.236.9203, Monday through Thursday, 9:00 AM to 7:00 PM EST, and Friday, 9:00 AM to 5:00 PM EST, for answers to your questions about insurance, billing, payment, or financial assistance and to request the out-of-pocket cost estimate service.
PATIENT ASSISTANCE

Financial Assistance

FoundationAccess™

Foundation Medicine is committed to providing patients with resources and support throughout the testing process. Financial assistance is available for qualifying patients who have out-of-pocket costs associated with Foundation Medicine testing. Foundation Medicine’s Financial Assistance Program is only available to patients whose tests were ordered within the United States and U.S. territories.

Financial assistance is based on need and can be applied for at any time before, during, or after testing. Payment plans may also be available based on patients’ financial situation. Qualifying patients can fill out a financial assistance application online (https://aid.foundationmedicine.com/) or via a downloadable form (https://www.foundationmedicine.com/info/detail/for-patients). If filling out the PDF application, fax it to 1.617.830.0279 or email it to client.services@foundationmedicine.com.

Some commercial health plans offer coverage for Foundation Medicine testing services. All Foundation Medicine tests are covered by Original Medicare and Medicare Advantage for qualifying beneficiaries. FoundationOne Heme has limited commercial health plan coverage. For questions, call 888.988.3639.

Oncology-related products: FoundationOne® CDx (companion diagnostic for patients across all solid tumors), FoundationOne® Liquid CDx (liquid biopsy test for solid tumors), FoundationOne® Heme (genomic profiling test for hematologic malignancies and sarcomas)

Patient and Reimbursement Assistance Website

foundationmedicine.com/info/detail/for-patients

292 survey respondents from 153 unique cancer programs and practices

Who Took Our Survey n=292
- Financial counselor/Navigator 53%
- Oncology nurse/Nurse navigator 21%
- Oncology social worker 12%
- Oncology pharmacist 5%
- Hospital administrator 3%
- Other 6%

Years of Experience Providing Financial Navigation Services n=270
- Less than 5 years 48%
- 5-10 years 23%
- 11-20 years 22%
- 20+ years 7%

One-third of respondents (36%) said they “do not have enough full-time employees (FTEs) to meet their demand for financial advocacy services” and another third (34%) said they “do not ALWAYS have enough FTEs to meet their demand for financial advocacy services.” n=183

One-third of respondents say they provide financial advocacy services to more than 20 patients per week. n=183

How many dedicated financial advocates work at your cancer program? n=284
- 1 to 3 FTEs 60%
- 4 to 5 FTEs 13%
- 6+ FTEs 13%
- None 10%
- Hiring our first 2%
- Other 5%

Roles and Responsibilities n=192
- Work directly with patients to address financial concerns
- Screen patients for their risk of financial toxicity and/or distress
- Identify and enroll patients in manufacturer financial assistance
- Identify and enroll patients in free-drug programs

74% 64% 61% 59%
Return on Investment (ROI) n=186

While nearly 1 in 4 cancer programs (23%) DO NOT track the impact of financial navigation services, the situation is changing. One-third of survey respondents (32%) say that they “are in the process of developing metrics and/or a tracking system for financial navigation services.”

The two most common metrics collected are “reduction in overall institutional debt” (15%) and “number of patients who have gained access to treatments by mitigating financial barriers” (12%).

What’s a Co-Pay Accumulator?

A co-pay accumulator—or accumulator adjustment program—is a strategy used by payers and pharmacy benefit managers (PBMs) that stop manufacturer co-pay assistance coupons from counting towards the deductible and the maximum out-of-pocket spending. When the co-pay card or coupon is exhausted, beneficiaries must pay the entire amount of their deductible before their plan benefits kick in.

A majority (71%) of respondents are unaware of co-pay accumulators. n=197

89% indicated they need better understanding and resources to feel adequately prepared to explain and assist patients in navigating these new rules. n=84

Biggest Organizational Challenges n=197

32% Difficulty finding funding and/or resources for patients
24% Ineffective organizational structure and/or processes
16% Limited staff and increasing demand
11% Patient education needs and/or low financial health literacy

What’s Non-Medical Switching?

Non-medical switching is when a payer changes a patient’s treatment regimen for reasons other than efficacy, side effects, or adherence. It is a drug formulary tactic used by payers to reduce drug costs.

64% of respondents are unaware of non-medical switching.

Of the 36% that are aware of this trend, 81% say “it always or sometimes impacts patient care.” n=190

Top Concerns of Financial Advocates n=174

1. Lack of resources
2. Navigating a highly complex, changing landscape
3. Patient education needs and/or low financial health literacy

Help Needed Stat! n=197

• Need help optimizing Medicare and/or Medicaid options
• Need training and materials on cost-related health literacy education
• Need help optimizing private insurance options
• Need help navigating manufacturer and/or advocacy patient assistance programs

Training and Resources

70% have not received any formal professional training on financial navigation. n=286

For those who received training (n=56), 60% received it through the ACCC Financial Advocacy Network Boot Camp and say it is a valuable resource.

Cornerstone Partner: Pfizer Oncology Silver Partners: Janssen Johnson & Johnson, and Pharmacyscics

The ACCC Financial Advocacy Network is supported by Pfizer, Janssen, Johnson & Johnson, and Pharmacyscics

The Association of Community Cancer Centers (ACCC) is the leading education and advocacy organization for the cancer care community. Founded in 1974, ACCC is a powerful network of 25,000 multidisciplinary practitioners from 2,100 hospitals and practices nationwide. As advances in cancer screening and diagnosis, treatment options, and care delivery models continue to evolve—so has ACCC—adapting its resources to meet the changing needs of the entire oncology care team. For more information, visit accc-cancer.org.

The ACCC Financial Advocacy Network is the leader in providing professional development training, tools, and resources that will empower providers to proactively integrate financial health into the cancer care continuum and help patients gain access to high-quality care for a better quality of life.

© 2020, Association of Community Cancer Centers. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means without written permission.
Agingcare.com®
agingcare.com

AgingCare connects families with in-home care, assisted living, and caregiver support. Included in its services is the Drug Assistance Program Locator: agingcare.com/Articles/prescriptiondrugassistance-program-locator-171753.htm. Search for prescription drug assistance programs by state, medication name, or browse a list of nationwide nonprofit assistance programs.

Aunt Bertha
findhelp.org

Aunt Bertha has created a social care network that connects people and programs—making it easy for people to find social services in their communities, for nonprofits to coordinate their efforts, and for customers to integrate social care into the work they already do.

Its interactive map (company.auntbertha.com/for-customers/socialcarenetwork/) illustrates comprehensive coverage of social care programs in every United States county, including state and national programs. Select any county to view the breakdown of program categories (such as housing and financial assistance) and use the map filter to select interactive geographic areas.

The open access search (findhelp.org) is free, open to the public, and easy to use. After searching by ZIP code, findhelp lists several options in the community that can help patients with prescription assistance, transportation for healthcare, and more.

A program or foundation’s eligibility will be listed along with its contact information. Aunt Bertha will provide “Next Steps” to help with the application process.

BenefitsCheckUp®
benefitscheckup.org

The National Council on Aging (NCOA) is a respected national leader and trusted partner helping older adults meet the challenges of aging through services like BenefitsCheckUp. BenefitsCheckUp is a comprehensive, free online tool that connects older adults with benefits they may qualify for. The BenefitsCheckUp team monitors the benefits landscape for updates and changes to policies and programs. It matches patients’ unique needs to benefit programs and eligibility requirements using its comprehensive tool.

There are over 2,500 federal, state, and private benefits programs available to help. After reviewing initial results, patients can enter more details to personalize their report. They will receive a customized report listing the benefits they are most likely to qualify for. Patients can start enrolling in programs right away. BenefitsCheckUp can help patients with the following types of expenses:

- Medication
- Food
- Utilities
- Healthcare
- Housing
- Income Assistance
- Tax relief
- Transportation
- Employment.

The Medicare Prescription Drug program (also known as Part D) offers extra help with prescription drug costs for people with Medicare who have limited incomes and resources. To get this help, patients must be enrolled in Medicare Part A and/or Medicare Part B and live in one of the 50 states or the District of Columbia. Patients may be able to get extra help paying for prescription drug costs if:

- Their income is less than $18,735 if not currently married or not living with their spouse, or $25,365 if currently married and living with their spouse.
- They have combined savings, investments, and real estate not worth more than $14,610 if not currently married or living with their spouse, or $29,160 if currently married and living with their spouse.

Apply online at: benefitscheckup.org/medicare-rx-extra-help-application-welcome.

CancerCare®
cancercare.org

CancerCare is a national organization that provides free, professional support services and information to help people manage the emotional, practical, and financial challenges of cancer. Its comprehensive services include case management, counseling and support groups over the phone, online and in-person, educational workshops, publications, and financial and co-payment assistance. All CancerCare services are provided by master’s-prepared social workers and world-leading
cancer experts. It offers limited financial assistance for cancer-related costs and co-pays, and its oncology social workers can help patients find additional resources. As a nonprofit organization, funding depends on the sources of support CancerCare receives at any given time. If CancerCare does not currently have funding to assist a patient, professional oncology social workers will always work to refer patients to other financial assistance resources. Check cancercare.org periodically for funding updates.

Financial Assistance Program
In order to be eligible for financial assistance, patients must:
- Have a diagnosis of cancer confirmed by an oncology healthcare provider
- Be in active treatment for cancer
- Live in the United States or Puerto Rico
- Meet CancerCare eligibility guidelines based on the federal poverty limit.

Steps for applying to this program, include:
1. Call 800.813.HOPE (4673) and speak with a CancerCare social worker to complete a brief interview. They can be reached Monday through Thursday, 10:00 AM to 6:00 PM EST, and Friday, 10:00 AM to 5:00 PM EST.
2. If patients are eligible to apply, CancerCare will:
   - Mail/email the patient an individualized barcoded application
   - Request documentation to verify patients’ income.
3. Patients must submit a completed application to the email or fax number listed on the form.

CancerCare® Co-Payment Assistance Foundation

cancercarecopay.org

The CancerCare Co-Payment Assistance Foundation is a nonprofit organization dedicated to removing insurance barriers by helping qualified patients afford the co-payments, coinsurance, and deductibles for their prescribed treatments. To qualify for assistance, patients must meet certain financial, medical, and insurance criteria. The funds are disease specific. The patient’s primary cancer diagnosis must match the program’s fund definition and the medication prescribed must be to treat the primary diagnosis.

If the foundation does not have funding for the patient’s type of cancer, its co-payment specialists can provide information about other patient assistance programs, support services, and additional resources that may be helpful.

In order to be eligible for assistance:
- Patient’s primary cancer diagnosis must be the same as one of the funds that the foundation covers.
- Patient must have a valid Social Security number to apply for assistance and receive treatment in the United States.
- Patient must be in active treatment or have a treatment plan in place prior to applying for assistance.
- Patient is required to have valid insurance coverage. Some funds are restricted to assist only those insured through a federal health insurance program, such as Medicare or TriCare.
- Patient income level must be at or below 500 percent of the federal poverty limit.

Patients can apply for this foundation through its online process (cancercare.org/copay-apply) or speak with a co-payment specialist at 866.55.COPAY (866.552.6729). Patients will be enrolled for up to one year from the time they are approved.

For more information, call 866.55.COPAY (866.552.6729), Monday through Thursday, 9:00 AM to 7:00 PM EST, and Friday, 9:00 AM to 5:00 PM EST.

Cancer Financial Assistance Coalition
cancerfac.org

The Cancer Financial Assistance Coalition (CFAC) is a coalition of financial assistance organizations joining forces to help patients with cancer experience better health and well-being by limiting financial challenges. It educates patients and providers about existing resources and links to other organizations that can disseminate information about the collective resources of its member organizations.

CFAC is a coalition of organizations and cannot respond to individual requests for financial assistance. To find out if financial help is available, use the CFAC database at: cancerfac.org. Search by cancer diagnosis or by specific type of assistance or need (i.e., co-pays, general living expenses, transportation, genetic testing). Patients and providers may also contact each CFAC member organization individually for guidance and possible financial assistance.
Co-Pay Relief

copays.org

The Patient Advocate Foundation (PAF) Co-Pay Relief Program provides direct financial assistance to qualified patients with co-payments, coinsurance, or cost-sharing associated with prescription medications through funds dedicated to specific disease states. In some instances, assistance with insurance premiums and/or ancillary services associated with the disease also may be available. Patients approved for assistance are required to have their verified diagnosis and treatment plan along with supporting documentation completed and returned within 30 days of approval to ensure continuation of the award.

Eligibility requirements:
• Patients must be currently insured and have coverage for medication(s) seeking financial assistance.
• Patients must have a confirmed diagnosis and treatment plan.
• Patients must reside and receive treatment in the United States.
• Patients’ income must fall at or below 300 percent or 400 percent of the federal poverty guideline with consideration for the cost of living index and number in the household.

Once approved, the award can be used immediately. Claims should be submitted via the Virtual Pharmacy Card, uploading them to the online portal, or faxed to PAF using the unique bar-coded fax cover sheet.

Patients and providers can apply online (https://copays.org/portal/#/login) or by calling 866.512.3861.

Good Days®

mygooddays.org

Good Days is a nonprofit advocacy organization that provides resources for lifesaving and life-extending treatments to people in need of access to care.

Good Days covers what insurance does not—the co-pays for treatments that can extend life and alleviate suffering. Good Days also has a premium assistance program for patients who need help paying their monthly medical insurance premiums. Its travel assistance program helps pay for travel costs to ensure patients have access to the care they need.

Good Days has streamlined the enrollment process so patients can receive immediate determination of eligibility for financial assistance.

Eligibility criteria:
• Patient must be diagnosed with a covered disease and program must be accepting enrollment.
• Patient must have a valid Social Security number to apply for assistance and receive treatment in the United States.
• Patient must be seeking assistance for a prescribed medication that is FDA approved to treat the covered diagnosis.
• Patient is required to have valid insurance coverage.
• Patient income level must meet program guidelines.

To enroll, go to mygooddays.org/apply to apply online, or you can download the English or Spanish enrollment form and fax completed forms to 214.570.3621. Contact GoodDays by phone (877.968.7233), Monday through Friday, from 8:00 AM to 5:00 PM CST.

HealthWell Foundation®

healthwellfoundation.org

When health insurance is not enough, HealthWell Foundation fills the gap by assisting with co-pays, premiums, deductibles, and out-of-pocket expenses. It provides financial assistance to help with:
• Prescription co-pays
• Health insurance premiums, deductibles, and coinsurance
• Pediatric treatment costs
• Travel costs.

Healthwell Foundation offers financial assistance through a number of disease funds, with new funds opening every year, so patients can get the care they need.

To be eligible, patients must meet certain criteria:
• HealthWell must have a disease fund that covers the patient’s illness, and their medication must be listed under the disease fund associated with the grant.
• Patients must have some form of health insurance, such as private insurance, Medicare, Medicaid, or TriCare.
• Patients must have an income up to 400 percent to 500 percent of the federal poverty level (HealthWell considers household income, the number in the household, and the cost of living in patients’ city or state).
• Patients must be receiving treatment in the United States.

Anyone with the patient’s express permission may apply on behalf of a patient in two ways:
1. Apply online using the HealthWell provider portal at https://healthwellfoundation.secure.force.com/
2. Apply by phone by calling 800.675.8416, Monday through Friday, 9:00 AM to 5:00 PM EST.

HealthWell strongly encourage providers, advocates, social workers, and pharmacy staff to use their respective portal to apply so that patients can readily access its hotline care managers.

Once patients are approved for a grant from one of the disease funds, they will receive assistance for a rolling 12 months, after which they can reapply if needed and if funding is available. Upon approval, patients will receive both a HealthWell Pharmacy Card and a Reimbursement Request Form for when they need it.

For any questions and to speak with a HealthWell representative, call 800.675.8416, Monday through Friday, 9:00 AM to 5:00 PM EST.

The Leukemia & Lymphoma Society Co-Pay Assistance Program ll.org

The Leukemia & Lymphoma Society (LLS) offers financial support toward the cost of co-pays for insurance and covered prescriptions and insurance premiums. Patients must qualify both medically and financially for this program. Patients have the complete freedom to choose their doctors, providers, suppliers, insurance companies, and treatment-related medications. Patients can make changes to these at any time without affecting their continued eligibility. The LLS Co-Pay Assistance Program offers financial help toward:

- Prescription medication related to prescribed treatment.

To be eligible for co-pay assistance, patients must:

- Have a household income at or below 500 percent of the United States federal poverty guidelines as adjusted by the cost of living index.
- Be a U.S. citizen or permanent resident of the U.S. or U.S. territory
- Have medical insurance
- Have a blood cancer diagnosis confirmed by a doctor. Patient must be in active treatment, scheduled to begin treatment, or is being monitored by their doctor. (See a list of covered diagnoses at ll.org/support/financial-support/co-pay-assistance-program).

Patients and providers can apply using the online portal (https://cprportal.lls.org/#/login) or by calling 877.577.2672, Monday through Friday, 8:30 AM to 5:00 PM EST.

Program continuation is dependant on the availability of funds, and the program could be modified or discontinued at any time if funding is limited or no longer available.

Patient Aid Program

The Patient Aid Program provides financial assistance to patients with blood cancer. Eligible patients will receive a one-time $100 stipend to help offset expenses. There are no income criteria to qualify for this program. Program continuation is dependant on the availability of funds and the program could be modified or discontinued at any time if funding is limited or no longer available. To be eligible, patients must:

- Be a United States citizen or permanent resident of the U.S. or U.S. territories
- Have a confirmed diagnosis of blood cancer, be in active treatment, scheduled to begin treatment, or in follow-up care, all attested to by the patient or care team member
- Patients may be insured or uninsured.

Patients are only eligible for one Patient Aid award. If patients have received a Patient Aid award in the past, they are not eligible to reapply. Apply online using the portal (https://unpportal.lls.org/#/login) or by phone at 877.557.2672, Monday through Friday, 8:30 AM to 5:00 PM EST.

Medicine Assistance Tool medicineassistancetool.org

Pharmaceutical Research and Manufacturers of America’s Medicine Assistance Tool (MAT) is a search engine designed to help patients, caregivers, and healthcare providers learn more about the resources available through the various biopharmaceutical industry programs. MAT is not its own patient assistance program, but rather a search engine for many of the patient assistance resources that the biopharmaceutical industry offers.

After completing its three-step process, users can review resources that may be available based on the medications and background information entered. Resources will be listed and can be printed by the user.
MAT offers other resources, including:
• A list of other healthcare assistance resources at https://medicineassistancetool.org/My-Resources?sec=all-resources&cat=13
• A list of discount drug card programs at https://medicineassistancetool.org/My-Resources?sec=all-resources&cat=3
• Information about the cost of prescription medicines at medicineassistancetool.org/Medicine-Cost-Information.

National Organization for Rare Disorders
The National Organization for Rare Disorders (NORD) is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its patient organization members, is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and patient services.

RareCare®
NORD has provided assistance programs to help patients obtain lifesaving or life-sustaining medication they could not otherwise afford. These programs provide medication, financial assistance with insurance premiums and co-pays, diagnostic testing assistance, and travel assistance for clinical trials or consultation with disease specialists. To find available NORD assistance programs, visit to its website (https://rarediseases.org/for-patients-and-families/help-access-medications/patient-assistance-programs-2/#-section-1).

Eligibility criteria can vary by program but most of NORD’s patient assistance programs require the following:
• Patient has an applicable diagnosis or physician referral
• Patient currently lives in the United States
• Patient meets NORD’s financial need criteria.

To apply for assistance, locate the program on its website by disease state. Then follow the related contact information. If there is no patient assistance program listed that meets a patient’s specific need, contact NORD at: 1-800-999-6673.

Maximum award levels vary by program. Awards are made for a calendar year, and patients may reapply for subsequent years. NORD is able to offer same day approval for programs.

MedicAlert Assistance Program
NORD’s MedicAlert Assistance Program provides MedicAlert products and services to eligible individuals in the rare disease community. If someone with a rare disease can’t speak for themselves in an emergency, MedicAlert can be their voice in providing important and potentially life-saving information. The program provides eligible individuals with a MedicAlert product and 3-years of membership.

This program is designed for those with a rare diagnosis who:
• Are a U.S. citizen or U.S. resident of six months or greater with evidence of residency, such as a utility bill showing the patient’s name and address
• Fall within the program’s financial guidelines and adhere to application requirements that are set in advance by NORD.

Awards are granted on a first come, first served basis. Patients may be referred to the program by their healthcare provider, their case managers, or they may self-refer. To apply, call 203.616.4325, Monday through Thursday, 8:30 AM to 7:00 PM EST, or Friday, 8:30 AM to 6:00 PM EST. The RareCare patient services representative will guide the applicant through the application process, verify eligibility for inclusion in the program, determine financial eligibility, and award assistance.

NeedyMeds
needymeds.org

NeedyMeds is a nonprofit that connects people to programs that will help them afford their medications and other healthcare costs. Each program has its own qualifying criteria. To find a patient assistance program (PAP) that patients may qualify for, click on the brand name or generic name search page under the “Healthcare Savings” tab on the NeedyMeds website, or search for the medication name using the search feature in the upper left hand corner of the screen. If using the brand or generic name medication search function:
1. Click on the first letter of the medication’s name in the alphabet bar.
2. Click on the name of the medicine to access the eligibility and contact information for the program(s).

PAPs can also be found by searching the Program Name List or by looking through the Company Name List, both found under the “Healthcare Savings” tab on the NeedyMeds website. If an application form is available through a PAP, look for it in the “Program Applications and Forms” list.
Program Application Assistance

There are many local programs and individuals that help people apply to prescription assistance programs. All will help for free or at a low cost. They may help with finding a program for prescription medications, completing the application forms, and working with healthcare providers who must sign the forms. Help can be found at: www.needymeds.org/local-programs. You can find local programs in two ways: 1. Enter the patient’s ZIP code to find a program in their area or 2. Search by state.

If a medicine does not appear on the brand name or generic name lists, then it is not available through a PAP. Other assistance options include:

- **Coupons, Rebates & More** lists offers of brand name or name medicine and medical supplies. These offers may be in the form of a printable coupon, rebate, savings card, 7-30 day free trial offers, or free samples. There are a variety of ways to receive the offers: some may be printed right from their website, others require registration, filling out a questionnaire, or even obtaining a sample from the doctor’s office.

- **NeedyMeds Drug Discount Card:** The card can help save up to 80 percent off the price of prescription medications. No personal information or registration is required, and the drug discount card is free of charge. The discount card can be used immediately. Simply present the card to the pharmacist, along with the prescription, at any participating pharmacies. The drug discount card cannot be used in combination with any insurance, so it cannot be used to lower a co-payment. Download a card and learn more about its benefits at: www.needymeds.org/drug-discount-card.

- **Diagnosis-Based Assistance:** There are many government- and privately-funded programs that help with costs associated with a specific diagnosis. Some programs are national in scope, while others are limited to people in specific states. Most have some type of eligibility requirements, usually financial ones. Some cover one specific diagnosis, while others cover whole categories (such as all types of cancers) or even all chronic medical illnesses. NeedyMeds has compiled a database (www.needymeds.org/copay-branch) of diagnosis-based assistance programs that can be searched. In most cases, it’s best to search by the type of diagnosis. Other ways to search for assistance are by looking for programs that serve a specific geographical area. If you know the name of a specific program about which you want more information, you can also search by the name of program.

Assistance with Government Programs

Every state has programs to help needy families and individuals with the cost of healthcare. NeedyMeds has compiled a database (https://www.needymeds.org/government-programs) of programs and helpful tools and information to navigate these programs. Users can search these programs by clicking on a state, D.C., Puerto Rico, or Guam. Programs and their guidelines vary from state to state. NeedyMeds also has a list of Medicaid sites where you can learn more about Medicaid in your state, as well as general information on Medicaid.

For all questions, call 1.800.503.6897, or email info@needymeds.org.

Patient Access Network Foundation

panfoundation.org

The Patient Access Network (PAN) helps underinsured people with life-threatening, chronic, and rare diseases get the medications and treatments they need by assisting with their out-of-pocket costs and advocating for improved access and affordability. On the patient’s behalf, you can apply for assistance using the online self-service portal (https://www.panfoundation.org/get-help/apply-for-assistance/) or by calling 866.316.7263, Monday through Friday, 9:00 AM to 7:00 PM EST.

To qualify for a financial assistance program, patients must:

- Be getting treatment for the disease named in the assistance program
- Be taking a medication that’s covered by their health insurance and listed in the assistance program
- Have an income at or below the federal poverty level listed by the assistance program
- Live and receive treatment in the United States or U.S. territories. They don’t have to be a U.S. citizen.

For questions about applications or income verification, call 1.866.316.7263.

Patient Advocate Foundation

patientadvocate.org

The Patient Advocate Foundation (PAF) is a nonprofit charity that provides direct services to patients with chronic, life-threatening, and debilitating diseases to help access care and treatment recommended by
Other Patient Assistance Programs & Resources

their doctor. It offers the following services:

**Case management services**

Case managers offer free, one-on-one support to patients and families to help them solve real-life problems related to a serious health condition. Case management services are available on behalf of patients meeting all of the following criteria:
- Have a confirmed diagnosis of a serious health condition, or they are getting testing for the condition
- Be in active treatment, had treatment within the past six months, or starting treatment in the next 60 days
- Be a United States citizen or permanent resident of the U.S.
- Be receiving treatment at a facility in the U.S. or in a U.S. territory.

To connect with case management services, call 1.800.532.5274 or apply online at [patientadvocate.org/connect-with-services/case-management-services-and-medcarelines/](https://patientadvocate.org/connect-with-services/case-management-services-and-medcarelines/).

**MedCareLine**

MedCareLine is PAF case management that focuses on certain health conditions, treatments, or groups of people. It's funded by grants, partners, and donors that have special interest in these conditions. Services are the same as PAF case management, but each program has different patient requirements. Go online ([https://www.patientadvocate.org/connect-with-services/case-management-services-and-medcarelines/](https://www.patientadvocate.org/connect-with-services/case-management-services-and-medcarelines/)) to see if your patients qualify for PAF’s MedCareLine.

**Co-Pay Relief Program**

The PAF Co-Pay Relief Program, one of the self-contained divisions of PAF, provides direct financial assistance to insured patients who meet certain qualifications to help them pay for the prescriptions and/or treatments they need. This assistance helps patients afford the out-of-pocket costs for these items that their insurance companies require. For more information, read the “Co-Pay Relief” on page 106.

**Financial Aid Funds**

This independent division of PAF provides small grants to patients who meet financial and medical criteria. Grants are provided on first-come first-served basis and are distributed until funds are depleted. Qualifications and processes for each fund may differ based on fund requirements. Patients who are interested in applying for financial assistance should start by calling this division at 855.824.7941 or by registering an account and submitting an application online at [financialaid.patientadvocate.org](http://financialaid.patientadvocate.org).

For questions, call 1.800.532.5274, Monday through Friday, 8:30 AM to 5:00 PM EST.

**RxAssist**

RxAssist offers a comprehensive database of patient assistance programs, as well as practical tools, news, and articles so that healthcare professionals and patients can find the information they need. Go to [rxassist.org/search](http://rxassist.org/search) and search by medication name or company name.

If an application is available online, users can either open (download) the application, type information directly onto the application on the screen and print it out, or print out the application and fill it out by hand. If there is no application online, use the phone number provided at the top of the “Program Details” page to call the company for information on how to get an application.

**RxAssist Prescription Savings Card**

With the RxAssist Prescription Savings Card, patients can save up to 85 percent where they already fill their prescriptions. Savings are possible with or without insurance, and there is no additional cost to use the card. The card is active for immediate use by patients, their family, and their friends. Visit [rxassist.org/coupon/generic?type=patients](https://www.rxassist.org/coupon/generic?type=patients), or call 1.877.537.5537 for more information.

**RxHope™**

RxHope.com

Healthcare providers and their staff can set up accounts online to order free medications for their patients through the RxHope automated patient assistance online system. If providers and staff would like to create a free account for one healthcare provider, visit [rxhope.com/Prescriber/SetupAccount.aspx](https://www.rxhope.com/Prescriber/SetupAccount.aspx). To set up a free account and place orders online, the following criteria are required:
- The user must be a healthcare provider or their staff
- A valid state license number for the healthcare provider
- An email address (this will become the user’s login)
- The medication for which the patient is applying
- The patient’s first and last name.

Once the above information is available, go to [rxhope.com/Prescriber/Register.aspx](https://www.rxhope.com/Prescriber/Register.aspx) and follow the instructions. You will be setting up your free account and creating an order for the patient all at the same time.
Patients can initiate the patient assistance process by following a few steps:

1. Enter contact information and select the medication for which they are applying
2. Review the program guidelines and requirements that will be listed on the screen
3. Follow the instructions and print out the request for a healthcare provider to complete.

To complete the request, make sure to click on the blue link that says “Apply Online Now.”

Rx Outreach®
rxoutreach.org

Rx Outreach is a fully-licensed nonprofit mail order pharmacy that ships medications directly to patients’ homes or the provider’s office. To make this process simple and cost-effective, Rx Outreach ships enough medication for 30, 60, 90, or 180 days at a time. Rx Outreach is available to qualifying individuals and families. Patients can be on Medicare, Medicaid, or other health insurance and still qualify. It serves people whose income is at or below 400 percent of the federal poverty line. Patients can quickly check their eligibility online at https://rxoutreach.org/find-out-if-youre-eligible/.

How to enroll in Rx Outreach:
1. Download and print the paper application (https://rxoutreach.org/wp-content/uploads/2020/09/RxOutreach_Web-Application-9.20.pdf), and fax the completed form to 1.800.875.6591. Faxed prescriptions must come directly from the provider’s office.
2. Create an account online at rxoutreach.org/how-to-enroll-in-rx-outreach/

3. Call 1.888.RXO1234 (1.888.796.1234).

Once patients are enrolled in Rx Outreach and have decided which medications they would like to order, their doctor should e-prescribe or fax the prescription to the program. Patients can mail their hard copy prescription to Rx Outreach as well.

For any questions, call 1.888.RXO.1234 (1.888.796.1234), Monday through Friday, 7:00 AM to 5:30 PM CST, or email questions@rxoutreach.org.

SingleCare®
singlecare.com/

SingleCare works directly with pharmacies to negotiate up to 80 percent off prescription prices. It passes these savings onto its members free of charge. Start with a search to look up prescriptions to find the lowest price in your area. Then download, text, or email yourself a free SingleCare coupon card. The card can be used at participating pharmacy locations. Show the coupon card to your pharmacist and the savings will be applied automatically.

The card is not a health insurance policy and is not intended as a substitute for health insurance. The card allows patients to obtain discounts on prescription drugs and/or pharmaceutical products purchased through participating pharmacies. The range of the discounts will vary depending on the prescription drug or other product and the participating pharmacy. Patients are required to pay for all prescription drugs at the time of purchase. SingleCare does not make payments to any pharmacy or healthcare provider. For more information, visit SingleCare.com or call 844.234.3057.
## Quick Reference Guide

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Brand Name</th>
<th>Drug Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abemaciclib</td>
<td>Verzenio®</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Abiraterone acetate</td>
<td>Yonsa®</td>
<td>Sun Oncology</td>
</tr>
<tr>
<td>Abiraterone acetate</td>
<td>Zytiga®</td>
<td>Janssen Biotech</td>
</tr>
<tr>
<td>Acalabrutinib</td>
<td>Calquence®</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Ado-trastuzumab emtansine</td>
<td>Kadcyla®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Afatinib</td>
<td>Gilotrif®</td>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td>Alectinib</td>
<td>Alecensa®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Alpelisib</td>
<td>Piqray®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Amivantamab-vmjw</td>
<td>Rybrevant*</td>
<td>Janssen Biotech Inc</td>
</tr>
<tr>
<td>Apalutamide</td>
<td>Erleada®</td>
<td>Janssen Biotech</td>
</tr>
<tr>
<td>Aprepitant</td>
<td>Cmvanti®</td>
<td>Heron Therapeutics</td>
</tr>
<tr>
<td>Aprepitant</td>
<td>Emend®</td>
<td>Merck</td>
</tr>
<tr>
<td>Arsenic trioxide</td>
<td>Trisenox®</td>
<td>Teva Oncology</td>
</tr>
<tr>
<td>Atezolizumab</td>
<td>Tecentriq®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Avelumab</td>
<td>Bavencio®</td>
<td>EMD Serono/Pfizer</td>
</tr>
<tr>
<td>Axicabtagene ciloleucel</td>
<td>Yescarta®</td>
<td>Kite Pharma</td>
</tr>
<tr>
<td>Axitinib</td>
<td>Inlyta®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Azacitidine</td>
<td>Vidaza®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Azacitidine</td>
<td>Onureg®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Belantamab mafodotin-blmf</td>
<td>Blenrep</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Belumosudil</td>
<td>Rezurock®</td>
<td>Kadmon Pharmaceuticals</td>
</tr>
<tr>
<td>Belzutifan</td>
<td>Welreg®</td>
<td>Merck</td>
</tr>
<tr>
<td>Bendamustine</td>
<td>Treanda®</td>
<td>Teva Oncology</td>
</tr>
<tr>
<td>Bendamustine HCl</td>
<td>Bendeka®</td>
<td>Teva Oncology</td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>Avastin®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Bevacizumab-bvzr</td>
<td>Zirabev®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Binimetinib</td>
<td>Mektovi®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Blinatumomab</td>
<td>Blincyto®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Bortezomib</td>
<td>Velcade®</td>
<td>Takeda Oncology</td>
</tr>
<tr>
<td>Bosutinib</td>
<td>Bosulif®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Brentuximab vedotin</td>
<td>Adocetris®</td>
<td>Seattle Genetics</td>
</tr>
<tr>
<td>Brequcutagene autoleucel</td>
<td>Tecartus®</td>
<td>Kite Pharma</td>
</tr>
<tr>
<td>Brigatinib</td>
<td>Alunbrig®</td>
<td>Takeda Pharma</td>
</tr>
<tr>
<td>Cabozantinib</td>
<td>Cabometyx®</td>
<td>Exelixis</td>
</tr>
<tr>
<td>Capecitabine</td>
<td>Xeloda®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Capmatinib</td>
<td>Tabrecta®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Brand Name</td>
<td>Drug Company</td>
</tr>
<tr>
<td>---------------------------</td>
<td>------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Abemaciclib</td>
<td>Verzenio®</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Abiraterone acetate</td>
<td>Yonsa®</td>
<td>Sun Oncology</td>
</tr>
<tr>
<td></td>
<td>Zytiga®</td>
<td>Janssen Biotech</td>
</tr>
<tr>
<td>Acalabrutinib</td>
<td>Calquence®</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Ado-trastuzumab emtansine</td>
<td>Kadcyla®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Afatinib</td>
<td>Gilotrif®</td>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td>Alectinib</td>
<td>Alecensa®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Alpelisib</td>
<td>Piqray®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Apalutamide</td>
<td>Erleada®</td>
<td>Janssen Biotech</td>
</tr>
<tr>
<td>Aprepitant</td>
<td>Cinvanti®</td>
<td>Heron Therapeutics</td>
</tr>
<tr>
<td></td>
<td>Emend®</td>
<td>Merck</td>
</tr>
<tr>
<td>Arsenic trioxide</td>
<td>Trisenox®</td>
<td>Teva Oncology</td>
</tr>
<tr>
<td>Atezolizumab</td>
<td>Tecentriq®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Avelumab</td>
<td>Bavencio®</td>
<td>EMD Serono/Pfizer</td>
</tr>
<tr>
<td>Axicabtagene ciloleucel</td>
<td>Yescarta®</td>
<td>Kite Pharma</td>
</tr>
<tr>
<td>Axitinib</td>
<td>Inlyta®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Azacitidine</td>
<td>Vidaza®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td></td>
<td>Onureg®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Belantamab mafodotin-blmf</td>
<td>Blenrep</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Belumosudil</td>
<td>Rezurock™</td>
<td>Kadmon Pharmaceuticals</td>
</tr>
<tr>
<td>Belzutifan</td>
<td>Welireg™</td>
<td>Merck</td>
</tr>
<tr>
<td>Bendamustine</td>
<td>Treanda®</td>
<td>Teva Oncology</td>
</tr>
<tr>
<td>Bendamustine HCI</td>
<td>Bendeka®</td>
<td>Teva Oncology</td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>Avastin®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Bevacizumab-bvzr</td>
<td>Zirabev®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Binimetinib</td>
<td>Mektovi®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Blinatumomab</td>
<td>Blincyto®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Bortezomib</td>
<td>Velcade®</td>
<td>Takeda Oncology</td>
</tr>
<tr>
<td>Bosutinib</td>
<td>Bosulif®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Brentuximab vedotin</td>
<td>Adcetris®</td>
<td>Seattle Genetics</td>
</tr>
<tr>
<td>Brexucabtagene autoleucel</td>
<td>Tecartus™</td>
<td>Kite Pharma</td>
</tr>
<tr>
<td>Brigatinib</td>
<td>Alunbrig®</td>
<td>Takeda Oncology</td>
</tr>
<tr>
<td>Cabozantinib</td>
<td>Cabometyx®</td>
<td>Exelixis</td>
</tr>
<tr>
<td>Capecitabine</td>
<td>Xeloda®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Capmatinib</td>
<td>Tabrecta™</td>
<td>Novartis</td>
</tr>
</tbody>
</table>
## Quick Reference Guide

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Brand Name</th>
<th>Drug Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carfilzomib</td>
<td>Kyprolis®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Cemiplimab-rwlc</td>
<td>Libtayo®</td>
<td>Regeneron/Sanofi</td>
</tr>
<tr>
<td>Ceritinib</td>
<td>Zykadia®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Cetuximab</td>
<td>Erbitux®</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Cobimetinib</td>
<td>Cotellic®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Copanlisib</td>
<td>Aliqopa®</td>
<td>Bayer Healthcare</td>
</tr>
<tr>
<td>Crizotinib</td>
<td>Xalkori®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Dabrafenib</td>
<td>Tafinlar®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Dacomitinib</td>
<td>Vizimpro®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Daratumumab</td>
<td>Darzalex®</td>
<td>Janssen Biotech, Inc</td>
</tr>
<tr>
<td>Daratumumab and hyaluronidase human-fihj</td>
<td>Darzalex Faspro®</td>
<td>Janssen Biotech, Inc</td>
</tr>
<tr>
<td>Darbepoetin alfa</td>
<td>Aranesp®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Darolutamid</td>
<td>Nubeqa®</td>
<td>Bayer Healthcare</td>
</tr>
<tr>
<td>Dasatinib</td>
<td>Sprycel®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Decitabine and cedazuridine</td>
<td>Inqovi®</td>
<td>Taiho Oncology</td>
</tr>
<tr>
<td>Deferasirox</td>
<td>Exjade®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Denosumab</td>
<td>Prolia®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Denosumab</td>
<td>Xgeva®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Dexrazoxane</td>
<td>Zinecard®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Dostarlimab-gxly</td>
<td>Jemperli</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Doxorubicin HCI liposome</td>
<td>Doxil®</td>
<td>Janssen Biotech, Inc</td>
</tr>
<tr>
<td>Durvalumab</td>
<td>Imfinzi®</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Duvelisib</td>
<td>Copiktra®</td>
<td>Verastem Oncology</td>
</tr>
<tr>
<td>Elotuzumab</td>
<td>Empliciti®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Eltrombopag</td>
<td>Promacta®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Enasidenib</td>
<td>Ihhifa®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Encorafenib</td>
<td>Braftovi®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Fam-trastuzumab deruxtecan-nxki</td>
<td>Padcev®</td>
<td>Astellas Pharma</td>
</tr>
<tr>
<td>Entrectinib</td>
<td>Rozlytrek®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Enzalutamide</td>
<td>Xtandi®</td>
<td>Astellas</td>
</tr>
<tr>
<td>Epirubicin hydrochloride</td>
<td>Ellence®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Epoetin alpha</td>
<td>Procrit®</td>
<td>Janssen Biotech, Inc</td>
</tr>
<tr>
<td>Epoetin alfa-epbx</td>
<td>Retacrit®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Erdafitinib</td>
<td>Balversa®</td>
<td>Janssen Biotech, Inc</td>
</tr>
<tr>
<td>Eribulin mesylate</td>
<td>Halaven®</td>
<td>Eisai</td>
</tr>
<tr>
<td>Erlotinib</td>
<td>Tarceva®</td>
<td>Astellas/Genentech</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Brand Name</td>
<td>Drug Company</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Carfilzomib</td>
<td>Kyprolis®</td>
<td>Amgen</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cemiplimab-rwlc</td>
<td>Libtayo®</td>
<td>Regeneron/Sanofi</td>
</tr>
<tr>
<td>Cetuximab</td>
<td>Erbitux®</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Ceritinib</td>
<td>Zykadia®</td>
<td>Norvartis</td>
</tr>
<tr>
<td>Cobimetinib</td>
<td>Cotellic®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Copanlisib</td>
<td>Aliqopa™</td>
<td>Bayer Healthcare</td>
</tr>
<tr>
<td>Crizotinib</td>
<td>Xalkori®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Dabrafenib</td>
<td>Tafinlar®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Dacomitinib</td>
<td>Vizimpro®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Daratumumab</td>
<td>Darzalex®</td>
<td>Janssen Biotech, Inc</td>
</tr>
<tr>
<td>Darbepoetin alfa</td>
<td>Aranesp®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Darolutamide</td>
<td>Nubeqa®</td>
<td>Bayer Healthcare</td>
</tr>
<tr>
<td>Dasatinib</td>
<td>Sprycel®</td>
<td>Bristol Myers Squib</td>
</tr>
<tr>
<td>Decitabine and cedazuridine</td>
<td>Inqovi®</td>
<td>Taiho Oncology</td>
</tr>
<tr>
<td>Deferasirox</td>
<td>Exjade®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Denosumab</td>
<td>Prolia®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Denosumab</td>
<td>Xgeva®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Dexrazoxane</td>
<td>Zinecard®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Dostarlimab</td>
<td>Jemperli</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Doxorubicin HCI liposome</td>
<td>Doxil®</td>
<td>Janssen Biotech, Inc</td>
</tr>
<tr>
<td>Durvalumab</td>
<td>Imfinzi®</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Duvelisib</td>
<td>Copiktra®</td>
<td>Verastem Oncology</td>
</tr>
<tr>
<td>Elotuzumab</td>
<td>Empliciti®</td>
<td>Bristol Myers Squib</td>
</tr>
<tr>
<td>Erlotinib</td>
<td>Tarceva®</td>
<td>Astellas/Genentech</td>
</tr>
<tr>
<td>Enzalutamide</td>
<td>Xtandi®</td>
<td>Astellas</td>
</tr>
<tr>
<td>Epirubicin hydrochloride</td>
<td>Ellence®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Epoetin alfa-epbx</td>
<td>Retacrit®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Erdafitinib</td>
<td>Balversa™</td>
<td>Janssen Biotech, Inc</td>
</tr>
<tr>
<td>Eribulin mesylate</td>
<td>Halaven®</td>
<td>Eisai</td>
</tr>
<tr>
<td>Entrectinib</td>
<td>Rozlytrek®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Enzalutamide</td>
<td>Xtandi®</td>
<td>Astellas</td>
</tr>
<tr>
<td>Epirubicin hydrochloride</td>
<td>Ellence®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Epoetin alfa-epbx</td>
<td>Retacrit®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Eribulin mesylate</td>
<td>Halaven®</td>
<td>Eisai</td>
</tr>
<tr>
<td>Encorafenib</td>
<td>Braftovi®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Brand Name</td>
<td>Drug Company</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>--------------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>Estramustine phosphate sodium</td>
<td>Emcyt®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Everolimus</td>
<td>Afinitor®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Exemestane</td>
<td>Aromasin®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Fam-trastuzumab deruxtecan-nxki</td>
<td>Enhertu®</td>
<td>Daiichi Sankyo/AstraZeneca</td>
</tr>
<tr>
<td>Filgrastim</td>
<td>Neupogen®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Fosaprepitant</td>
<td>Faslodex®</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Fulvestrant</td>
<td>Iressa®</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>Mynolux®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Gemtuzumab ogzaminic</td>
<td>Mylotarg™</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Gilteritinib</td>
<td>Xospata®</td>
<td>Astellas Pharma</td>
</tr>
<tr>
<td>Glasdegib</td>
<td>Daurismo™</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Goserelin acetate implant</td>
<td>Zoladex®</td>
<td>TerSera Therapeutics</td>
</tr>
<tr>
<td>Granisetron</td>
<td>Sustol®</td>
<td>Heron Therapeutics</td>
</tr>
<tr>
<td>Hyaluronidase-zzxf</td>
<td>Phesgo®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Ibrutinib</td>
<td>Imbruvica®</td>
<td>Pharmalytics, Inc</td>
</tr>
<tr>
<td>Idecabtagene vicleucel</td>
<td>Abecma™</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Idarubicin hydrochloride</td>
<td>Idamycin®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Imatinib mesylate</td>
<td>Gleevec®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Inifgratinib</td>
<td>Truseltiq™</td>
<td>OED Therapeutics</td>
</tr>
<tr>
<td>Inotuzumab ogzaminic</td>
<td>Besponsa®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Interferon alfa-2b</td>
<td>Intron® A</td>
<td>Merck</td>
</tr>
<tr>
<td>Ipilimumab</td>
<td>Yervoy®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Irinotecan hydrochloride</td>
<td>Camptosar®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Irinotecan liposome</td>
<td>Oniyx®</td>
<td>Ipsen Biopharmaceutical</td>
</tr>
<tr>
<td>Isatuximab-irfc</td>
<td>Sarcis®</td>
<td>Sanofi Genzyme</td>
</tr>
<tr>
<td>Ivosidenib</td>
<td>Tibsovo®</td>
<td>Servier Pharmaceuticals</td>
</tr>
<tr>
<td>Ixazomib</td>
<td>Ninlaro®</td>
<td>Takeda Oncology</td>
</tr>
<tr>
<td>Lanreotide</td>
<td>Somatumine® Depot</td>
<td>Ipsen Pharma</td>
</tr>
<tr>
<td>Lapatinib</td>
<td>Tykerb®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Larotrectinib</td>
<td>Vitrakvi®</td>
<td>Bayer Healthcare</td>
</tr>
<tr>
<td>Lenalidomide</td>
<td>Revlimid®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Lenvatinib</td>
<td>Lenvima®</td>
<td>Eisai</td>
</tr>
<tr>
<td>Letrozole</td>
<td>Femara®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Leuprolide acetate</td>
<td>Lupron Depot®</td>
<td>Abbvie</td>
</tr>
<tr>
<td>Liscabtagene maraleucel</td>
<td>Breyanzi®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Loncastuximab tesirine-Ipil</td>
<td>Zynlonta®</td>
<td>ADC Therapeutics</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Brand Name</td>
<td>Drug Company</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Estramustine phosphate sodium</td>
<td>Emcyt®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Everolimus</td>
<td>Afinitor®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Exemestane</td>
<td>Aromasin®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Fam-trastuzumab deruxtecan-nxki</td>
<td>Enhertu®</td>
<td>Daiichi Sankyo/AstraZeneca</td>
</tr>
<tr>
<td>Filgrastim</td>
<td>Neupogen®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Fosaprepitant</td>
<td>Emend®</td>
<td>Merck</td>
</tr>
<tr>
<td>Fulvestrant</td>
<td>Faslodex®</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>Iressa®</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Gemtuzumab ozogamicin</td>
<td>Mylotarg</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Gilteritinib</td>
<td>Xospata®</td>
<td>Astellas Pharma</td>
</tr>
<tr>
<td>Glasdegib</td>
<td>Daurismo™</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Goserelin acetate implant</td>
<td>Zoladex®</td>
<td>TerSera Therapeutics</td>
</tr>
<tr>
<td>Granisetron</td>
<td>Sustol®</td>
<td>Heron Therapeutics</td>
</tr>
<tr>
<td>Hyaluronidase-zzxf</td>
<td>Phesgo™</td>
<td>Genentech</td>
</tr>
<tr>
<td>Ibrutinib</td>
<td>Imbruvica®</td>
<td>Pharmalytics, Inc</td>
</tr>
<tr>
<td>Idecabtagene vicleucel</td>
<td>Abecma™</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Idarubicin hydrochloride</td>
<td>Idamycin®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Imatinib mesylate</td>
<td>Gleevec®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Infigratinib</td>
<td>Truseltiq™</td>
<td>QED Therapeutics</td>
</tr>
<tr>
<td>Inotuzumab ozogamicin</td>
<td>Besponsa®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Interferon alfa-2b</td>
<td>Intron® A</td>
<td>Merck</td>
</tr>
<tr>
<td>Ipilimumab</td>
<td>Yervoy®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Irinotecan hydrochloride</td>
<td>Camptosar®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Irinotecan liposome</td>
<td>Onivyde®</td>
<td>Ipsen Biopharmaceutical</td>
</tr>
<tr>
<td>Isatuximab-irfc</td>
<td>Sarclisa®</td>
<td>Sanofi Genzyme</td>
</tr>
<tr>
<td>Ivosidenib</td>
<td>Tibsovo®</td>
<td>Servier Pharmaceuticals</td>
</tr>
<tr>
<td>Ixazomib</td>
<td>Ninlaro®</td>
<td>Takeda Oncology</td>
</tr>
<tr>
<td>Lanreotide</td>
<td>Somatuline® Depot</td>
<td>Ipsen Pharma</td>
</tr>
<tr>
<td>Lapatinib</td>
<td>Tykerb®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Larotrectinib</td>
<td>Vitrakvi®</td>
<td>Bayer Healthcare</td>
</tr>
<tr>
<td>Lenalidomide</td>
<td>Revlimid®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Lenvatinib</td>
<td>Lenvima®</td>
<td>Eisai</td>
</tr>
<tr>
<td>Letrozole</td>
<td>Femara®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Leuprolide acetate</td>
<td>Lupron Depot®</td>
<td>Abbvie</td>
</tr>
<tr>
<td>Lisocabtagene maraleucel</td>
<td>Breyanzi®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Loncastuximab tesirine-lpyl</td>
<td>Zynlonta®</td>
<td>ADC Therapeutics</td>
</tr>
</tbody>
</table>
# Quick Reference Guide

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Brand Name</th>
<th>Drug Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lorlatinib</td>
<td>Lorbrena®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Lurbinectedin</td>
<td>Zepzelca™</td>
<td>PharmaMar, S.A.</td>
</tr>
<tr>
<td>Luspatercept-aamt</td>
<td>Reblozyl®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Margetuximab-cmkb</td>
<td>Margenza™</td>
<td>Macrogenics</td>
</tr>
<tr>
<td>Melphalan flufenamide</td>
<td>Pepaxto®</td>
<td>Oncopeptides</td>
</tr>
<tr>
<td>Midostaurin</td>
<td>Rydapt®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Moxetumomab pasudotox-tdfk</td>
<td>Lumoxiti™</td>
<td>Innate Pharma</td>
</tr>
<tr>
<td>Naxitamab-gqgk</td>
<td>Danyelza®</td>
<td>Y-mAbs Therapeutics</td>
</tr>
<tr>
<td>Necitumumab</td>
<td>Portrazza®</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Neratinib</td>
<td>Nerlynx®</td>
<td>Puma Biotechnology</td>
</tr>
<tr>
<td>Nilotinib</td>
<td>Tasigna®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Niraparib</td>
<td>Zejula®</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>Nivolumab</td>
<td>Opdivo®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Obinutuzumab</td>
<td>Gazyva®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Octreotide acetate</td>
<td>Sandostatin® LAR Depot</td>
<td>Novartis</td>
</tr>
<tr>
<td>Ofatumumab</td>
<td>Arzerra®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Olaparib</td>
<td>Lynparza®</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Olaratumab</td>
<td>Lartruvo®</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Omacetaxine mepesuccinate</td>
<td>Synribo®</td>
<td>Teva Pharmaceuticals</td>
</tr>
<tr>
<td>Osimertinib</td>
<td>Tagrisso®</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Paclitaxel protein-bound particles</td>
<td>Abraxane®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Palbociclib</td>
<td>Ibrance®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Palonosetron hydrochloride</td>
<td>Aloxi®</td>
<td>Eisai</td>
</tr>
<tr>
<td>Panitumumab</td>
<td>Vectibix®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Panobinostat</td>
<td>Farydak®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Pegfilgrastim</td>
<td>Neulasta®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Pegfilgrastim</td>
<td>Neulasta® Onpro® kit</td>
<td>Amgen</td>
</tr>
<tr>
<td>Pegfilgrastim</td>
<td>Nyvepria™</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Pegfilgrastim-cbqv</td>
<td>Udenyca®</td>
<td>Coherus BioSciences</td>
</tr>
<tr>
<td>Pegfilgrastim-jmdb</td>
<td>Fulphila®</td>
<td>Mylan</td>
</tr>
<tr>
<td>Peginterferon alfa-2b</td>
<td>Sylatron™</td>
<td>Merck</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>Keytruda®</td>
<td>Merck</td>
</tr>
<tr>
<td>Pemetrexed</td>
<td>Alimta®</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Pemigatinib</td>
<td>Pemazyre®</td>
<td>Incyte Corp</td>
</tr>
<tr>
<td>Pertuzumab</td>
<td>Perjera®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Pertuzumab, trastuzumab, and hyaluronidase-zzxf</td>
<td>Phesgo™</td>
<td>Genentech</td>
</tr>
<tr>
<td>Phone number</td>
<td>Website</td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>1-877-744-5675</td>
<td><a href="http://www.pfizeroncologytogether.com/hcp">www.pfizeroncologytogether.com/hcp</a></td>
<td></td>
</tr>
<tr>
<td>1-833-533-5299</td>
<td><a href="http://www.zepzelca.com/financial-assistance/">www.zepzelca.com/financial-assistance/</a></td>
<td></td>
</tr>
<tr>
<td>1-800-861-0048</td>
<td><a href="http://www.mybmscases.com/app/login#/">http://www.mybmscases.com/app/login#/</a></td>
<td></td>
</tr>
<tr>
<td>1-844-633-6469</td>
<td><a href="https://www.margenza.com/support-and-resources/patient-resources-and-support">https://www.margenza.com/support-and-resources/patient-resources-and-support</a></td>
<td></td>
</tr>
<tr>
<td>1-844-300-6626</td>
<td>oncoursesupport.com</td>
<td></td>
</tr>
<tr>
<td>1-800-277-2254</td>
<td><a href="http://www.patient.novartisoncology.com">www.patient.novartisoncology.com</a></td>
<td></td>
</tr>
<tr>
<td>1-844-694-6628</td>
<td><a href="http://www.innatecares.com/">www.innatecares.com/</a></td>
<td></td>
</tr>
<tr>
<td>1-833-339-6227</td>
<td><a href="https://danyelzahcp.com/access-and-resources/y-mabs-connect/">https://danyelzahcp.com/access-and-resources/y-mabs-connect/</a></td>
<td></td>
</tr>
<tr>
<td>1-866-472-8663</td>
<td><a href="http://www.lillypatientone.com">www.lillypatientone.com</a></td>
<td></td>
</tr>
<tr>
<td>1-855-816-5421</td>
<td><a href="http://www.nerlynx.com/access-and-support">www.nerlynx.com/access-and-support</a></td>
<td></td>
</tr>
<tr>
<td>1-800-277-2254</td>
<td><a href="http://www.patient.novartisoncology.com">www.patient.novartisoncology.com</a></td>
<td></td>
</tr>
<tr>
<td>1-844-447-5662</td>
<td><a href="http://www.togetherwithgskoncology.com/hcp-resources/">www.togetherwithgskoncology.com/hcp-resources/</a></td>
<td></td>
</tr>
<tr>
<td>1-800-861-0048</td>
<td><a href="http://www.mybmscases.com/app/login#/">www.mybmscases.com/app/login#/</a></td>
<td></td>
</tr>
<tr>
<td>1-866-422-2377</td>
<td><a href="http://www.genentech-access.com/hcp">www.genentech-access.com/hcp</a></td>
<td></td>
</tr>
<tr>
<td>1-800-277-2254</td>
<td><a href="http://www.patient.novartisoncology.com">www.patient.novartisoncology.com</a></td>
<td></td>
</tr>
<tr>
<td>1-800-277-2254</td>
<td><a href="http://www.patient.novartisoncology.com">www.patient.novartisoncology.com</a></td>
<td></td>
</tr>
<tr>
<td>1-844-275-2360</td>
<td><a href="http://www.myaccess360.com">www.myaccess360.com</a></td>
<td></td>
</tr>
<tr>
<td>1-866-472-8663</td>
<td><a href="http://www.lillypatientone.com">www.lillypatientone.com</a></td>
<td></td>
</tr>
<tr>
<td>1-888-838-2872</td>
<td><a href="http://www.tevacares.org">www.tevacares.org</a></td>
<td></td>
</tr>
<tr>
<td>1-844-275-2360</td>
<td><a href="http://www.myaccess360.com">www.myaccess360.com</a></td>
<td></td>
</tr>
<tr>
<td>1-800-861-0048</td>
<td><a href="http://www.mybmscases.com/app/login#/">http://www.mybmscases.com/app/login#/</a></td>
<td></td>
</tr>
<tr>
<td>1-877-744-5675</td>
<td><a href="http://www.pfizeroncologytogether.com/hcp">www.pfizeroncologytogether.com/hcp</a></td>
<td></td>
</tr>
<tr>
<td>1-866-613-4724</td>
<td>Other patient assistance programs</td>
<td></td>
</tr>
<tr>
<td>1-888-427-7478</td>
<td><a href="https://www.amgenassist360.com/hcp/">https://www.amgenassist360.com/hcp/</a></td>
<td></td>
</tr>
<tr>
<td>1-800-277-2254</td>
<td><a href="http://www.patient.novartisoncology.com">www.patient.novartisoncology.com</a></td>
<td></td>
</tr>
<tr>
<td>1-888-427-7478</td>
<td><a href="https://www.amgenassist360.com/hcp/">https://www.amgenassist360.com/hcp/</a></td>
<td></td>
</tr>
<tr>
<td>1-888-427-7478</td>
<td><a href="http://www.amgenassist360.com/hcp/">www.amgenassist360.com/hcp/</a></td>
<td></td>
</tr>
<tr>
<td>1-877-744-5675</td>
<td>pfizeroncologytogether.com/hcp</td>
<td></td>
</tr>
<tr>
<td>1-844-483-3692</td>
<td><a href="http://www.coheruscomplete.com/home.html">www.coheruscomplete.com/home.html</a></td>
<td></td>
</tr>
<tr>
<td>1-833-695-2623</td>
<td><a href="http://www.mylanadvocate.com">www.mylanadvocate.com</a></td>
<td></td>
</tr>
<tr>
<td>1-855-257-3932</td>
<td><a href="http://www.merckhelps.com/SYLATRON">www.merckhelps.com/SYLATRON</a></td>
<td></td>
</tr>
<tr>
<td>1-855-257-3932</td>
<td><a href="http://www.merckaccessprogram.com/hcp">www.merckaccessprogram.com/hcp</a></td>
<td></td>
</tr>
<tr>
<td>1-866-472-8663</td>
<td><a href="http://www.lillypatientone.com">www.lillypatientone.com</a></td>
<td></td>
</tr>
<tr>
<td>1-866-708-8806</td>
<td>hcp.incytecares.com/pemazyre/home.aspx</td>
<td></td>
</tr>
<tr>
<td>1-866-422-2377</td>
<td><a href="http://www.genentech-access.com/hcp">www.genentech-access.com/hcp</a></td>
<td></td>
</tr>
<tr>
<td>1-866-422-2377</td>
<td>genentech-access.com/hcp</td>
<td></td>
</tr>
</tbody>
</table>
## Quick Reference Guide

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Brand Name</th>
<th>Drug Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polatuzumab vedotin-piiq</td>
<td>Polivy®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Pomalidomide</td>
<td>Pomalyst®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Ponatinib</td>
<td>Iclusig®</td>
<td>Takeda Oncology</td>
</tr>
<tr>
<td>Pralsetinib</td>
<td>Gavreto®</td>
<td>Blueprint Medicines/Genentech</td>
</tr>
<tr>
<td>Radium Ra 223 dichloride</td>
<td>Xofigo®</td>
<td>Bayer Healthcare</td>
</tr>
<tr>
<td>Ramucircumab</td>
<td>Cyramza®</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Regorafenib</td>
<td>Stivarga®</td>
<td>Bayer Healthcare</td>
</tr>
<tr>
<td>Relugolix</td>
<td>Orgovoxx®</td>
<td>Myovant Sciences</td>
</tr>
<tr>
<td>Ribocilicib</td>
<td>Kisqali®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Ripretinib</td>
<td>Quinlock®</td>
<td>Deciphera Pharm</td>
</tr>
<tr>
<td>Rituximab</td>
<td>Rituxan®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Rituximab-abbs</td>
<td>Truxima®</td>
<td>Teva Oncology</td>
</tr>
<tr>
<td>Rituximab-arx</td>
<td>Riabni™</td>
<td>Amgen</td>
</tr>
<tr>
<td>Rituximab-pvvr</td>
<td>Ruxience®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Rituximab and hyaluronidase human</td>
<td>Rituxan Hycela®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Rolapitant</td>
<td>Varubi®</td>
<td>TerSera Therapeutics</td>
</tr>
<tr>
<td>Romiplostim</td>
<td>Nplate®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Rucaparib</td>
<td>Rubraca®</td>
<td>Clovis Oncology</td>
</tr>
<tr>
<td>Ruxolitinib</td>
<td>Jakafi®</td>
<td>Incyte</td>
</tr>
<tr>
<td>Sancituzumab govitecan-hziy</td>
<td>Trodelvy®</td>
<td>Immunomedics</td>
</tr>
<tr>
<td>Selinexor</td>
<td>Xpovio®</td>
<td>Karyopharm Therapeutics</td>
</tr>
<tr>
<td>Selpercatinib</td>
<td>Retevmo™</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Selumetinib</td>
<td>Koselugo®</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Sipuleucel-t</td>
<td>Provenge®</td>
<td>Dendreon</td>
</tr>
<tr>
<td>Siltuximab</td>
<td>Sylvant®</td>
<td>Janssen Biotech, Inc</td>
</tr>
<tr>
<td>Sonidegib</td>
<td>Odomzo®</td>
<td>Sun Oncology</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>Nexavar®</td>
<td>Bayer Healthcare</td>
</tr>
<tr>
<td>Sotorasib</td>
<td>Lumakras™</td>
<td>Amgen</td>
</tr>
<tr>
<td>Sunitinib malate</td>
<td>Sutent®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Talazoparib</td>
<td>Talzenna®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Talimogene laherparepvec</td>
<td>Imlytic®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Tafasitamab-cxix</td>
<td>Monjuvi®</td>
<td>MorphoSys</td>
</tr>
<tr>
<td>Tbo-filgrastim</td>
<td>Granix®</td>
<td>Teva Oncology</td>
</tr>
<tr>
<td>Temozolomide</td>
<td>Temodar®</td>
<td>Merck</td>
</tr>
<tr>
<td>Temsirolimus</td>
<td>Torisel®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Tepotinib</td>
<td>Tepmetko®</td>
<td>EMD Serono</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Brand Name</td>
<td>Drug Company</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Polatuzumab vedotin-piiq</td>
<td>Polivy®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Pomalidomide</td>
<td>Pomalyt®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Ponatinib</td>
<td>Iclusig®</td>
<td>Takeda Oncology</td>
</tr>
<tr>
<td>Ramucircumab</td>
<td>Cyramza®</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Relugolix</td>
<td>Orgovyx™</td>
<td>Myovant Sciences</td>
</tr>
<tr>
<td>Ribociclib</td>
<td>Kisqali®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Ripretinib</td>
<td>Quinlock®</td>
<td>Deciphera Pharm</td>
</tr>
<tr>
<td>Rituximab</td>
<td>Rituxan®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Rituximab-abbs</td>
<td>Truxima®</td>
<td>Teva Oncology</td>
</tr>
<tr>
<td>Rituximab-arrx</td>
<td>Riabni™</td>
<td>Amgen</td>
</tr>
<tr>
<td>Rituximab and hyaluronidase human</td>
<td>Rituxan Hycela®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Rolapitant</td>
<td>Varubi®</td>
<td>TerSera Therapeutics</td>
</tr>
<tr>
<td>Romiplostim</td>
<td>Nplate®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Rucaparib</td>
<td>Rubraca®</td>
<td>Clovis Oncology</td>
</tr>
<tr>
<td>Ruxolitinib</td>
<td>Jakafi®</td>
<td>Incyte</td>
</tr>
<tr>
<td>Selpercatinib</td>
<td>Retevmo™</td>
<td>Eli Lilly and Company</td>
</tr>
<tr>
<td>Sipuleucel-t</td>
<td>Provenge®</td>
<td>Dendreon</td>
</tr>
<tr>
<td>Siltuximab</td>
<td>Sylvant®</td>
<td>Janssen Biotech, Inc</td>
</tr>
<tr>
<td>Sonidegib</td>
<td>Odomzo®</td>
<td>Sun Oncology</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>Nexavar®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Sotorasib</td>
<td>Lumakras™</td>
<td>Amgen</td>
</tr>
<tr>
<td>Sunitinib malate</td>
<td>Sutent®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Talazoparib</td>
<td>Talzenna®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Talimogene laherparepvec</td>
<td>Imlygic®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Tafasitamab</td>
<td>Monjuvi®</td>
<td>MorphoSys</td>
</tr>
<tr>
<td>Tbo-filgrastim</td>
<td>Granix®</td>
<td>Teva Oncology</td>
</tr>
<tr>
<td>Temozolomide</td>
<td>Temodar®</td>
<td>Merck</td>
</tr>
<tr>
<td>Temsirolimus</td>
<td>Torisel®</td>
<td>Pfizer</td>
</tr>
</tbody>
</table>

*Quick Reference Guide*
# Quick Reference Guide

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Brand Name</th>
<th>Drug Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thalidomide</td>
<td>Thalomid®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Tisagenlecleucel</td>
<td>Kymriah®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Tivozanib</td>
<td>Fotivda®</td>
<td>AVEO Pharmaceuticals</td>
</tr>
<tr>
<td>Trafectedin</td>
<td>Yondelis®</td>
<td>Janssen Biotech, Inc</td>
</tr>
<tr>
<td>Trametinib</td>
<td>Mekinist®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Trastuzumab-anns</td>
<td>Kanjinti®</td>
<td>Amgen</td>
</tr>
<tr>
<td>Trastuzumab-dttb</td>
<td>Ontruzant®</td>
<td>Merck</td>
</tr>
<tr>
<td>Trastuzumab-pkrb</td>
<td>Herzuma®</td>
<td>Teva Oncology</td>
</tr>
<tr>
<td>Trastuzumab-qyyp</td>
<td>Trazimera®</td>
<td>Pfizer</td>
</tr>
<tr>
<td>Trastuzumab</td>
<td>Herceptin®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Trastuzumab and hyaluronidase-oysk</td>
<td>Herceptin Hylecta®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Trifluridine and tipiracil</td>
<td>Lonsurf®</td>
<td>Taiho Oncology, Inc</td>
</tr>
<tr>
<td>Trilaciclib</td>
<td>Cosela®</td>
<td>G1 Therapeutics</td>
</tr>
<tr>
<td>Tucatinib</td>
<td>Tukysa®</td>
<td>Seattle Genetics</td>
</tr>
<tr>
<td>Umbralisib</td>
<td>Ukoniq®</td>
<td>TG Therapeutics</td>
</tr>
<tr>
<td>Vemurafenib</td>
<td>Zeirolaf®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Venetoclax</td>
<td>Venclexta®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Vismodegib</td>
<td>Erivedge®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Vorinostat</td>
<td>Zolinza®</td>
<td>Merck</td>
</tr>
<tr>
<td>Zanubrutinib</td>
<td>Brukinsa®</td>
<td>BeiGene</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Brand Name</td>
<td>Drug Company</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>Thalomid®</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td>Tisagenlecleucel</td>
<td>Kymriah™</td>
<td>Novartis</td>
</tr>
<tr>
<td>Tivozanib</td>
<td>Fotivda®</td>
<td>AVEO Pharmaceuticals</td>
</tr>
<tr>
<td>Trabectedin</td>
<td>Yondelis®</td>
<td>Janssen Biotech, Inc</td>
</tr>
<tr>
<td>Trametinib</td>
<td>Mekinist®</td>
<td>Novartis</td>
</tr>
<tr>
<td>Trastuzumab</td>
<td>Herceptin®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Trastuzumab</td>
<td>Herceptin Hylecta™</td>
<td>Genentech</td>
</tr>
<tr>
<td>Trastuzumab and hyaluronidase-oysk</td>
<td>Herceptin Hylecta™</td>
<td>Genentech</td>
</tr>
<tr>
<td>Trifluridine and tipiracil</td>
<td>Lonsurf®</td>
<td>Taiho Oncology, Inc</td>
</tr>
<tr>
<td>Trilaciclib</td>
<td>Cosela™</td>
<td>G1 Therapeutics</td>
</tr>
<tr>
<td>Vemurafenib</td>
<td>Zelboraf®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Venetoclax</td>
<td>Venclexta®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Vismodegib</td>
<td>Erivedge®</td>
<td>Genentech</td>
</tr>
<tr>
<td>Vorinostat</td>
<td>Zolinza®</td>
<td>Merck</td>
</tr>
<tr>
<td>Zanubrutinib</td>
<td>Brukinsa®</td>
<td>BeiGene</td>
</tr>
</tbody>
</table>

Other patient assistance programs

1-877-744-5675
www.patient.novartisoncology.com
1-888-838-2872
tevacares.org
1-866-422-2377
www.genentech-access.com/hcp
1-844-824-4648
www.taihopatientsupport.com
1-833-418-6663
cosela.com/patient-support
1-855-473-2873
www.seagensecure.com/patient_tukysa/
1-877-848-9777
https://ukoniq.com/patientsupport
1-866-422-2377
www.genentech-access.com/hcp
1-866-422-2377
www.genentech-access.com/hcp
1-888-838-2872
tevacares.org
1-855-473-2873
www.seagensecure.com/patient_tukysa/
1-877-848-9777
https://ukoniq.com/patientsupport
1-866-422-2377
www.genentech-access.com/hcp
1-866-422-2377
www.genentech-access.com/hcp
1-888-838-2872
tevacares.org
1-855-473-2873
www.seagensecure.com/patient_tukysa/
1-877-848-9777
https://ukoniq.com/patientsupport

1-833-234-4363
https://www.brukinsa.com/hcp/patient-support
Survivorship Resources

The evolution of immunotherapies have given rise to a new class of cancer survivors who require unique tools and resources.

Access this new suite of provider and patient materials today!

- **TOOLKIT:** IO Survivorship Templates
- **PUBLICATION:** Survivorship Care Plans for Patients Receiving Immunotherapy
- **PDF:** IO Medical Wallet Card
- **LECTURE SERIES:** Survivorship in the Era of IO
- **PODCAST:** Survivorship Care After Immunotherapy

Access these resources and more at accc-cancer.org/immunotherapy

The ACCC Immuno-Oncology Institute is supported by Bristol Myers Squibb (charitable donation) and Merck & Co. (Care Coordination educational grant).

The Association of Community Cancer Centers (ACCC) is the leading education and advocacy organization for the cancer care community. Founded in 1974, ACCC is a powerful network of 25,000 multidisciplinary practitioners from 2,100 hospitals and practices nationwide. As advances in cancer screening and diagnosis, treatment options, and care delivery models continue to evolve—so has ACCC—adapting its resources to meet the changing needs of the entire oncology care team. For more information, visit accc-cancer.org or call 301.984.9496. Follow us on Facebook, Twitter, and LinkedIn; read our blog, ACCCBuzz; and tune in to our podcast, CANCER BUZZ.

The ACCC Immuno-Oncology Institute is the leader in optimizing the delivery of cancer immunotherapies for patients by providing clinical education, advocacy, research, and practice management solutions for cancer care teams across all healthcare settings.
Transform Care for Older Adults with Cancer
Practical Resources for the Multidisciplinary Oncology Team

Geriatric Oncology Gap Assessment
Assess your program’s performance against validated measures and best practices related to older adult care.

Nine domains offer four levels to help identify current practices of care. A personalized report provides a score and recommendations for improvement.

COGNITION
How does your program assess cognitive function?

LEVEL 1 Not sure/not performing.
LEVEL 2 Ask simple questions of the patient or caregiver during the interview.
LEVEL 3 Perform a validated screening tool that includes one of the following: Mini Cog, clock drawing test, 3-item recall.
LEVEL 4 Perform one of the following validated screening tools: BOMC, MOCA, or MMSE.

Online Resource Library
Explore validated assessment tools, offering solutions in all care delivery settings.

Search by Featured Domains including:
• Cognition
• Comorbidities
• Functional Status
• Nutrition
• Pharmacy/Medication Management
• Psychological Health

How-To Guide
Offers practical solutions for implementing geriatric screening and assessment without investing significant resources. The key is to start with something simple and feasible.

ACCC-CANCER.ORG/GERIATRIC

In partnership with:

The Association of Community Cancer Centers (ACCC) is the leading education and advocacy organization for the cancer care community. Founded in 1974, ACCC is a powerful network of 28,000 multidisciplinary practitioners from 2,100 hospitals and practices nationwide. As advances in cancer screening and diagnosis, treatment options, and care delivery models continue to evolve—so has ACCC—adapting its resources to meet the changing needs of the entire oncology care team. For more information, visit accc-cancer.org or call 301.984.9496. Follow us on Facebook, Twitter, and LinkedIn; read our blog, ACCCBuzz; and tune in to our podcast, CANCER BUZZ.

Thank you to Pfizer Oncology for their collaboration and support in developing these resources.
measures and best practices related to older adult care.

Transform Care for Older Adults with Cancer

Practical Resources for the Multidisciplinary Oncology Team

ASSOCIATION OF COMMUNITY CANCER CENTERS

Thank you to Pfizer Oncology for their collaboration and support in developing these resources.

Visit accc-cancer.org or call 301.984.9496. Follow us on Facebook, Twitter, and LinkedIn; read our blog, ACCCBuzz; and tune in to our podcast, CANCER BUZZ.